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CHAPTER 1 
GENERAL INTRODUCTION: FLUORINE CHEMISTRY AND RING-CLOSING 
METATHESIS 
 
 
 
Keywords: Fluorine Chemistry / Fluorine Reagents / Ring-Closing Metathesis 
 
 
Abstract 
The subject of fluorine chemistry and its application to pharmaceuticals and 
agrochemicals is reviewed. The birth, growth and maturation of fluorine chemistry 
and fluorine reagents are discussed. In addition, the topic of metathesis is introduced 
as well as the concept of using ring-closing metathesis to synthesize fluoride- and 
trifluoromethyl-substituted carbo- and heterocyles with potential biological activity. 
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1.1 FLUORINE CHEMISTRY 
 
 The scientific and commercial interest in fluorine chemistry largely grew after 
1980 by the need to replace industrial chlorofluorocarbons (CFCs). This was due to 
the fact that CFCs were identified to deliver a significant contribution to the 
destruction of stratospheric ozone through liberation of chlorine radicals via 
photolysis. The class of CFCs was eventually phased out as a result of the 1987 
Montreal Protocol.1 The hydrofluorocarbons (HFCs), which are chlorine-free and 
believed to have no significant contribution to ozone destruction, were later 
introduced as replacement for the CFCs in refrigeration and blowing agent 
applications. Besides these first applications of fluorinated compounds, over the 
years fluorine has become recognized as a key element for use in heat-transfer 
agents, liquid crystals, dyes, surfactants, plastics, elastomers, membranes and other 
materials.2 Furthermore, many fluorine-containing biologically active compounds are 
finding applications as pharmaceuticals and agrochemicals.2b 
In fact, the incorporation of fluorine and/or fluorine-containing groups into 
an organic molecule often drastically perturbs the chemical, physical, and biological 
properties of the parent compound leading to the invention of novel materials, drugs 
and agrochemicals. The effects observed due to incorporation of fluorine in 
biologically active materials and small molecules are summarized in Figure 1.3 
 
Fluorine effects in active agents
mimicking of
enzyme substrates
blocking effect in 
metabolic transformation
increased lipophilicity 
to a higher bioavailability
Fluorine effects in materials
high thermal stabilityhigh oxidative stability
exceptional
mechanical properties
 
Figure 1. Effects of incorporation of fluorine in biologically active materials and small 
molecules. 
 
The capacity to mimic enzyme substrates and the eventual higher 
lipophilicity, which increases the rate of transport of a drug to the desired active site, 
are only two examples of these effects. Moreover, the strong covalent C-F bond (116 
kCal/mol) compared to the C-H bond (100 kCal/mol) can often avoid unwanted 
metabolic transformations. As a consequence of this key role of fluorine, the interest 
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of the pharmaceutical industry for incorporation of fluorine into biologically active 
molecules, strongly increased during the past decade. 
The introduction of fluoro and/or trifluoromethyl substituents gave origin to 
different kinds of drugs (Chart 1);2b,4 examples are the anti-depressants fluoxetine (1) 
and prozac (2), the cholesterol metabolism modulator cerivastatin (3), the 
cardiovascular drug celikalim (4) and the anti-inflammatory drug triflumidate (5). 
The last example, the antibacterial agent ciprofloxacin (6), is a drug where the 
introduction of the fluorine substituent increased the rate of cell penetration by up to 
70 times. 
 
N
O
CO2HF
N
N
H
6: ciprofloxacin
  (antibacterial)
N
Me
Me
Me
Me
MeO
F
CO2Na
OH OH
3: cerivastatin
(modulator of cholesterol metabolism)
F
O +NH2Me Cl
-
1: fluoxetine hydrochloride
(anti-depressant)
F3C
O N
H
Me
2: prozac
(anti-depressant)
ON
O
HO Me
Me
F3CO
4: celikalim
(cardiovascular drug)
O SO2CF3
CO2Et
5: triflumidate
(antiinflammatory)  
Chart 1. Fluoride- and trifluoromethyl-containing drugs. 
 
Not less has been the interest from agrochemical companies. In the past few 
years, environmental concerns have imposed massive constraints on crop protection 
products, demanding increased effectiveness towards lower dose levels of 
agricultural chemicals released into the environment. Fluorinated molecules have 
played an important role in these developments, leading to a range of herbicides, 
insecticides and fungicides of which some examples are described in Chart 2. 4b 
The first two molecules are herbicidal compounds. Herbicides are divided in 
different classes based on their mode of action. 
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12: fluotrimazole
  (fungicide)
9: flufenoxuron
(insecticide)
8: trifluralin
(herbicide)
7: diflufenican
(herbicide)
10: cyhalothrin
(insecticide)
11: flutriafol
(fungicide)
N
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NO
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NO2
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F3C
Cl
O
F
NH O
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NO
F
F
F
F
Me
F
F
O
O
Me Me
F3C
Cl F
HO
N
N
N
N
N
N
F3C
F
 
Chart 2. Examples of fluorinated and trifluoromethylated agrochemicals. 
 
Diflufenican (7) is a carotenoid biosynthesis inhibitor, leading to deactivation 
of the photosynthesis in plants. Trifluralin (8) for example, acts via inhibition of root 
and shoot growth of seedlings immediately after germination. Hence, it is used as a 
preplanting herbicide for selective control of annual grasses and broadleaf weeds in 
cotton and other crops. This compound is one of the most successful commercial 
fluorine-containing herbicides over the past 25 years, with peak sales in the mid 
1980s reaching $ 400 million per year. Other fluorine-containing molecules found 
application as insecticides. Generally, they control the growth of insects via 
disrupting the molting process by inhibiting chitin biosynthesis. Flufenoxuron (9) is 
an example that acts via this mechanism and has been commercially available since 
the mid 1970s. The other insecticide cyhalothrin (10) is part of the pyrethroids. 
Originally this substance class was isolated from the plant species Chrysanthemum 
cinerariafolium, but the natural products were not sufficiently stable for commercial 
use. Cyhalothrin (10) is one of many analogues that have been synthesized, 
containing a vinylic trifluoromethyl substituent which dramatically enhances the 
activity. The last two examples in Chart 2, flutriafol (11) and fluotrimazole (12) are 
fungicides that inhibit sterol biosynthesis and where the fluorine substituent is 
essential for a high level of effectiveness. The compounds shown in Charts 1 and 2 
are only a few examples of the enormous amount of fluorine-containing drugs and 
agrochemicals that are nowadays available.  
The synthesis of fluorinated compounds has been documented several times, 
first by Wilkinson,5 later by Seebach,6 and more recently in 1999 by Schofield.7  
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A brief SciFinder search on “fluorine” confirms the steady increase in terms of 
publications since 1967 up to now (Fig. 2). 
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Figure 2. Growth of publications on fluorinated compounds indexed by SciFinder. 
 
As a result of the large efforts in academic and industrial research, there has 
been much progress in synthetic fluorine chemistry, but nevertheless incorporation 
of fluorine substituents in organic molecules remains a synthetic challenge. For 
example, the introduction of fluorine substituents in (hetero)cyclic systems has so far 
to a large extent been focused on aromatic molecules resulting in various well-
established synthetic methods for doing so.8 However, there is a strong contrast with 
the availability of methods to introduce the same substituents in non-aromatic 
heterocyclic systems.3,9 Current methodology to introduce fluorine into organic 
molecules relies on the availability of fluorinating reagents (Chart 3). Molecular 
fluorine (13) and tetra-n-butylammonium dihydrogen trifluoride (15) are examples of 
generally used fluorinating reagents for monofluorination, organozinc derivative (17) 
for di- and trifluoromethylation. 
In addition, several relatively mild electrophilic fluorinating reagents such as 
Selectfluor™ (19) and N-fluorocollidine triflate (21) have appeared. A recent 
application of the Selectfluor™ reagent is its use in the construction of asymmetric 
fluorinated carbon centers as elegantly demonstrated by Prakash et al.10 
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(electrophilic fluorinating reagents)
13
(general fluorinating reagents)
14 15 16 17
18
F2 HF
N+
F
F–
F
LiCFBr2 CF3CCl2ZnCl
N
F
SS
O
CF3
OO
F3C
O
19
N+
20
O–
S
OO
F3C
H
F
N+
F
Me Me
O–
S
OO
F3C
21
N
F
S
OO
Me
Me
22
Me
N+
N+
Cl
F
BF4
–
BF4
–
 
Chart 3. Fluorinating reagents. 
 
Additionally, a variety of trifluoromethylating agents are known and shown 
in Chart 4. 
 
F3C I
(nucleophilic or electrophilic 
reactions)
23
F3C S
(radical reactions)
24
O
O
Cl F3C S
O
O
Ph
25
(difluorocarbene reactions)
CF2I2
26
BrCF2CO2Me
27
S+
CF3TfO
–28
CF3SiMe3
29
 
Chart 4. Trifluoromethylating reagents. 
 
Iodotrifluoromethane (23) and the acetylenic trifluone 25 are some of the 
reagents used to introduce the trifluoromethyl group in non-aromatic cyclic systems, 
most likely via radical processes. Alternatively, difluorocarbenes generated from 26 
and 27 are used in combination with a source of fluoride to introduce trifluoromethyl 
substituents. Finally, there are reagents such as trifluoromethyltrimethylsilane (28), 
which generally acts as a nucleophile, and trifluoromethyldibenzothiophenium 
triflate (29),11 which act as an electrophile.  
In addition to these fluorinating reagents, one can also make use of the 
´fluorous pool´ and use commercially available fluorine-containing starting materials 
for conversion into (hetero)cyclic systems. This approach generally is more flexible 
and requires regular reaction conditions, avoiding the use of the often corrosive 
and/or extremely reactive fluorinating reagents. A variety of such 
trifluoromethylated starting materials present in the ‘fluorous pool’ are shown in 
Chart 5.  
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HO2C
F3C
MeO2C
F3C
30 31
F3C
CO2Et
F3C
NO2
32 33
H
OF3C
34
Ph
OF3C
O
F3C
CO2Et
O
CO2HF3C
O
NF3C
O
36 37 38
35
 
Chart 5. Trifluoromethyl-containing compounds from the ‘fluorous pool’. 
 
2-(Trifluoromethyl)acrylic acid (30) and its derivatives (for example 31) are 
examples of CF3-carrier reagents which readily undergo Diels-Alder or Michael 
addition reactions, which may lead to the construction of CF3-substituted ring 
systems. Also the α,β-unsaturated olefins 32 and 33 have been used in Diels-Alder or 
1,3-dipolar cycloaddition reactions to prepare rings. Compounds 34 and 35 are useful 
building blocks that readily undergo further reactions, as well as ethyl 1,1,1-
trifluoroacetoacetate (36), trifluoromethylpyruvic acid (37) and N-
trifluoroacetylmorpholine (38). 
 
4039
F F F
O
F
O
O
F
Cl
41 42 43  
Chart 6. Fluorinated reagents from the ‘fluorous pool’. 
 
The olefins in Chart 6 are only some of the many F-carrier reagents available 
at this moment. As in the case of the CF3-carrier reagents, several of these 
compounds behave as dienes or dienophiles in Diels-Alder reactions leading to ring 
systems containing a fluoride substituent. A particular useful reagent for allylation is 
1-chloro-2-fluoropropene (43). 
 Despite all the existing methods to prepare fluorinated compounds and the 
availability of complementary fluorinated compounds from the ‘fluorous pool’, there 
is still a strong demand for the development of new methodology to incorporate 
fluorine in molecules. 
Hence, in this thesis, we will focus on developing generally applicable 
methods for the synthesis of new fluorinated and trifluoromethylated heterocyclic 
compounds that may eventually find applications in the development of drugs or 
agrochemicals. 
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1.2 INTRODUCTION ON RING-CLOSING METATHESIS 
 
From the 1950s to nowadays, metathesis reactions increasingly conquered the 
chemistry world eventually culminating in awarding the 2005 Nobel Prize for 
chemistry to the researchers Chauvin, Grubbs and Schrock for their efforts in this 
area.12 Ring-Closing Metathesis (RCM)13 is one of several kind of metathetic 
transformations, including Cross-Metathesis (CM),14 Ring-Opening Metathesis 
(ROM),15 Ring Opening-Metathesis Polymerization (ROMP)16 and Acyclic Diene 
Metathesis Polymerization (ADMET),15a,17 which can be performed with suitable 
metathesis catalysts. Initially, Ring-Closing Metathesis started with the cyclization of 
simple monosubstituted terminal olefins of type 2 (Scheme 1). 
 
X
1
X
2
RCM
X = CRR1, O, NR  
Scheme 1. RCM as a general approach to obtain ring systems. 
 
The mechanism is shown in Scheme 2, which proceeds via a series of [2+2] 
cycloadditions each time followed by a retro[2+2]cycloaddition. In the first cycle the 
catalyst interacts with the substrate to release styrene, but in the next cycle ethene is 
released. Besides the release of a gas, the ring-closing metathesis process is 
entropically driven because it cuts one substrate molecule into two products. 
 
H2C CH2
H2C [M]
[M]
H2C
RCM
M
R
[M]
R
R
R = H, Ph
 
Scheme 2. Basic catalytic cycle of RCM. 
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Although not specifically shown, all individual steps involved are reversible 
and, as a consequence, the overall transformation is in principle also reversible. It is 
important to notice that the intrinsic competition between RCM, ADMET and CM 
can be controlled to some extent by adjusting the dilution of the reaction mixture and 
the relative concentrations of reagents, but is generally also strongly influenced by 
preexisting conformational constraints in the substrate. 
The first catalysts that were used for RCM were Fisher carbene complexes,18 
which are very active, but also extremely sensitive to moisture and air. Eventually, 
ruthenium carbene complexes were developed.19 The first ruthenium carbene 
complex introduced by Grubbs and co-workers20 that was widely used was 
Ru(=CHPh)Cl2(PCy3)2 (Grubbs I, Scheme 3,)19 c,d that was considerably stable, 
however, its activity was largely restricted to monosubstituted olefins. For example, 
its reactivity on olefins bearing an electron-withdrawing substituent such as Br or Cl 
was tested by the Grubbs group in 1997,21 but gave no successful result. 
The second generation Grubbs catalysts B122 and B2 (Scheme 3), are even 
more stable due to the imidazolinium carbene ligand, which is more strongly 
electron donating than the phosphine moieties in catalyst A.  
 
 
Scheme 3. RCM catalysts. 
 
Its reactivity is significantly increased, so that the catalyst can be used for 
RCM of heavily functionalized olefins in the presence of virtually any functional 
group. The comparable Grubbs/Hoveyda catalyst B2, containing a bridging styrenyl 
ether moiety has a similar reaction profile. Very recently, new Grubbs catalysts have 
been developed (e.g. B3), which are expected to even further widen the scope of 
RCM.23 However, these catalysts were published after the work in this thesis was 
carried out. 
In the past few years, widespread use of the Grubbs-II catalyst has 
demonstrated that RCM is not only restricted to isolated or alkyl-substituted olefins, 
but is also applicable to olefins that bear heteroatoms such as oxygen24 and 
nitrogen.25 Furthermore, it has been demonstrated that P-, Si- and B-substituted 
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olefins can be readily cyclized under the influence of the same catalysts.26,27 Recent 
other RCM examples, that once more emphasize the versatility and importance of 
this particular transformation, include application to α-alkoxyethers by our own 
group,24f and to vinyl chlorides by the Weinreb group.28 The latter example is 
especially important, since it shows for the first time that vinyl halides can 
successfully participate in this reaction. When our project started, there were no 
reports yet concerning RCM of vinyl fluorides, except for a single example of 
metathesis of 1,1-difluoroethylene with ruthenium catalyst B1, resulting in a stable 
complex.29 In addition, a few articles concerning metathesis of olefins with fluoride 
atoms at the allylic position have been published.30 
At this point, we were challenged to use fluoroalkenes and 
trifluoromethylalkenes as potential metathesis substrates, to probe the viability of 
using RCM to prepare fluoride- and trifluoromethyl-substitued carbo- and 
heterocyles with potential biological activity (Scheme 4). 
 
Y
X
3
X
Y
4
RCM
X = CRR1, NR, O
Y = CF3, F  
Scheme 4. RCM as a general approach to introduce non-alkyl substituents into rings. 
 
1.3 PURPOSE AND OUTLINE OF THE THESIS 
 
The purpose of this research was to investigate whether ring-closing 
metathesis can be used as a generally applicable technique for the introduction of 
fluoride and trifluoromethyl substituents in heterocyclic systems starting from the 
corresponding linear starting olefins.  
Chapter 1 is intended to provide an overview of the importance of fluorine 
chemistry starting from the 1980s till nowadays and to describe the various reagents 
available for introducing fluoro and/or trifluoromethyl substituents in organic 
molecules. In addition, a short introduction on ring-closing metathesis is presented. 
Chapter 2 describes the synthesis of a new trifluoromethyl-containing 
allylating reagent which is required in the ring-closing metathesis of 
trifluoromethylated olefins. In the same chapter, preliminary proof for the viability of 
the RCM concept for generating fluorinated heterocycles is established. 
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The synthesis of a series of RCM precursors and the successful cyclization of 
these precursor molecules into the corresponding nitrogen heterocycles is described 
in Chapters 3 and 4. This resulted in modest libraries of trifluoromethyl-containing 
heterocyclic building blocks (Chapter 3) and fluoride-containing heterocyclic 
building blocks (Chapter 4). 
The general applicability of RCM is then further demonstrated in Chapter 5, 
in which additional series of fluoride- and trifluoromethyl-containing nitrogen 
heterocycles have been developed, this time by employing a synthetically more 
practical Mitsunobu strategy. 
Finally, this research was extended to cyclic hydrazine derivatives, 
succeeding in synthesizing orthogonally protected fluorinated cyclic six- and seven-
membered hydrazines by RCM from the corresponding fluorinated olefin precursors 
(Chapter 6). 
Summaries in English and Dutch conclude the thesis. 
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CHAPTER 2 
TRIFLUOROMETHYL- AND FLUORIDE-CONTAINING ALLYLATING AGENTS: 
PROOF OF CONCEPT 
 
 
 
Keywords: (Trifluoromethyl)allylating agent / Ring-closing metathesis / 
Fluoroacrylamide cyclization / Trifluoromethylated cyclopentene synthesis 
 
 
Abstract٭ 
The development of a practical synthetic route to a new (trifluoromethyl)allylating 
reagent via a Diels–Alder/retro-Diels–Alder strategy is presented. Furthermore, 
initial successful cyclizations of fluorinated and trifluoromethylated olefins via Ring-
Closing Metathesis are described.  
 
 
 
 
 
 
 
 
 
 
٭ V. De Matteis, F. L. van Delft, R. de Gelder, J. Tiebes, F. P. J. T. Rutjes, “Fluorinated 
(hetero)cycles via ring-closing metathesis of fluoride- and trifluoromethyl-functionalized 
olefins”, Tetrahedron Lett. 2004, 45, 959–963. 
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2.1 INTRODUCTION 
 
Over the past decade or so, it has become increasingly clear that fluorine 
substituents often display a positive effect on the pharmacokinetics and 
pharmacodynamic properties of potential drugs.1 As a result, the introduction of 
fluorinated substituents has become an important tool to modulate the properties of 
biologically active substances. The similarity in size renders the fluorine atom an 
obvious candidate to replace hydrogen, often without significant disruption of the 
molecular geometry and shape. In addition, due to the strongly electronegative 
nature of fluorine, it also has a dramatic effect on the electronic properties of the 
parent compound. Hence, on a molecular level this enables one to modulate both the 
lipophilicity profile and the electrostatic interactions with a given target structure of 
a drug candidate. On the physiological level, a better bioavailability, an increased 
selectivity for target organs, and a generally far lower effective dose than for the 
analogous non-fluorinated ligands can be achieved. 
Most of the biologically active fluorinated compounds up to date possess 
either a fluoride- or trifluoromethyl-substituted aromatic system due to the relative 
facile access to these structural units. Such (hetero)aromatics are either commercially 
available or can be readily prepared via well-established synthetic methodology. 
Inversely, until now the synthesis of fluorinated non-aromatic (hetero)cycles is much 
less established.2 Stimulated by the general relevance of (partially) saturated 
fluorinated heterocycles and the poor accessibility of such structural units, and 
additionally the interest from the pharmaceutical and agrochemical industry in 
fluorine- and trifluoromethyl-containing (hetero)cyclic building blocks, we set out to 
explore new synthetic methodology in order to gain access to these molecules. 
We identified the Ring-Closing Metathesis (RCM) reaction of fluoroolefins 
and trifluoromethylolefins as a possible method for the synthesis of fluorine 
containing molecules.  
In order to study the use of RCM as a route to access both trifluoro -and 
fluoro-substituted (hetero)cyclic olefins 1, a facile and straightforward pathway to 
the trifluoromethylated and fluorinated olefins 2 had to be developed (Scheme 1). 
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Y
X
1
X
Y
2
RCM Y
LG
3
Z = H2, O
LG = leaving group
X = CRR1, NR, O
Y = CF3, F
Z
 
Scheme 1. RCM approach to fluorinated (hetero)cyclic systems. 
 
In our view, alkylation of suitable starting materials with compounds of type 
3 would serve this purpose, in which LG is a good leaving group such as chloride, 
bromide or tosylate. However, these latter compounds are not commercially 
available in case of the trifluoromethyl substituent. In case of the fluoride substituent, 
the fluoroacrylate precursor (2-fluoroacryloyl fluoride, 3: Z = O, LG = F) can be 
readily prepared from 3,3,2,2,-tetrafluoropropanol in three steps.3 The allyl fluoride 
precursor (1-chloro-2-fluoro-2-propene, 3: Z = H2, LG = Cl) is commercially available, 
but also rather expensive. 
 
2.2 SYNTHESIS OF THE TRIFLUOROMETHYL-CONTAINING ALLYLATING 
AGENT 
 
Initially, attempts were undertaken to commence with commercially available 
2-trifluoromethylacrylic acid (4, TFMAA) to prepare 2-trifluoromethyl-2-propenol 
either directly via LiAlH4 reduction,4 or indirectly via acid chloride formation5 or 
ester formation2,6 followed by LiAlH4 reduction.7 Direct LiAlH4 reduction, however, 
provided starting material when the reaction was carried out in Et2O at 0 °C and led 
to decomposition at higher temperatures. In case of acid chloride formation using 
phthaloyl dichloride or thionyl chloride at 100 °C and for ester formation using 
dimethyl sulfate (K2CO3, dry acetone, reflux, 5 h), diazomethane (Et2O, room 
temperature) or benzyl bromide (ammonium TFMAA, DMSO, room temperature, 14 
h) followed by LiAlH4 reduction the product was also not formed in appreciable 
yields. Two reasons can be invoked to explain these results. First of all, the α,β-
unsaturated system is very reactive due to the electron-withdrawing substituents, 
rendering it prone to conjugate type addition and other types of side reactions. 
Secondly, the acid chloride and ester intermediates are quite volatile, which can be 
problematic while working at a small scale. 
Since straightforward reduction of 2-trifluoromethylacrylic acid in our hands 
appeared either unreliable or laborious, we decided to develop a novel pathway for 
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its synthesis. To avoid the volatility and the reactivity problems of the α,β-
unsaturated system, we envisaged that it would be advantageous to protect the 
olefin in some way. Hence, we chose to mask the double bond in a Diels–Alder 
reaction with cyclopentadiene, which may then be unveiled in a later stage. The 
Diels–Alder/retro-Diels–Alder concept8 is based on the thermal reversibility of the 
[4+2] cycloaddition process. First the reactive alkene system (the dienophile) is 
protected with a suitable diene as a Diels–Alder adduct. The adduct is then subjected 
to the desired chemical modifications and at the end the alkene moiety is regenerated 
in a [4+2] cycloreversion under appropriate thermal conditions. 
According to the Diels–Alder/retro-Diels–Alder concept, 2-
trifluoromethylacrylic acid (4) was reacted with freshly distilled cyclopentadiene to 
give the Diels–Alder adduct 5 as a 2:1 mixture of endo/exo-diastereoisomers in 
excellent yield after recrystallization.9 This mixture was esterified ((MeO)2SO2, 
acetone, K2CO3, reflux, 5 h), reduced (LiAlH4, Et2O, rt, 5 h) and reacted with TsCl 
(TsCl, pyridine, rt, 24 h) to yield tosylate 8 in an excellent overall yield (Scheme 2).  
 
CF3
CO2H CH2Cl2
rt, 12 h
CF3
CO2H
CO2H
CF3
+
4 5a 5b
97% (ca. 2:1)
(MeO)2SO2
K2CO3
acetone, reflux
CO2Me
CF3
6 (99%)
LiAlH4
Et2O, rt
CH2OH
CF3
7 (82%)
TsCl,
pyridine
rt, 24 h
CH2OTs
CF3
8 (92%)  
Scheme 2. Masking of trifluoromethylacrylic acid (4). 
 
At this stage, the retro-Diels–Alder reaction was investigated. This 
cycloreversion can be accomplished thermally, either in solution (static thermolysis) 
or in the gas phase (dynamic thermolysis). For gas phase reactions the Flash Vacuum 
Thermolysis (FVT) technique has been particularly successful on sufficiently volatile 
substrates.10,11 Initially, we chose to unmask the olefin using Flash Vacuum 
Thermolysis (FVT) conditions. In a later stage, thermal solution phase reactions were 
also investigated using a high boiling solvent such as diphenyl ether. 
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2.2.1 RETRO-DIELS–ALDER THROUGH FLASH VACUUM THERMOLYSIS 
 
It is well known that temperature influences the course of chemical reactions. 
Most reactions are performed between the sublimation point of dry ice (–78 °C) and 
the boiling point of high-boiling solvents (circa 300 °C).12 When performed at     
higher temperatures, they are generally called pyrolytic or thermolytic chemical 
reactions.13, 11b 
To perform the latter reactions special equipment is necessary. In our case, an 
FVT set-up was used that was previously developed within the Organic Chemistry 
department of the Radboud University Nijmegen (Fig. 1).11a 
 
 
Figure 1. Flash Vacuum Thermolysis set-up developed at the Radboud University Nijmegen.  
 
The FVT process as outlined in Fig. 1 is a dynamic process in which the 
substrate first sublimates (pressure 1–10–3 mbar) and then passes through a hot tube 
(made of quartz, length 180 mm, width 16 mm) which is situated in a thermolysis 
oven where the actual thermolysis takes place. The products are collected in a 
receiving cooler, which is either cooled with liquid nitrogen or dry ice/acetone. The 
low concentration in the gas phase prevents intermolecular reactions and reduces the 
residence time in the hot zone, minimizing the problems encountered in classical 
flow pyrolysis. Using this set-up, a variety of conditions were investigated, some of 
which are depicted in Table 1. 
Both T1 (sublimation oven) and T2 (thermolysis oven) were varied, while the 
pressure was kept at 0.04 mbar. Comparing entries 1–3, it is clear that T1 has to be 
sufficiently high in order to obtain a good conversion. Eventually, the best results 
were obtained on a 100–200 mg batch scale with T1 = 120 °C, and T2 = 600 °C 
providing the required tosylate 9 in essentially pure form and excellent yield. 
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Table 1. Retro Diels–Alder reaction by FVT. 
CH2OTs
CF3
8
CF3
OTsconditions
9  
Entry Conditions Yield (%) 
1 FVT, T1 = 80 °C, T2 = 600 °C, 0.04 mbar 10 
2 FVT, T1 = 120 °C, T2 = 650 °C, 0.04 mbar 90 
3 FVT, T1 = 120 °C, T2 = 600 °C, 0.04 mbar 95 
 
The tosylate was used without further purification for subsequent follow-up 
chemistry, but could even be further purified over a short silica gel column. 
Subjection of alcohol 7 to the FVT conditions also provided the corresponding 
alcohol (T1 = 50 °C, T2 = 550 °C, 0.04 mbar), but due to the lower yield and the fact 
that additional tosylation of the resulting allylic alcohol required a subsequent 
purification, we decided to choose for the highest yield and the most practical 
procedure. 
Although the FVT pathway represents an efficient synthesis of the 
trifluoromethylated alkylating agent,14 a drawback is the fact that this procedure is 
rather laborious and time consuming and therefore difficult to scale up. For this 
reason, we have been exploring pathways that would provide alternative means for 
the retro-Diels–Alder reaction. 
 
2.2.2 RETRO-DIELS–ALDER IN DIPHENYL ETHER 
 
An alternative to FVT is a static thermolysis process in a high boiling solvent, 
in which a thermal solution phase reaction induces a selective decomposition process 
into two or more substances. Diphenyl ether (bp 259 °C) was chosen as a solvent for 
our retro-Diels–Alder reaction. The reactions were carried out in a flask that was 
heated with a sand bath and equipped with a reflux condenser. Again, a series of 
reactions were performed to screen several conditions, some of which are described 
in Table 2. 
It was immediately clear that temperatures above 260 °C and long reaction 
times (entry 1) had to be avoided. On the other hand, lower temperatures (entry 2) 
gave rise to low conversions (entry 2). Eventually, optimal conditions were reached 
at 250 °C with a reaction time of 8 h to give the tosylate 9 in 82% yield after filtration 
over a short path of silica gel. Although this result by itself was satisfactory, scaling 
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up of this reaction appeared somewhat problematic due to the fact that reaction 
times had to be optimized again for each experiment to limit the decomposition 
process. 
 
Table 2. Retro Diels–Alder reaction in diphenyl ether. 
CH2OTs
CF3
8
CF3
OTsconditions
9  
Entry Conditions Yield (%) 
1 diphenyl ether, 260 °C, 12 h 31 
2 diphenyl ether, 190 °C, 5 h 10 
3 diphenyl ether, 250 °C, 8 h 82 
 
Finally, we also considered using a monomode microwave oven to perform 
the retro-Diels–Alder reaction. In view of the vast increase of examples of microwave 
reactions that show the capacity of this technique for increasing reaction yields or 
reducing reaction times, this particular decomposition event might also benefit from 
it. Initially, we performed the reactions in solvents that were lower boiling than 
diphenyl ether (THF, toluene), but the system did not reach sufficiently high 
temperatures to lead to the retro-Diels–Alder reaction. Then diphenyl ether was 
used, but due the relative apolar character of the solvent, the microwave could not 
reach temperatures higher than 200 °C and only starting material was recovered. 
Therefore, in all cases a small amount of the ionic liquid 1-butyl-3-
methylimidazolium hexafluorophosphate (BMIMPF6) was added, so that reflux 
temperatures could be readily reached. The irradiation power and the reaction times 
were varied, and reactions were also carried out in both open and closed vessels 
(Table 3). 
It appeared that the retro reaction gave only decomposition of the starting 
material when it was performed in closed vessels, probably due to the high pressure 
of the closed system. In open systems equipped with a condenser, however, the 
cycloreversion proceeded much better. A high irradiation power (>200 W) gave low 
conversions due to fast decomposition of the starting material (entries 1 and 2). In 
case of a lower power level (185 W, entry 3), the initial conversion was also low, but 
mainly due to an incomplete reaction. 
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Table 3. Retro Diels–Alder reaction in microwave. 
CH2OTs
CF3
8
CF3
OTsconditions
9  
Entry Conditions Yield (%) 
1 300 W, diphenyl ether, BMIMPF6, 250 °C, 30 min trace 
2 200 W, diphenyl ether, BMIMPF6, 240 °C, 20 min 27 
3 185 W, diphenyl ether, BMIMPF6, 232 °C, 30 min 41 
4 182 W, diphenyl ether, BMIMPF6, maleic anhydride,  
240 °C, 50 min 
68 
5 182 W, diphenyl ether, BMIMPF6, 240 °C, 50 min 85 
 
In a single instance, maleic anhydride was used to trap the released 
cyclopentadiene and hence facilitate driving the retro-Diels–Alder reaction to 
completion, but without reaching better results (entry 4). Eventually optimal 
conditions were reached (entry 5): tosylate 8, dissolved in diphenyl ether, was heated 
in the presence of six drops of BMIMIPF6 in an open vessel and irradiated at 182 W 
for 50 min (temperature of the vessel was 240 °C) to give the tosylate 9 in 85% yield. 
Having established a relatively fast and reliable microwave protocol, we now have 
been able to scale up the production of this potentially important trifluoromethylated 
allylating agent to multigram scale. 
 
2.3 SYNTHESIS OF THE FLUORIDE-CONTAINING ALLYLATING AGENT 
 
In order to introduce a fluoroacrylate moiety, we relied on the acid fluoride 
12, which had been described previously in literature (Scheme 3).3 
This sequence commences with 2,2,3,3-tetrafluoropropanol (10), which upon 
elimination of HF, followed by acid-mediated isomerization can be transformed into 
the desired acylating agent 12. 
 
F
FOH
F F
F
F MeLi
10
OH
F
F
11 (91%)
F
H2SO4
12 (49%)
O
 
Scheme 3. Synthesis of 2-fluoro-acryloyl fluoride. 
 
Besides a reagent with which a fluoracrylate moiety can be introduced, we 
also investigated the synthesis of a new fluoroallylating reagent as an alternative to 
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buying commercially available but rather expensive 1-chloro-2-fluoro -2-propene. 
The new fluoroallylating reagent could be accessible via reduction of 2-fluoroacryloyl 
fluoride (12) into 2-fluoro-2-propenol. However, since direct reductive methods in 
our hands failed to convert acyl fluoride 12 into 2-fluoro-2-propenol and inspired by 
the successful synthesis of compound 915 we envisioned that temporary masking of 
the double bond might also solve this problem (Scheme 4). 
 
110 ºC,  16  h
F
CO2Ph
CO2Ph
F
+
14a 14b
40% (ca. 2:1)
LiAlH4
Et2O, rt
F
F
O
12
PhOH,
DMAP
CH2Cl2
F
OPh
O
13
CH2Cl2
CH2OH
H
CH2OH
F
15 17 16
O
NaBH4
Et2O, rt
 
Scheme 4. Attempted synthesis of 2-fluoro-2-propenol. 
 
Thus esterification of 12 (DMAP, phenol, dry CH2Cl2), followed by Diels–
Alder reaction with cyclopentadiene (in CH2Cl2, at 110 °C in a sealed glass vial for 10 
h), provided the adduct 14 as a 2:1 mixture of endo- and exo-products in 40% yield.16 
Unexpectedly, however, reductive methods (e.g. LiAlH4, NaBH4) failed to produce 
the intended product 17, which was planned to undergo the retro-Diels–Alder 
reaction. The failure may be due to intramolecular displacement of the fluoride by 
the generated alkoxide to form an epoxide. Proof for such a mechanism was obtained 
from the reaction of 14 with NaBH4, where we were indeed able to isolate small 
amounts of the epoxide 16. While using the stronger reducing agent LiAlH4, the same 
reaction may occur, followed by hydride-mediated opening of the epoxide to form 
the alcohol 15. More definite proof for loss of the fluoride was obtained via tosylation 
of 15 (TsCl, pyridine, rt), followed by retro-Diels–Alder reaction with the FVT 
technique (oven temperature 600 °C, 0.04 mbar), which only yielded tosylated allyl 
alcohol. A series of other reducing agents applied under a variety of conditions (e.g. 
same reagents at lower temperatures, use of DIBALH at low temperatures) also 
failed to give the target compound 17, and generally showed loss of the fluoride 
substituent. Finally, we decided to abandon this approach, and to use instead 
commercially available 2-fluoro-1-chloro-2-propene. 
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2.4 PROOF OF PRINCIPLE 
 
In order to probe the viability of the concept of vinyl fluoride metathesis, we 
initially conducted several experiments involving vinyl chloride precursors (Table 4). 
Despite some early reports of the Grubbs group describing unsuccessful attempts 
involving vinyl halides with the first generation catalyst (Grubbs-I, see Chapter 1),17 
we anticipated that better results might be obtained with the second generation 
catalyst Grubbs-II. Indeed, the vinyl chloride precursors 18 and 19 readily ring-
closed to the corresponding cycloalkenes 23 and 24 in good yields using the Grubbs-
II catalyst in toluene at 100 °C for the indicated time (Table 4). Use of the 
Grubbs/Hoveyda-II catalyst under the same conditions gave approximately the same 
results. Encouraged by the vinyl chloride cyclizations, we commenced with the 
synthesis of the vinyl fluoride-containing precursor 20. In the same time Brown 
group and Haufe group were also working on the same target and in their paper 
published respectively on Organic Letters18 and on Tetrahedron Letters19, they show 
that this precursor subjected to the RCM did not precede to form the corresponding 
unsaturated five member ring (entries 3), however; Brown’s group has been able to 
provide the six- and seven-membered products using Grubbs-II in dichlorometane at 
reflux temperature for the indicated time (entry 4,5). 
 
Table 4. RCM of vinyl chloride- and vinyl fluoride-containing olefins. 
Entry    Precursor Cat (mol %) Time (h) Product (yield) 
 
 
 
1 
 
EtO2C CO2Et
Cl
 
18 
 
 
 
12 
 
 
 
120 
 
 
 
23 (68%) 
 
 
 
2 
 
N
Cl
Bz  
19 
 
 
 
15 
 
 
 
72 
 
 
 
24 (51%) 
 
 
 
3 
4 
5 
 
EtO2C CO2Et
F
n
 
20: n = 1 
21: n = 2 
22: n = 3 
 
 
 
10 
10 
10 
 
 
 
4 
4 
4 
 
 
 
25: n = 1 (0%)19 
26: n = 2 (73%)18 
27: n = 3 (77%)18 
N
Cl
Bz
EtO2C CO2Et
Cl
EtO2C CO2Et
F
n
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These results it appeared that beside the difficulties in synthesizing the five member 
ring, clearly show the viability of using RCM as a suitable way to incorporate 
fluoride substituents in ring systems. It also strengthened our confidence that this 
strategy could be more widely applied to synthesize different kinds of heterocyclic 
building blocks with potential biological activity. 
In addition to the vinyl fluoride metathesis, we focused on incorporation of 
trifluoromethyl substituents in cyclic systems in a similar manner. Having reliable 
access to tosylate 9, a set of RCM precursors 28–31 was prepared via well-established 
procedures (Table 5). The malonate and malononitriles 28–31 were prepared via 
consecutive alkylation of commercially available malonic esters and cyanides with 
allyl bromide and tosylate 9 under standard conditions.  
The malonates 28 and 29 and malononitriles 30 and 31 (entries 1–4) gave 
facile cyclization to the corresponding cyclopentenes in moderate to good yields 
under the previously optimized conditions (Grubbs-II catalyst, added in portions 
during the reaction, toluene, 100 °C). The cyanides gave partial decomposition under 
these reaction conditions so that different temperatures were tried, of which 
precursor 31 gave the best result at 55 °C. Thus, it has been shown that also 
trifluoromethyl-substituted olefins readily cyclize to the corresponding cyclic olefins. 
Again, this strategy might well represent a broadly applicable pathway leading to 
potentially biologically active compounds. 
 
Table 5. RCM of trifluoromethyl-substituted olefins. 
Entry Precursor Cat (mol %) Time (h) Product (yield) 
 
 
 
1 
2 
 
 
 
28: R = R1 = Et 
29: R = tBu, R1 = Me 
 
 
 
4 
7 
 
 
 
4 
2 
 
 
 
32: R = R1 = Et (88%) 
33: R = tBu, R1 = Me (45%) 
 
 
 
3 
4 
 
 
 
30: R = CO2Me 
31: R = CN 
 
 
 
3 
15 
 
 
 
4 
24 
 
 
 
34: R = CO2Me (52%) 
35: R = CN (42%)a 
a The reaction was conducted at 55 °C 
 
RO2C CO2R
1
F3C
RO2C CO2R
1
F3C
R C
F3C
N R C
F3C
N
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2.5 CONCLUSION 
 
In conclusion, in search of efficient transformations to incorporate fluoride and 
trifluoromethyl substituents in (hetero)cyclic systems, we have achieved several 
items. First of all, a novel, reliable and efficient method has been developed for the 
synthesis of 2-trifluoromethyl-2-propenol and the corresponding tosylate, which is a 
strategic synthon for incorporating trifluoromethyl-substituted olefins into various 
systems. Secondly, the viability of RCM on olefins bearing trifluoromethyl and 
fluoride substituents has been successfully demonstrated via the synthesis of a series 
of trifluoromethyl- and fluoride-substituted cyclopentenes. 
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2.7 EXPERIMENTAL SECTION 
 
General Information: All reactions were carried out under an atmosphere of dry 
nitrogen. Solvents were distilled from the appropriate drying agents immediately 
prior to use. Infrared (IR) spectra were recorded on an ATI Mattson Genesis Series 
FTIR spectrometer and absorptions are reported in cm–1. NMR spectra were recorded 
using a Bruker DMX300 (300 MHz) spectrometer from CDCl3 solutions (unless 
otherwise reported) using TMS as internal standard. Mass spectra and accurate mass 
measurements were carried out using a Fisons (VG) Micromass 7070E or a Finnigan 
MAT900S instrument. Rf values were obtained using thin layer chromatography 
(TLC) on silica gel-coated plates (Merck silica gel 60 F254) with the indicated solvent 
(mixture). Flash chromatography was performed with Acros Organics silica gel 
(0.035–0.070 nm). Melting points were determined with a Büchi melting point B-545 
apparatus. The microwave reactions were carried out in a monomode CEM Discover 
microwave. 
 
2-Trifluoromethylbicyclo[2.2.1]hept-5-ene-2-carboxylic acid (5):7 
Cyclopentadiene (30 mL, 42.8 mmol) was added dropwise in 30 min to 
a solution of 2-(trifluoromethyl)acrylic acid (5.01 g, 35.7 mmol) in 
CH2Cl2 (20 mL) at 0–5 °C. The mixture was stirred overnight at rt; then 
CH2Cl2 and the excess of cyclopentadiene were removed under 
reduced pressure to give 5 (7.13 g, 97%) after recrystallization (CHCl3/heptane 15:6) 
in a 2:1 mixture of endo/exo-diastereoisomers as a white solid. Mp: 84.4–85.4 °C; IR 
(neat, cm–1): 3155, 2890, 2922, 2904, 1707, 1407, 1282, 1246, 1155, 1120, 1070;1H NMR 
(300 MHz, CDCl3, both diastereoisomers) δ = 11.1 (br s, 1H, CO2H), 6.34–6.29 (m, 1H, 
CF3
CO2H
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CH=CH), 6.11–6.03 (m, 1H, CH=CH), 3.48 + 3.38 (br s, 1H, CF3CCH), 2.98 (br s, 1H, 
CF3CCH2CH), 2.04 (br s, 2H, CF3CCH2), 1.77 (d, J = 9.3 Hz, 1H, CH2bridge), 1.52–1.54 (m, 
1H, CH2bridge); 13C NMR (100 MHz, CDCl3, two diastereoisomers) δ = 176.4 + 175.1, 
140.7 + 140.2, 134.9 + 132.3, 126.3 + 125.7 (both q, J = 285 Hz, CF3), 60.3 (q, J = 33.0 Hz, 
CCF3), 49.8 + 48.6, 47.8 + 47.7, 42.7 + 41.9, 32.3 + 32.2; HRMS (EI) calcd for C9H9O2F3 
(M+) 206.0555, found 206.0554. 
 
2-Trifluoromethylbicyclo[2.2.1]hept-5-ene-2-carboxylic acid methyl ester (6):4  
A solution of 5 (646 mg, 3.13 mmol) in dry acetone (5 mL), dimethyl 
sulfate (0.38 mL, 4 mmol) and K2CO3 (554 mg, 4 mmol) was refluxed 
for 5 h. The solution was then decantated and the acetone layer was 
evaporated to give the crude product 6 (685 mg, 99%, 2:1 mixture of 
endo/exo-isomers) as a light brown oil. IR (neat, cm–1): 2902, 2848, 1741, 
1265, 1149, 1047, 1101; 1H NMR (300 MHz, CDCl3, both diastereoisomers) δ = 6.31–
6.25 (m, 1H, CH=CH), 6.04–5.97 (m, 1H, CH=CH), 3.69 (s, 3H), 3.44 + 3.36 (br s, 1H, 
CF3CCH), 2.96 (s, 1H, CF3CCH2CH), 2.04–2.08 (m, 2H, CF3CCH2), 1.77 + 1.74 (br s, 1H, 
CH2bridge), 1.47 + 1.45 (br s, 1H, CH2bridge); 13C NMR (75 MHz, CDCl3, both 
diastereoisomers) δ = 170.1 + 169.5, 140.2 + 134.5, 139.8 + 132.1, 126.3 + 125.8 (both q, J 
= 279.7 Hz, CF3), 59.8 (q, J = 21.8 Hz, CCF3), 58.7, 53.4 + 52.9, 48.6 + 47.8 (both q, J = 1.5 
Hz, CHCCF3), 42.7 + 42.0, 32.8 + 32.6; HRMS (EI) calcd for C10H11F3O2 (M+) 220.0711, 
found 220.0711. 
 
2-Trifluoromethylbicyclo[2.2.1]hept-5-ene-2-methanol (7):4  
A solution of 6 (776 mg, 3.52 mmol) in anhydrous Et2O (6 mL) was 
added to a suspension of LiAlH4 (134 mg, 3.52 mmol) in anhydrous 
Et2O (6 mL) over 30 min at rt and the reaction was stirred for 5 h. 
EtOAc (8 mL) was added slowly, followed by saturated aqueous 
Na2SO4 (a few drops) and solid Na2SO4. After stirring for a few min, 
the mixture was filtrated. The solvent was evaporated and the crude product 7 (554.2 
mg, 82%) was obtained as a white solid (2:1 mixture of endo/exo-isomers). Mp = 52.7 
°C; IR (neat, cm–1): 3261, 2979, 2892, 1379, 1246, 1197, 1032, 1144; 1H NMR (300 MHz, 
CDCl3, both diastereoisomers) δ = 6.25–6.02 (m, 2H, CH=CH), 3.99–3.92 + 3.83-3.77 (m, 
2H, CH2OH), 3.32-3.24 + 3.20-3.11 (m, 1H, CF3CCH), 3.07-3.03 + 2.94-2.88 (m, 1H, 
CF3CCH2CH), 1.88-1.77 (m, 2H, CF3CCH2), 1.48-1.36 (m, 2H, CH2bridge); 13C NMR (75 
MHz, CDCl3, both diastereoisomers, the quaternary carbons were not visible) δ = 
138.4 + 138.1, 135.5 + 133.5, 130.1 (q, J = 280.3 Hz, CF3), 66.9 + 66.0 (q, J = 1.5 Hz, 
CH2OH), 47.9 + 45.7 (q, J = 1.4 Hz, CbridgeCF3), 42.7 + 41.9, 32.1 + 31.3, 30.0; HRMS (EI) 
calcd for C9H11F3O (M+) 192.0762, found 192.0766. 
 
Toluene-4-sulfonic acid 2-trifluoromethylbicyclo[2.2.1]hept-5-en-2-ylmethyl ester 
(8):20 
A solution of 7 (127 mg, 0.66 mmol) and p-toluenesulfonyl chloride 
(136 mg, 0.71 mmol) in dry pyridine (0.63 mL) was kept at room 
temperature for 24 h. The reaction mixture was poured into chilled 
hydrochloric acid (2 mL) and extracted with ether (3 × 5 ml). The extract was washed 
with dilute hydrochloric acid (5 mL), aqueous sodium bicarbonate (5 mL), saturated 
aqueous sodium chloride (5 mL) and dried with MgSO4. After removal of the 
CF3
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solvent, the crude product 8 (210 mg, 92%) was obtained as a white solid. Mp = 50.8 
ºC; IR (neat, cm–1): 3066, 2985, 1365, 1176, 980, 831, 725; 1H NMR (300 MHz, CDCl3, 
both diastereoisomers) δ = 7.78-7.72 (m, 2H, ArH), 7.34-7.31 (m, 2H, ArH), 6.23-6.19 
(m, 1 H, CF3CCCH=CH), 6.09-6.06 + 6.01-5.98 (m, 1H, CF3CCCH=CH), 4.28, 4.12 (AB 
system of one isomer, J = 12.0 Hz), 4.09, 4.01 (AB system of other isomer, J = 12.0 Hz), 
3.14 + 3.10 (br s, 1H, CF3CCH), 2.91 (br s, 1H, CF3CCH2CH), 2.44 (s, 3H, CH3), 1.93-
1.75 (m, 2H, CF3CCH2), 1.49-1.43 (m, 2H, CH2bridge); 13C NMR (75 MHz, CDCl3, both 
diastereoisomers) δ = 144.9 + 144.8, 138.8 + 138.6, 134.9 + 133.0, 132.5 + 130.2, 129.8, 
127.9, 127.4 (q, J = 280.3 Hz, CF3), 71.6 + 71.2 (q, J = 1.5 Hz, CH2CCF3), 52.0-51.5 (m, 
CCF3), 47.8 + 47.5, 46.0 + 45.9, 42.7 + 42.1, 32.7, 31.6, 22.0; HRMS (EI) calcd for C16H17 
F3O3S (M+) 346.0851, found 346.0849. 
 
Toluene-4-sulfonic acid 2-trifluoromethylallyl ester (9) via FVT:  
Compound 8 (410 mg, 1.19 mmol) was introduced in the flash vacuum 
thermolysis (FVT) instrument under the following conditions: 
temperature of the first oven was 120 ºC, temperature of the second oven was 600 °C, 
pressure of 0.04 mbar for 4 h. The ester 9 (314 mg, 95%) was obtained as a colorless 
oil. IR (neat, cm–1): 3118, 3068, 3041, 2962, 1598, 1369, 1176,1132, 1176, 972, 841, 777; 1H 
NMR (200 MHz, CDCl3) δ = 7.77 (d, J = 8.5 Hz, 2H, ArH), 7.34 (d, J = 7.8 Hz, 2H, ArH), 
5.89 (br s, 1H, CH=CCF3), 5.73 (d, J = 1.2 Hz, 1H, CH=CCF3), 4.62 (s, 2H, CH2O), 2.45 
(s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 145.3, 132.4, 131.9 (q, J= 31.0 Hz CCF3), 
129.9, 127.9, 123.5 (q, J = 5.1 Hz, CH2=CCF3), 122.1 (q, J = 270.8 Hz, CF3), 65.6, 21.9; 
HRMS (EI) calcd for C11H11 F3O3S (M+) 280.0381 found 280.0375. 
 
Toluene-4-sulfonic acid 2-trifluoromethylallyl ester (9) in diphenyl ether:  
Compound 8 (1.01 g, 2.89 mmol) in Ph2O (25 mL) was heated in a flask 
at 250 °C with a sand bath and equipped with a reflux condenser for 8 h. 
The Ph2O was then removed using column chromatography (heptane) and the 
product was separated from impurities (heptane/EtOAc 10:1 to 3:1) to give 9 (600 mg, 
82%) as a colorless oil.  
 
Toluene-4-sulfonic acid 2-trifluoromethylallyl ester (9) using a microwave:  
A mixture of ester 8 (1.01 g, 2.89 mmol) and 1-butyl-3-
methylimidazolium hexafluorophosphate (six drops) in Ph2O (25 mL) 
was heated in a resealable vial in a microwave for 50 min at 240 °C and 182 W. The 
Ph2O was then removed using column chromatography (heptane) and the product 
was separated from impurities (heptane/EtOAc 10:1 to 3:1) to give 9 (687 mg, 85%) as 
a colorless oil.  
 
2-Fluorobicyclo[2.2.1]hept-5-ene-2-carboxylic acid phenyl ester (14): 
 To a solution of 2-fluoroacryloyl fluoride21 (12, 300 mg, 3.26 mmol) 
and N,N-dimethylaminopyridine (DMAP, 398 mg, 3.26 mmol) in dry 
CH2Cl2 (80 mL) was added phenol (307 mg, 3.26 mmol). The reaction 
was stirred at room temperature until it was complete (TLC). To this 
crude reaction mixture was added cyclopentadiene (4.5 mL, 6.52 mmol) in CH2Cl2 (80 
mL) at 110 °C in a sealed glass vial for 10 h. After the mixture was cooled to room 
temperature, CH2Cl2 and the excess of cyclopentadiene were removed under reduced 
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pressure and the residue was purified by column chromatography (heptane/EtOAc 
6:1) to give 14 (413 mg, 40%) as a colorless oil (2:1 mixture of endo/exo-isomers). 1H 
NMR (300 MHz, CDCl3, both diastereoisomers) δ = 6.52–6.38 (m, 1H, CH=CH), 6.17–
6.02 (m, 1 H, CH=CH), 3.39–3.20 (m, 1H, CFCCH), 3.04–2.97 (m, 1H, CFCCH2CH), 
2.58–1.51 (m, 4H, CF3CCH2, CH2bridge); 13C NMR (75 MHz, CDCl3, two 
diastereoisomers) δ = 171.06 (d, J = 29.3 Hz, C=OCF) + 168.5 (d, J = 28.1 Hz, C=OCF), 
150.4, 142.1 + 140.3, 132.3 + 130.9, 129.4, 126.1, 121.3, 101.1 (d, J = 196.1 Hz, CF), 52.07, 
49.8 + 48.6, 48.8 , 42.5 + 41.6, 40.6 + 40.3. 
 
Bicyclo[2.2.1]-5-heptene-2-yl methanol (15) and subsequent Flash Vacuum 
Thermolysis:  
A solution of 14 (413 mg, 1.28 mmol) in anhydrous diethyl ether (1 mL) 
was added to a suspension of LiAlH4 (48.5 mg, 1.28 mmol) in 
anhydrous diethyl ether (1 mL) over 30 min at room temperature and 
the reaction was stirred for 5 h. EtOAc (1 mL) was added slowly, followed by 
saturated aqueous Na2SO4 (a few drops) and solid Na2SO4. After stirring for a few 
min, the mixture was filtrated. The solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 6:1) to give 15 (133 mg, 73%) 
as a colorless oil (2:1 mixture of endo/exo-isomers). 1H NMR (300 MHz, CDCl3, both 
diastereoisomers) δ = 6.13–5.92 (m, 2H, CH=CH), 3.72–3.49 + 3.41–3.21 (m, 2H, 
CH2OH), 2.92–2.80 (m, 2H, C=CCH, C=CCH), 1.85–1.56 (m, 2H, C=CCHCH2), 1.48–
1.36 (m, 2H, CH2bridge). This product was directly subjected to the tosylation reaction. 
Solution of 14 (133 mg, 094 mmol) and tosyl chloride (193 mg, 1.012 mmol) in dry 
pyridine (0.8 mL) was stirred at room temperature for 24 h. The reaction mixture was 
poured into cold 1N HCl and extracted with diethyl ether. The extract was washed 
with dilute aqueous HCl, aqueous NaHCO3, brine and dried (MgSO4). After 
evaporation of the solvent, the corresponding tosylate (216 mg, 77%) was obtained as 
a yellow oil. Subjection of the tosylate (148 mg, 0.5 mmol) to flash vacuum 
thermolysis (600 °C, 0.04 mbar) provided allyl tosylate (102 mg, 79%) as a colorless 
oil. 1H NMR (400 MHz, THF-d8) δ = 7.78 (d, J = 8.5 Hz, 2H, ArH), 7.40 (d, J = 8.2 Hz, 
2H, ArH), 5.87–5.78 (m, 1H, H2C=CH), 5.29 (d, J = 17.2 Hz, 1H, CH=CH), 5.18 (d, J = 
11.5 Hz, 1H, CH=CH), 4.49 (d, J = 5.8 Hz, 2H, CH2O), 2.42 (s, 3H, CH3). 
 
Epoxide (16):  
To a solution of 14 (300 mg, 1.29 mmol) in MeOH (2 mL), at 0 °C, NaBH4 
(59 mg, 1.55 mmol) was added in small portions. The reaction mixture was 
stirred for 3 h, quenched with saturated aqueous NaHCO3 (2 mL) and 
extracted with ether (3 × 2 mL). The combined organic layers were washed 
with saturated aqueous NaHCO3 and brine, dried (MgSO4) and evaporated. The 
residue was purified using column chromatography (heptane/EtOAc 10:1) to give 16 
(19 mg, 12%) as a colorless oil. This product also contained several other minor 
impurities. 1H NMR (200 MHz, CDCl3,) δ = 6.37–6.33 (m, 1H, CH=CH), 6.05–6.02 (m, 1 
H, CH=CH), 3.88–3.70 (m, 3H, CH2O, COCH), 3.05 (br s, 1H, COCH2CH), 2.81 (br s, 
2H, COCH2), 1.58-1.51 (m, 2H, CH2bridge). GC-LRMS calcd for C8H10O (M+) 122, found 
122. 
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2-Allyl-2-(2-chloroallyl)malonic acid diethyl ester (18):22  
To a suspension of NaH (363 mg, 12.1 mmol) in THF (30 mL) at 0 °C 
was added dropwise diethyl allyl malonate (2.37 mL, 12.0 mmol). The 
cooling bath was removed and the mixture stirred at room 
temperature until the evolution of hydrogen had ceased. After recooling the mixture 
to 0 °C, 2,3-dichloro-1-propene (1.11 mL, 12.0 mmol) was added dropwise and 
stirring was continued at room temperature until the reaction was complete. THF 
was removed and the residue was taken up in ether (15 mL). It was washed with 
saturated aqueous NaCl (10 mL) and NaHCO3 (10 mL) and the aqueous layer was 
reextracted with ether (3 × 15 mL). The combined organic layers were dried over 
MgSO4. After removal of the solvent the residue was purified using column 
chromatography (heptane/EtOAc 6:1 to 3:1) to give 18 (986 mg, 30%) as a colorless 
oil. IR (neat, cm–1): 2979, 2924, 2852, 1734, 1443, 1365, 1286, 1219, 1153, 1097; 1H NMR 
(200 MHz, CDCl3) δ = 5.73-5.59 (m, 1H, H2C=CH), 5.32 (s, 1H, ClC=CH ), 5.23 (s, 1H, 
ClC=CH), 5.16-5.10 (m, 2H, H2C=CH ), 4.23-4.12 (m, 4H, 2 × CH2CH3), 3.04 (s, 2H, 
ClCCH2), 2.77 (dd, J = 7.4, 0.9 Hz, 2H, H2C=CHCH2), 1.26 (t, J = 7.3 Hz, 6H, 2 × 
CH2CH3); 13C NMR (75 MHz, CDCl3) δ = 170.0, 137.2, 132.1, 119.5, 117.3, 61.8, 56.8, 
42.4, 36.4, 14.4; HRMS calcd for C13H19O4Cl (M+) 274.0972, found, 274.0970. 
 
N-Allyl-N-(2-chloroallyl)benzamide (19):23,24  
To a stirred solution of allyl-(2-chloroallyl)amine (655 mg, 5.00 mmol) 
and triethylamine (0.84 mL, 6.0 mmol) in CH2Cl2 (13 mL) was added 
benzoyl chloride (0.58 mL, 5.0 mmol) at 0 °C. The reaction mixture was 
stirred for 12 h at room temperature and quenched with saturated 
aqueous NH4Cl (10 mL). The aqueous layer was then extracted with 
CH2Cl2 (3 × 10 mL) and dried over MgSO4. After removal of the solvent the residue 
was purified using column chromatography (heptane/EtOAc 6:1) to give 19 (1.01 g, 
86%) as a colorless oil. IR (neat, cm–1): 3084, 3053, 2980, 1965, 1636, 1411, 1290,1260, 
988, 923, 789, 703; 1H NMR (300 MHz, CDCl3) δ = 7.43-7.36 (m, 5H, ArH), 5.96-5.58 
(m, 1H, H2C=CH), 5.40 (d, J = 0.7 Hz, 1H, ClC=CH), 5,35 (d, J = 0.7 Hz, 1H, ClC=CH), 
5.27-5.11 (m, 2H, H2C=CH), 4.34-3.89 (m, 4H, ClCCH2 + HCCH2); 13C NMR (75 MHz, 
CDCl3, some signals appear as rotamers) δ = 171.7, 137.2, 135.6, 132.5, 129.8, 128.4, 
126.5, 118.2, 114.3, 54.16 + 51.20, 49.64 + 47.06; HRMS calcd for C13H14NOCl (M+) 
235.0764, found 235.0760. 
 
General procedure for the RCM reactions 
To a 0.01 M solution of the diene in dry toluene under an inert atmosphere, Grubbs-II 
catalyst was added at 100 °C. Stirring was continued until the reaction was complete 
(indicated by TLC or GC), followed by concentration of the reaction mixture and 
subsequent purification with column chromatography. 
 
3-Chlorocyclopent-3-ene-1,1-dicarboxylic acid diethyl ester (23):  
To a solution of 18 (100 mg, 0.36 mmol) in dry toluene (40 mL) 
Grubbs–II (12 mol%) was added at 100 °C in small portions. The 
reaction was complete in 120 h. The solvent was evaporated and the 
residue purified using column chromatography (heptane/EtOAc 10:1) to give 23 (61 
mg, 68%) as a colorless oil. IR (neat, cm–1): 2954, 2927, 2871, 1730, 1365, 1269, 1246, 
EtO2C CO2Et
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1184, 1145, 1066, 1020; 1H NMR (300 MHz, CDCl3,) δ = 5.56-5.53 (m, 1H, ClC=CH), 
4.21 (q, J = 7.2 Hz, 4H, 2 × CH2CH3), 3.17 (dd, J = 2.2, 4.2 Hz, 2H, ClCCH2), 3.03 (dd, J = 
2.4, 4.7 Hz, 2H, HCCH2), 1.26 (t, J = 6.9 Hz, 6H, 2 × CH2CH3); 13C NMR (75 MHz, 
CDCl3) δ = 169.2, 134.9, 123.4, 56.6, 54.3, 42.6, 39.7, 14.4; HRMS calcd for C11H15O4Cl 
(M+) 246.0659 found, found 246.0660. 
 
N-Benzoyl-3-chloro-2,5-dihydropyrrole (24):  
To a solution of 19 (100 mg, 0.43 mmol) in dry toluene (40 mL) Grubbs-II 
(15 mol%) was added at 100 °C in small portions. The reaction was 
complete in 72 h. The solvent was evaporated and the residue purified 
using column chromatography (heptane/EtOAc 6:1) to give 24 (45 mg, 
51%) as a colorless oil. IR (neat, cm–1): 3053, 2922, 2859, 2245, 1647, 1627, 
1405, 1325, 1072,787, 750; 1H NMR (300 MHz, CDCl3, some signals appear as 
rotamers) δ = 7.48-7.41 (m, 5H, ArH), 5.85 + 5.68 (br s 1H, ClC=CH), 4.46 + 4.22 (br s, 
4H, ClCCH2 + HCCH2); 13C NMR (75 MHz, CDCl3, some signals appear as rotamers) 
δ = 169.6 + 169.5, 135.7, 135.4, 130.2, 129.3, 128.4, 126.7, 57.9 + 55.7, 55.6 + 55.1; HRMS 
calcd for C11H10NOCl (M+) 209.0421, found 209.0422. 
 
2-Allyl-2-(2-trifluoromethylallyl)malonic acid diethyl ester (28):22 
 To a suspension of NaH (9.6 mg, 0.4 mmol) in THF (2 mL) at 0 °C 
was added dropwise diethyl allyl malonate (59.2 µl, 0.3 mmol). The 
cooling bath was removed and the mixture stirred at room 
temperature until the evolution of hydrogen ceased. After recooling the mixture to 0 
°C, compound 9 (84 mg, 0.3 mmol) was added dropwise and stirring was continued 
at room temperature until the reaction was complete. THF was removed and the 
residue was taken up in ether (3 mL) and in saturated solution of NaCl (3 mL) and 
NaHCO3 (3 mL), the ether layer was separated and the aqueous layer was extracted 
with ether (3 × 5 mL). The combined organic layers were dried over MgSO4. After 
removal of the solvent the residue was purified using column chromatography 
(heptane/EtOAc 10:1) to give 28 (67 mg, 73%) as a colorless oil. IR (neat, cm–1): 2983, 
2937, 1734, 1444, 1367, 1290, 1219, 1172, 1126; 1H NMR (200 MHz, CDCl3) δ = 5.84 (d, J 
= 1.3 Hz, 1H, CF3C=CH), 5.77-5.56 (m, 1H, CH2=CH), 5.45 (d, J = 1.3 Hz, 1H, 
CF3C=CH), 5.17-5.06 (m, 2H, H2C=CH), 4.20 (q, J = 7.2 Hz, 2H, CH2CH3), 4.19 (q, J = 7.2 
Hz, 2H, CH2CH3), 2.88 (br s, 2H, CF3CCH2), 2.71 (dt, J = 7.3, 1.1 Hz, 2H, H2C=CHCH2), 
1.25 (t, J = 7.0 Hz, 6H, 2 × CH2CH3); 13C NMR (75 MHz, CDCl3): δ = 170.0, 133.7 (q, J = 
59.4 Hz, CCF3), 131.8, 123.2 (q J = 268.3, CF3), 121.8, 119.5, 61.8, 57.0, 36.9, 31.4 14.30; 
HRMS calcd for C14H19F3O4 (M+) 308.1235, found 308.1232. 
 
2-Allyl-2-(2-trifluoromethylallyl)malonic acid tert-butyl ester methyl ester (29):  
To a suspension of NaH (71 mg, 2.96 mmol) in THF (8 mL) at 0 °C 
was added dropwise tert-butyl methyl malonate (0.48 mL mg, 2.87 
mmol). The cooling bath was removed and the mixture stirred at 
room temperature until the evolution of hydrogen had ceased. After 
recooling the mixture to 0 °C, 3-bromo-2-propene (0.3x mL, 2.87 mmol) was added 
dropwise and stirring was continued at room temperature until the reaction was 
complete. THF was removed and the residue was taken up in ether (8 mL) and 
washed with saturated aqueous NaCl (8 mL) and NaHCO3 (8 mL). The aqueous layer 
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was reextracted with ether (3 × 8 mL) and the combined organic layers were dried 
over MgSO4. After removal of the solvent the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 2-allyl-malonic acid tert-butyl ester 
methyl ester (263 mg, 43%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ = 5.80-5.71 
(m, 1H, CH2=CH), 5.13-5.01 (m, 2H, CH2=CH), 3.72 (s, 3H, CH3), 3.34 (t, J = 15 Hz, 1H, 
C=OCH), 2.59 (t, J = 7.5 Hz, 2H, H2C=CHCH2), 1.45 (s, 9H, tert-Bu). Using the 
procedure as described above, 2-allyl-malonic acid tert-butyl ester methyl ester (51.8 
mg, 0.24 mmol) was added dropwise to a suspension of NaH (11.5 mg, 0.48 mmol) in 
THF (2 mL) at 0 °C. The mixture was stirred at room temperature for 15 min and 
cooled again to 0 °C, compound 9 (68 mg, 0.24 mmol) was added dropwise and 
stirring was continued at room temperature until the reaction was complete. THF 
was removed and the residue was taken up in ether (3 mL) and washed with 
aqueous saturated NaCl (3 mL) and NaHCO3 (3 mL). The aqueous layer was 
reextracted with ether (3 × 5 mL). The combined organic layers were dried over 
MgSO4, concentrated and the residue was purified using column chromatography 
(heptane/EtOAc 6:1) to give 29 (66 mg, 86%) as a yellow oil. IR (neat, cm–1): 2980, 
2923, 1731, 1636, 1441, 1372, 1152, 1140; 1H NMR (400 MHz, CDCl3) δ = 5.8 (d, J = 1.0 
Hz, 1H, CF3C=CH), 5.71-5.57 (m, 1H, CH2=CH), 5.44 (d, J = 1.2 Hz, 1H, CF3C=CH), 
5.13 (d, J = 1.2 Hz, 1H, CH2=CH), 5.09-5.05 (m, 1H, CH2=CH), 3.70 (s, 3H, CH3), 2.83 
(br s, 2H, CF3CCH2), 2.71 (d, J = 7.5 Hz, 2H, H2C=CHCH2), 1.43 (s, 9H, tert-Bu); 13C 
NMR (100 MHz, CDCl3) δ = 171.2, 169.2, 134.1 (q, J = 22.3 Hz, CCF3), 132.2, 123.1 (q, J = 
246.0 Hz, CF3), 119.6, 119.5, 82.6, 57.4, 52.5, 36.7, 31.1, 27.9; HRMS calcd for C11H13F3O4 
(M+) 266.0766, found 266.0766. 
 
2-Allyl-2-cyano-4-trifluoromethyl-4-pentenoic acid methyl ester (30): 
 To a suspension of NaH (142 mg, 5.91 mmol) in THF (16 mL) at 0 °C 
was added dropwise methyl cyanoacetate (0.51 mL, 5.74 mmol). The 
cooling bath was removed and the mixture stirred at room temperature 
until the evolution of hydrogen had ceased. After recooling the mixture to 0 °C, 3-
bromo-2-propene (0.5 mL, 5.74 mmol) was added dropwise and stirring was 
continued at room temperature until the reaction was complete. THF was removed 
and the residue was taken up in ether (18 mL) and washed with saturated aqueous 
NaCl (10 mL) and NaHCO3 (10 mL), the ether layer was separated and the aqueous 
layer was extracted with ether (3 × 10 mL). The combined organic layers were dried 
over MgSO4. After removal of the solvent the residue was purified using column 
chromatography (heptane/EtOAc 10:1 to 6:1) to give 2-cyano-pent-4-enoic acid 
methyl ester (239 mg, 30%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ = 5.81-5.76 
(m, 1H, CH2=CH), 5.28-5.21 (m, 2H, CH2=CH), 3.81 (s, 3H, CH3), 3.57 (t, J = 7.2 Hz, 1H, 
HCCN), 2.71-2.66 (m, 2H, CH2=CHCH2). Using the same procedure previously 
described, the 2-cyano-pent-4-enoic acid methyl ester (111 mg, 0.80 mmol) was 
added dropwise to a suspension of NaH (23 mg, 0.96 mmol) in THF (3 mL) at 0 °C. 
The cooling bath was removed and the mixture stirred at room temperature until the 
evolution of hydrogen ceased. After recooling the mixture to 0 °C, compound 9 (245 
mg, 0.87 mmol) was added dropwise and stirring was continued at room 
temperature until the reaction was complete. THF was removed and the residue was 
taken up in ether (3 mL) and in saturated solution of NaCl (3 mL) and NaHCO3 (3 
mL), the ether layer was separated and the aqueous layer was extracted with ether (3 
MeO2C
F3C
CN
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× 5 mL). The combined organic layers were dried over MgSO4. After removal of the 
solvent the residue was purified using column chromatography (heptane/EtOAc 6:1) 
to give 30 (138 mg, 70%) as a yellow oil. IR (neat, cm–1): 2954, 2928, 2850, 2225, 1753, 
1630, 1450, 1312, 1230, 1178, 1122; 1H NMR (300 MHz, CDCl3) δ = 5.95 (s, 1H, 
CF3C=CH), 5.81-5.67 (m, 1H, CH2=CH), 5.71 (s, 1H, CF3C=CH), 5.21-5.15 (m, 2H, 
CH2=CH), 3.78 (s, 3H, CH3), 2.83-2.49 (m, 4H, CF3CCH2 + HCCH2); 13C NMR (75 MHz, 
CDCl3) δ = 167.7, 132.3 (q, J = 30.7 Hz, CCF3), 129.6, 125.4 (q, J = 247.6 Hz, CF3), 123.0, 
121.62, 117.52, 53.7, 48.9, 42.6, 35.3; HRMS calcd for C11H13NO2F3 (M + H)+ 248.0898, 
found 248.0888.  
 
2-Allyl-2-(2-trifluoromethylallyl)malononitrile (31):25 
 To a suspension of NaH (34 mg, 1.42 mmol) in THF (4 mL) at 0 °C was 
added dropwise 2-allyl-malonitrile (75.7 mg, 0.71 mmol). The cooling bath 
was removed and the mixture stirred at room temperature until the 
evolution of hydrogen ceased. After recooling the mixture to 0 °C, 
compound 9 (200 mg, 0.71 mmol) was added dropwise and stirring was continued at 
room temperature until the reaction was complete. THF was removed and the 
residue was taken up in ether (4 mL) and washed with saturated aqueous NaCl (4 
mL) and NaHCO3 (4 mL), the ether layer was separated and the aqueous layer was 
extracted with ether (3 × 5 mL). The combined organic layers were dried over MgSO4. 
After removal of the solvent the residue was purified using column chromatography 
(heptane/EtOAc 6:1) to give 31 (137 mg, 91%) as a colorless oil. IR (neat, cm–1): 2984, 
2924, 1597, 1428, 1368, 1325, 1174, 1126; 1H NMR (200 MHz, CDCl3) δ = 6.16 (t, J = 1.4 
Hz, 1H, CF3C=CH), 6.03-5.82 (m, 1H, CH2=CH), 5.99-5.97 (m, 1H, CF3C=CH), 5.51-5.40 
(m, 2H, H2C=CH), 2.83-2.76 (m, 4H, CF3CCH2 + H2C=CHCH2); 13C NMR (75 MHz, 
CDCl3): δ = 130.86 (q, J = 31.3 Hz, CCF3),129.9, 127.8,125.1(q, J = 5.5 Hz, CH2CF3), 123.9, 
122.4 (q J = 270.8, CF3), 42.3, 36.9, 35.5; HRMS calcd for C10H9N2F3 (M+) 214.0718, 
found 214.0723. 
 
3-Trifluoromethylcyclopent-3-ene-1,1-dicarboxylic acid diethyl ester (32): 
 To a solution of 28 (65 mg, 0.21 mmol) in dry toluene (26 mL) Grubbs-
II (4 mol%) was added at 100 °C in small portions. The reaction was 
complete in 4 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 6:1) to give 32 
(52 mg, 88%) as a colorless oil. IR (neat, cm–1): 2985, 2939,1733, 1671, 1446, 1367, 1276, 
1253, 1159, 1122, 1037; 1H NMR (300 MHz, CDCl3) δ = 6.14-6.12 (m, 1H, CF3C=CH), 
4.20 (q, J = 7.2 Hz, 4H, 2 × CH2CH3), 3.18-3.14 (m, 4H, CF3CH2 + HCCH2), 1.26 (t, J = 
7.3, 6H, 2 × CH2CH3); 13C NMR (75 MHz, CDCl3) δ = 170.6, 132.1, 130.7 (q, J = 33.6 Hz, 
CCF3), 121.8 (q, J = 266.8 Hz, CF3), 62.2, 59.1, 40.6, 38.2, 14.3; HRMS calcd for 
C12H15F3O4 (M+) 280.0923, found 280.0918.  
 
3-Trifluoromethylcyclopent-3-ene-1,1-dicarboxylic acid tert-butyl ester methyl 
ester (33):  
To a solution of 29 (60 mg, 0.186 mmol) in dry toluene (24 mL) 
Grubbs-II (7 mol%) was added at 100 °C in small portions. The 
reaction was complete in 2 h. The mixture was evaporated and the 
product was purified using column chromatography (heptane/EtOAc 10:1 to 6:1) to 
CO2EtEtO2C
CF3
CO2CH3
CF3
t-BuO2C
F3C
CNNC
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give 33 (25 mg, 45%) as a colorless oil. IR (neat, cm–1): 2958, 2923, 1734, 1675, 1437, 
1372, 1277, 1259, 1151, 1121, 1035; 1H NMR (300 MHz, CDCl3) δ = 6.13-6.11 (m, 1H, 
CF3C=CH), 3.75 (s, 3H, CH3), 3.14-3.09 (m, 4H, CF3CCH2 + HCCH2), 1.44 (s, 9H, tert-
Bu); 13C NMR (75 MHz, CDCl3) δ = 171.5, 159.6, 132.1, 130.6 (q, J = 33.2 Hz, CCF3), 
121.8 (q, J = 266.8 Hz, CF3), 82.6, 59.8, 53.1, 40.5, 38.1, 28.1; HRMS calcd for C13H17F3O4 
(M+) 294.1079, found 294.1081. 
 
1-Cyano-3-trifluoromethylcyclopent-3-enecarboxylic acid methyl ester (34): 
 To a solution of 30 (133 mg, 0.538 mmol) in dry toluene (40 mL) 
Grubbs-II (3 mol%) was added at 100 °C in small portions. The reaction 
was complete in 4 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1 to 6:1) to give 34 (61 
mg, 52%) as a colorless oil. IR (neat, cm–1): 2963, 2920, 2850, 2250, 1748, 1675, 1437, 
1368, 1281, 1230, 1161, 1117, 1022; 1H NMR (300 MHz, CDCl3) δ = 6.25-6.22 (m, 1H, 
CF3C=CH), 3.87 (s, 3H, CH3), 3.36-3.15 (m, 4H, CF3CCH2 + HCCH2); 13C NMR (75 
MHz, CDCl3) δ = 168.0, 131.5 (q, J = 3.5 Hz, C=CCF3), 130.6 (q, J = 34.5 Hz, CCF3), 
127.8, 121.1 (q, J = 263.6 Hz, CF3), 54.4, 45.61, 43.5, 41.1; HRMS calcd for C9H8NO2F3 
(M+) 219.0507, found 219.0505. 
 
3-Trifluoromethycyclopent-3-ene-1,1-dicarbonitrile (35):  
To a solution of 31 (145 mg, 0.68 mmol) in dry toluene (58 mL) Grubbs-II 
(15 mol%) was added at 55 °C in small portions. The reaction was 
complete in 24 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 6:1) to give 35 
(53 mg, 42%) as a colorless oil. IR (neat, cm–1): 2963, 2924, 2855, 1674, 1595, 1372, 1256, 
1182, 1122, 11014; 1H NMR (300 MHz, CDCl3) δ = 6.33 (s, 1H, CF3C=CH), 3.38 (brs, 4H, 
CF3CH2 + HCCH2); 13C NMR (75 MHz, CDCl3) δ = 131.2 (q, J = 31.1 Hz, CCF3), 125.9 (q, 
J = 291.6 Hz, CF3), 123.47 (q, J = 4.9 Hz, CF3C=CH), 115.3, 42.7 (q, J = 2.3 Hz, CF3CCH2), 
42.4, 41.9; HRMS calcd for C8H6F3N2 (M+) 187.0483, found 187.0481.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CO2CH3
CF3
NC
CN
CF3
NC
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CHAPTER 3 
RING-CLOSING METATHESIS-MEDIATED SYNTHESIS OF 
TRIFLUOROMETHYL-CONTAINING NITROGEN HETEROCYCLES 
 
 
 
Keywords: Trifluoromethyl-substituted diolefins / Ring-closing metathesis / 
Trifluoromethyl-containing nitrogen heterocycles 
 
 
Abstract٭ 
A ring-closing metathesis mediated pathway to trifluoromethyl-containing 
piperidines is detailed. This pathway commences with the synthesis of a series of 
trifluoromethyl-substituted diolefins using a newly developed (trifluoromethyl) 
allylating agent, followed by successful cyclization using Ring-Closing Metathesis to 
provide the corresponding functionalized piperidines. 
 
 
 
 
 
 
 
 
 
٭ V. De Matteis, F. L. van Delft, H. Jacobi, S. Lindell, J. Tiebes, F. P. J. T. Rutjes, “RCM-
Mediated synthesis of trifluoromethyl-containing nitrogen heterocycles”, J. Org. Chem. 2006, 
71, 7527–7532. 
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3.1 INTRODUCTION 
 
The growing interest of the pharmaceutical industry in biologically active 
trifluoromethyl-containing compounds is refletted nowadays by the many 
trifluoromethylated products on the market such as analgesics, cardiovascular, 
respiratory, psychopharmacologic, neurological and gastrointestinal drugs, but also 
anti-infective therapeutics.1 Some particular examples of important trifluoromethyl-
containing drugs are collected in Chart 1. 
 
O
HO
HO
N
HN
O
CF3
O
1: trifluridine
(antiviral)
N
H
O
Cl
O
F3C
2: efavirenz
(antiviral)
N
N
F3C
Me
S
3: celebrex
(anti-inflammatory)
NH2
O O
 
Chart 1. Trifluoromethylated heterocycles. 
 
Trifluridine (1)2 and efavirenz (2)3 are both antiviral drugs, and celebrex (3)1 is 
an anti-inflammatory drug. Another example is shown in Chart 2.  
 
7: fludelone6: desoxyepothilone B
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Me OH
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Me OH
Me
Me
Me
OH
Me
R
O
O
4: R = H epothilone A
5: R = CH3 epothilone B  
Chart 2. Epothilones A and B, desoxyepothilone B and trifluoromethyl analogue fludelone. 
 
Desoxyepothilone B (6) is a promising anticancer drug, currently evaluated in 
clinical trials, which has been synthesized by the Danishefsky group as a derivative 
of the natural product epothilone B (5).4 Thousands of derivatives of the naturally 
occurring epothilones A (4) and B (5) have been synthesized, of which more recently 
a new promising candidate emerged, which is in clinical trials at the moment. This 
new epothilone derivative, a trifluoromethyl-substituted derivative of 6, called 
RCM to CF3-containing nitrogen heterocycles 
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fludelone (7), shows an extremely high therapeutic efficacy against various 
carcinomas, thus again showing the beneficial effect of the fluorinated substituent.5 
Considering the general biological relevance of trifluoromethyl-containing 
heterocycles, combined with the difficulty of introducing trifluoromethyl 
substituents in non-aromatic ring systems,6 we started to investigate whether Ring-
Closing Metathesis (RCM) could serve as a potential approach to synthesize 
trifluoromethyl-substituted heterocyclic building blocks.7 Retrosynthetically, we 
envisaged that trifluoromethylated olefins (viz. 8, Scheme 1) might serve as suitable 
precursors for the preparation of the corresponding ring systems 10 using Ru-
carbene type RCM catalysts. Such an approach would be easily applicable starting 
from the allylating reagent 9, which was described in Section 2.2.1. 
 
F3C
X
10
X
CF3
8
RCM
X = NR, O
CF3
OTs
9
 
Scheme 1. Retrosynthetic approach. 
 
Nowadays, owing to the emergence of relatively stable, tolerant and versatile 
Ru-carbene catalysts8, the applicability of RCM processes is well-established.9 As a 
result, a wide range of differently substituted olefins have been successfully 
transformed into the corresponding (hetero)cyclic systems. Only relatively few 
examples of olefins with allylic fluoride substituents exist,10,11 which are all examples 
of mono-substituted olefins. We now describe the first examples of disubstituted 
trifluoromethyl-containing olefins,12 including the functionalization to heavily 
functionalized nitrogen heterocyclic systems. 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
40 
3.2 SYNTHESIS OF THE TRIFLUOROMETHYL-CONTAINING NITROGEN 
HETEROCYCLES 
 
Having reliable access to tosylate 9, a preliminary investigation was 
performed to synthesize trifluoromethyl-containing heterocyclic building blocks (12) 
via RCM of olefins of type 11 (Scheme 2). 
 
X
F3C
(  )n
X
F3C
(  )n
X = NR, O
RCM
11 12  
Scheme 2. RCM approach to trifluoromethylated heterocyclic systems. 
 
The RCM precursors 13-18 were prepared following well-established 
procedures and have been subjected to the RCM reaction using catalyst Grubbs-II 
added in portions to the reaction mixture in toluene at 100 °C for the indicated time 
(Table 1).  
 
Table 1. RCM examples of trifluoromethyl-substituted olefins to heterocyclic systems. 
Entry Precursor Cat (mol %) Time (h) Product (yield) 
 
 
 
1 
2 
 
 
 
13 X = CF3, Y = H (77%) 
14 X = CH3, Y = CF3 (99%) 
 
 
 
3 
7 
 
 
 
72 
4 
 
 
 
19 X = CF3, Y = H (0%) 
20 X = CH3, Y = CF3 (0%) 
 
 
 
3 
4 
 
 
 
15 R = Bz (34%) 
16 R = Boc (63%) 
 
 
 
10 
10 
 
 
 
24 
2 
 
 
 
21 R = Bz (68%) 
22 R = Boc (97%) 
 
 
 
5 
 
 
 
17 (47%) 
 
 
 
7 
 
 
 
48 
 
 
 
23 (0%) 
 
 
6 
 
 
18 (99%) 
 
 
5 
 
 
24 
 
 
24 (78%) 
N
X
Bn
O
Y
N
X
Bn
O
Y
N
F3C
R N
F3C
R
N
F3C
Bn
O
F3C
Ph
O
F3C
Ph
N
F3C
Bn
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The precursors were prepared via acylation of the amine (13, reaction with 
the acid chloride derived from 2-trifluoromethylacrylic acid),13 or by alkylation of the 
corresponding amine or alcohol with tosylate 9 (precursors 14-18); involving either 
the amine, Et3N, Et2O, room temperature overnight (for 14 and 15), NaH, acylating 
agent, rt, DMF (for 16 and 17) or the alcohol, NaH, acylating agent, rt, THF (for 18). 
Unfortunately, both acrylamides 13 and 14 did not produce any cyclized 
product (entries 1 and 2). Probably, in these cases both olefins become too electron 
deficient for the RCM reaction to take place. In contrast, the diolefins 15 and 16 – 
bearing an acyl group at the nitrogen – readily cyclized to the desired pyrrolidines 21 
and 22 in good yields, 68% and 97%, respectively, using Grubbs-II, which was added 
in portions to the reaction mixture in toluene, at 100 °C (entries 3 and 4). An attempt 
to cyclize 17 to the corresponding tetrahydropyridine 23 failed, which may well be 
due to the presence of the basic amine functionality (entry 5). Gratifyingly, the ether 
precursor 18 underwent facile cyclization under identical conditions to give the 
trifluoromethyl-substituted dihydrofuran 24 in good yield (entry 6).This preliminary 
study gave us an initial idea of the viability of these types of metathesis reactions, 
and we set out to explore its possibilities for generating potentially biologically active 
heterocyclic compounds of type 26 (Scheme 3). 
 
N
PG
R
F3C RCM
N
PG
R
F3C CF3
OTs
R = Ar, CO2Me, CO2tert-Bu, CONHCH2Ar
PG = Boc, CO2Me, SO2Ar
26 25 9
 
Scheme 3. RCM approach to trifluoromethylated heterocyclic compounds. 
 
A set of precursor molecules 29-33 was prepared via a one-pot three-
component reaction,14 followed by standard introduction of the trifluoromethyl-
containing side chain (Scheme 4).  
 
RO NH2
O
27: R = Me
28: R = tert-Bu
R1CHO
allylSiMe3
BF3·OEt2
CH2Cl2
0 °C to rt
HN R1
CO2R
NaH, then 9
DMF, rt
N R1
CO2R
F3C
29-33 34-38  
Scheme 4. Synthesis of precursor molecules prepared via a one-pot three-component 
reaction. 
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All compounds 29-33 were prepared starting from carbamates 27 and 28, and reacted 
in the presence of BF3·OEt2 with allyltrimethylsilane and the appropriate aldehyde to 
give the three-component reaction products in moderate to reasonable yields (Table 
2). 
 
Table 2. Yields of the RCM precursors. 
Entry 3-CR Product (yield) Alkylation product (yield) 
 
 
 
1 
2 
 
 
 
29 R = Me (50%) 
30 R = tert-Bu (22%) 
 
 
 
34 R = Me (56%) 
35 R = tert-Bu (62%) 
 
 
 
3 
 
 
 
31 (68%) 
 
 
 
36 (60%) 
 
 
 
 
4 
HN
MeO2C
Cl
Cl  
32 (51%) 
N
MeO2C
F3C
Cl
Cl  
37 (70%) 
 
 
 
5 
 
 
 
33 (30%) 
 
 
 
38 (46%) 
 
Especially the low yield (22%) in case of the tert-butyl protected amine 30 
might be due to partial decomposition of the acid labile carbamate under the mildly 
acidic conditions. The yield of compound 33 was also low, which might be attributed 
to the instability of the methoxy-substituted aldehyde under these conditions. Next, 
the products 29-33 were alkylated with tosylate 9 (1 equiv, NaH, DMF, rt), which 
proceeded uneventfully to produce the metathesis precursors 34-38 in moderated to 
reasonable yields. 
Precursor molecules 34 and 35 were then subjected to the previously 
described RCM conditions (Grubbs-II, toluene) at a somewhat lower temperature of 
80 °C to prevent decomposition from taking place. This led to the corresponding 
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N
MeO2C
Cl
Cl
F3C
trifluoromethyl-substituted cyclic building blocks 39 and 40 in good to excellent yield 
(Table 3). 
 
Table 3. RCM results. 
Entry Precursor Cat (mol %) Time 
(min) 
Product (yield) 
 
 
 
 
1 
 
 
34 
 
 
 
 
4 
 
 
 
 
60 
 
 
 
 
39 (80%) 
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N
Boc
F
F3C
 
35 
 
 
 
4 
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40 (99%) 
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36 
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41(63%)a 
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42(79%)a 
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N
ArSO2
H
N
O
F3C
Cl  
38 
 
 
 
5 
 
 
 
40 
 
43(80%)a 
a The reaction was conducted in a microwave. 
 
To investigate whether the reaction times could be decreased, cyclizations of 
compounds 36-38 were performed in a microwave oven at 80 °C and 300 W (entries 
3–5). As shown in the Table 3, the reaction times indeed were decreased to only 30 
min, while the yields were largely comparable to those in the first two entries. 
Confident by these successful cyclizations, a different set of RCM precursors 
46-49 was prepared (Scheme 5). 
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H2N CO2H
ArSO2Cl
base
CH2Cl2
N
SO2 O
H
N
Ar1
44
HN
SO2 O
X
51-54
F3C
MeO MeO
ClCl
45: X = OH (80%)
46-49: X = NHCH2Ar
1a
b
 
Reagents and conditions: (a) EDCI, HOBT, ArCH2NH2, CH2Cl2, 2 h, rt; (b) NaH, DMF, 
then compound 9, 12 h, rt. 
Scheme 5. Synthesis of precursor molecules 51-54. 
 
Table 4. Yields of RCM precursors 51-54. 
Entry Sulfonamide (yield) Amide (yield) 
 
 
 
1 
 
 
 
46 (76%) 
 
 
 
51 (45%) 
 
 
 
2 
 
 
 
47 (99%) 
 
 
 
52 (44%) 
 
 
 
3 
 
 
 
48 (87%) 
 
 
 
53 (60%) 
 
 
 
4 
 
 
 
49 (99%) 
 
 
 
54 (47%) 
 
The reaction sequence commenced with straightforward nitrogen protection 
of allylglycine (44) with 5-chloro-2-methoxybenzenesulfonyl chloride (Et3N, CH2Cl2, 
1 h, rt) to afford the acid 45 in 80% yield. The acid 45 was then coupled to four 
different benzylic amines under standard peptide coupling conditions (EDCI, HOBt, 
CH2Cl2, rt), which also proceeded smoothly to afford the amides 46-49. Finally, the 
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trifluoromethylallyl substituent was introduced via coupling with 9 (NaH, DMF, 12 
h, rt) leading to RCM precursors 51-54. This step appeared to be somewhat more 
problematic as is shown by the moderate yields, which is probably due to the fact 
that there is an amide function present in the molecule. This might lead to some side 
reactions, or loss of the base and therefore incomplete conversion (Table 4).  
 
Table 5. RCM results. 
Entry Precursor Time (min) Product (yield) 
 
 
 
1 
 
 
 
50 (61%) 
 
 
 
30 
 
 
 
55 (67%) 
 
 
 
2 
 
 
 
51a 
 
 
 
60 
 
 
 
56 (70%)a 
 
 
 
3 
 
 
 
52a 
 
 
 
30 
 
 
 
57(98%)a 
 
 
 
4 
 
 
 
53a 
 
 
 
60 
 
 
 
58(70%)a 
 
 
 
5 
 
 
 
54a 
 
 
 
60 
 
 
 
59(90%)a 
a Ar = 4-Cl-2-MeOC6H3 
Precursor 50 was prepared from Boc-protected allylglycine methyl ester15 in a 
similar alkylation with 9 as described above in 61% yield (Table 5). Upon subjection 
of 50 to similar RCM conditions, this time in toluene at 100 °C, with Grubbs-II added 
in portions to the reaction mixture, RCM product 55 was obtained in a satisfactory 
yield of 67% (entry 1). Precursors 51-54 were subjected to identical conditions and 
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readily proceeded to provide the trifluoromethylated heterocycles 56-59 in good to 
excellent yields.  
Considering the versatility of this approach and the generally good yields in the 
cyclization processes, this pathway can be applied to generate appreciable amounts 
of material for biological testing. 
 
3.3 CONCLUSION 
 
In summary, a detailed account is provided on investigations toward an 
RCM-mediated pathway leading to trifluoromethyl-substituted heterocycles. This 
involves the application of a new (trifluoromethyl)allylating reagent in the synthesis 
of a series of RCM precursors and the successful cyclization of these precursor 
molecules to the corresponding nitrogen heterocycles. Thus, we have clearly 
established that RCM represents a viable pathway to this class of biologically 
relevant fluorinated piperidines.  
 
3.4 EXPERIMENTAL SECTION 
 
N-Allyl-N-benzyl-2-trifluoromethylacrylamide (13):13, 16  
N-benzylbut-3-en-1-amine (111 mg, 0.75 mmol) was added dropwise 
to a solution of the acid chloride derived from 2-trifluoromethyl 
acrylic acid (210 mg, 0.75 mmol) in Et2O (2 mL) at 0 °C. The reaction 
mixture was stirred at room temperature overnight, concentrated and 
the residue was purified using column chromatography (heptane/EtOAc 10:1) to give 
product 13 (156 mg, 77%) as a white solid. 1H NMR (300 MHz) δ = 7.30-7.22 (m, 5H, 
ArH), 6.04 (s, 1H, CF3C=CH), 5.81 (s, 1H, CF3C=CH), 5.80-5.74 (m, 1H, H2C=CH), 5.25-
5.17 (m, 2H, H2C=CH), 4.59-4.58 (m, 2H, CH2Ph), 3.90-3.86 (m, 2H, NCH2CH). 
 
N-Benzyl–N-(2-trifluoromethylallyl)acrylamide (14):  
Compound 9 (72 mg, 0.26 mmol) was added dropwise to a solution of 
benzylamine (147 mg, 1.37 mmol) and Et3N (46 µL, 0.3 mmol) in Et2O 
(2 mL) at room temperature. The reaction mixture was stirred 
overnight, concentrated and the residue was purified using column 
chromatography (heptane/EtOAc 3:1) to give N-benzyl-2-(trifluoromethyl)prop-2-en-
1-amine (28 mg, 52%) as a colorless oil. 1H NMR (300 MHz) δ = 7.29 (s, 5H, ArH), 5.78 
(s, 1H, CF3C=CH), 5.60 (s, 1H, CF3C=CH), 3.78 (s, 2H, CH2Ph), 3.41 (s, 2H, 
NCH2CCF3),1.62 (br s, 1H, NH); 13C NMR (75 MHz, CDCl3, signals of the CCF3 carbon 
are not visible): δ = 139.6, 128.4, 128.1, 127.1, 123.5 (q, J = 271 Hz, CF3), 118.8, 52.9, 47.5. 
To a solution of N-benzyl-2-(trifluoromethyl)prop-2-en-1-amine (28 mg, 0.13 mmol) 
and Et3N (20 µL, 0.13 mmol) in Et2O (2 mL) at room temperature was added slowly 
methacryloyl chloride (13 µL, 0.13 mmol). After stirring for 12 h, the residue was 
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concentrated to give the crude product 14 (37 mg, 99%) as a colorless oil. The crude 
product was used for the RCM reaction without further purification. 1H NMR (300 
MHz) δ = 7.33-7.17 (m, 5H, ArH), 5.87 (s, 1H, CF3C=CH), 5.42 (s, 1H, CF3C=CH), 5.19 
(s, 1H, HC=CCH3), 5.09 (s, 1H, HC=CCH3), 4.60 (s, 2H, CH2Ph), 4.10 (s, 2H, 
NCH2CCF3), 1.99 (s, 3H, CH3). 
 
N-Allyl-N-(2-trifluoromethylallyl)benzamide (15): 
 To a suspension of NaH (26 mg, 1.06 mmol) in DMF (2 mL) was 
added at rt N-allylbenzamide17 (86 mg, 0.53 mmol). After stirring 
for 15 min, compound 9 (150 mg, 0.53 mmol) was added dropwise. 
The reaction was stirred for 12 h, quenched with water (2 mL) and 
extracted with Et2O (3 × 2 mL). The ether layers were dried (MgSO4), evaporated and 
the residue was purified using column chromatography (heptane/EtOAc 10:1) to give 
15 (48 mg, 34%) as a colorless oil. IR (neat, cm–1): 3040, 2963, 2902, 1731, 1630, 1412, 
1264, 1091, 1027, 802, 620; 1H NMR (300 MHz) δ = 7.45-7.24 (s, 5H, ArH), 5.89 (s, 1H, 
CF3C=CH), 5.78-5.58 (m, 1H, H2C=CH), 5.53 (s, 1H, CF3C=CH), 5.26-5.15 (m, 2H, 
H2C=CH), 4.32-3.85 (m, 4H, CF3CCH2 + CHCH2); 13C NMR (75 MHz, CDCl3, the 
quaternary carbons are not visible due to rotamers) δ = 171.9, 135.4, 132.3 (br s), 129.9, 
128.4, 126.4, 118.4, 99.2, 51.4, 42.9; HRMS (EI) calcd for C14H14F3NO (M+) 269.1028, 
found 269.1022. 
 
N-Allyl-N-(2-trifluoromethylallyl)carbamic acid tert-butyl ester (16):  
To a suspension of NaH (56 mg, 2.32 mmol) in DMF (4 mL) was 
added at rt N-Boc-allylamide18 (182 mg, 1.16 mmol). After stirring for 
15 min, compound 9 (326 mg, 1.16 mmol) was added dropwise. The 
reaction was stirred for 12 h, quenched with water (4 mL) and 
extracted with Et2O (3 × 4 mL). The ether layers were dried (MgSO4), evaporated and 
the residue was purified using column chromatography (heptane/EtOAc 10:1) to give 
16 (193 mg, 63%) as a colorless oil. IR (neat, cm–1): 2976, 2928, 1705, 1549, 1459, 1407, 
1368, 1325, 1251, 1174, 1126, 927, 871, 772; 1H NMR (300 MHz) δ = 5.82-5.68 (m, 1H, 
H2C=CH), 5.76 (s, 1H, CF3C=CH), 5.37 (s, 1H, CF3C=CH), 5.19-5.08 (m, 2H, H2C=CH), 
4.07-3.77 (m, 4H, CF3CCH2 + CHCH2), 1.44 (s, 9H, 3 CH3); 13C NMR (75 MHz, CDCl3, 
some signals appear as rotamers) δ = 154.9, 124.9, 123.1 (q, J = 270 Hz, CF3), 121.3, 
118.4-116.8 (m, CF3C=CH), 80.5, 49.6 + 49.1, 45.0, 28.5; HRMS (EI) calcd for 
C11H15F3NO2 (M – Me)+ 250.1055, found 250.1057. 
 
Benzylbut-3-enyl-(2-trifluoromethylallyl)amine (17): 
Compound 9 (137.2 mg, 0.49 mmol) was added dropwise to a 
solution of N-benzylbut-3-en-1-amine19 (80 mg, 0.49 mmol) and 
Et3N (68 µL, 0.49 mmol) in Et2O (1 mL). The reaction mixture was 
stirred at room temperature overnight, filtrated and concentrated to 
give product 17 (59 mg, 47%) as a yellow oil. The crude product was used for the 
RCM reaction without further purification. 1H NMR (300 MHz) δ = 7.29-7.23 (m, 5H, 
ArH), 5.78-5.67 (m, 3 H, H2C=CH, CF3C=CH2), 5.02-5.96 (m, 2H, H2C=CH), 3.58 (s, 2H, 
CH2Ph), 3.16 (s, 2H, NCH2CCF3), 2.51-2.48 (m, 2H, NCH2), 2.25-2.22 (m, 2H, 
NCH2CH2). 
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[1-(2-Trifluoromethylallyloxy)allyl]benzene (18):  
To a suspension of NaH (26 mg, 1.06 mmol) in THF (2 mL) was 
added at rt 1-phenylprop-2-en-1-ol17 (71.0 mg, 0.53 mmol). After 
stirring for 15 min, compound 9 (150 mg, 0.53 mmol) was added 
dropwise. The reaction was stirred for 12 h, quenched with water (2 mL) and 
extracted with Et2O (3 × 2 mL). The ether layers were dried (MgSO4), evaporated and 
the residue was purified using column chromatography (heptane/EtOAc 10:1) to give 
18 (127 mg, 99%) as a colorless oil. IR (neat, cm–1): 3084, 3058, 3023, 2924, 2850, 1454, 
1325, 1174, 1130, 1083, 1174, 1130, 932, 798, 746, 694; 1H NMR (300 MHz, CDCl3) δ = 
7.32-7.23 (m, 5H, ArH), 5.97-5.86 (m, 1H, CH2=CH), 5.80 (br d, J = 1.4 Hz, 1H, 
CF3C=CH), 5.71 (br d, J = 1.4 Hz, 1H, CF3C=CH), 5.31-5.20 (m, 2H, CH2=CH), 4.79 (br 
d, J = 6.6 Hz, 1H, OCH), 4.14-4.08 (m, 2H, OCH2); 13C NMR (75 MHz, CDCl3, the 
quaternary carbon was not visible) δ = 140.1, 138.1, 128.5, 127.8, 126.7, 122.9 (q, J = 
270.8 Hz, CF3), 119.4, 116.8, 82.8, 64.8; HRMS calcd for C13H13OF3 (M+) 242.0919 found 
242.0908. 
 
General procedure for the RCM reactions 
To a 0.01 M solution of the diolefin in dry toluene under an inert atmosphere, 
Grubbs-II was added at the indicated temperature. Stirring was continued until the 
reaction was complete (indicated by TLC or GC), followed by concentration of the 
reaction mixture and subsequent purification with column chromatography. 
 
N-Benzoyl-3-trifluoromethyl-2,5-dihydropyrrole (21): 
To a solution of 15 (45 mg, 0.167 mmol) in dry toluene (20 mL) Grubbs-II (10 
mol%) was added at 100 °C in small portions. The reaction was complete in 
24 h. The mixture was evaporated and the product was purified using 
column chromatography (heptane/EtOAc 6:1) to give 21 (28 mg, 68%) as a 
yellow solid. Mp: 89-92 °C; IR (neat, cm–1): 3058, 2919, 2867, 1713, 1632,1385, 1303, 
1269, 1165, 1122, 1043, 789, 694, 672; 1H NMR (300 MHz, CDCl3, some signals appear 
as rotamers) δ = 7.52-7.42 (m, 5H, ArH), 6.44 + 6.26 (d, J = 1.8 Hz, 1H, CF3C=CH), 4.61 
+ 4.36 (br s, 4H, CF3CCH2 + HCCH2 13C NMR (75 MHz, CDCl3, some signals appear as 
rotamers, the signal CCF3 is not visible) δ = 170.3 + 169.9, 131.6, (q, J = 180 Hz, CF3), 
130.4 +130.3, 130.1 + 129.0 (q, J = 4.9 Hz, CCCF3), 128.6 + 128.5, 126.8 + 126.8, 122.2, 
56.0 + 53.3, 53.8 + 51.3; HRMS (EI) calcd for C12H10F3NO (M+) 241.0715, found, 
241.0714. 
 
3-Trifluoromethyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester (22): 
To a solution of ester 16 (100 mg, 0.377 mmol) in dry toluene (40 mL) 
Grubbs-II (10 mol%) was added at 100 °C in small portions. The reaction 
was complete in 2 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 22 
(87 mg, 97%) as a brown oil. IR (neat, cm–1): 3058, 2919, 2867, 1713, 1632,1385, 1303, 
1269, 1165, 1122, 1043, 789, 694, 672; 1H NMR (300 MHz, CDCl3, some signals appear 
as rotamers) δ = 6.32 + 6.27 (br s, 1H, CF3C=CH), 4.26 (br s, 4H, CF3CCH2 + HCCH2), 
1.47 (s, 9H, (CH3)3); 13C NMR (75 MHz, CDCl3, some signals appear as rotamers) δ = 
153.7, 130.1-129.7 (m), 129.3 (q, J = 35.1 Hz, CCF3), 122.8 (q, J = 263.9 Hz, CF3), 80.5 + 
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80.4, 53.4 + 53.2, 50.8 + 50.6, 28.6; HRMS (EI) calcd for C10H14F3NO2 (M+) 237.0977, 
found, 237.0978. 
 
2-Phenyl-4-trifluoromethyl-2,5-dihydrofuran (24): 
To a solution of 18 (68 mg, 0.28 mmol) in dry toluene (25 mL) Grubbs-
II (5 mol%) was added at 100 °C in small portions. The reaction was 
complete in 24 h. The mixture was evaporated and the product was 
purified using column chromatography (n-pentane/Et2O from 20:0 to 
20:1) to give 24 (47 mg, 78%) as a colorless oil. IR (neat, cm–1): 3092, 3062, 3027, 2919, 
2855, 1679, 1454, 1372, 1329, 1273, 1161, 1122, 1035, 1161, 1122, 871, 802, 750, 694; 1H 
NMR (300 MHz, CDCl3) δ = 7.38-7.23 (m, 5H, ArH), 6.40-6.38 (m, 1H, CF3=CH), 5.93-
5.89 (m, 1H, PhCH), 5.01-4.80 (m, 2H, OCH2); 13C NMR (75 MHz, CDCl3, the signal 
CCF3 is not visible) δ = 139.4, 134.1 (q, J = 4.6 Hz,CCCF3), 128.7, 128.5, 126.3, 124.7 (q, J 
= 251.6 Hz, CF3), 73.0, 66.7; HRMS calcd for C11H8OF3 (M+) 213.0527 found 213.0526. 
 
1-(4-Fluorophenyl)but-3-enyl-(2-trifluoromethylallyl) carbamic acid methyl ester 
(34):14c,20  
To a solution of methyl carbamate 27 (1.01 g, 13.3 mmol) in 
CH2Cl2 (27 mL) were added at 0 °C 4-fluorobenzaldehyde (1.43 
mL, 13.3 mmol), BF3·OEt2 (1.68 mL, 13.32 mmol) and 
allyltrimethylsilane (1.68 mL, 13.32 mmol). The mixture was 
reacted for 3 h at room temperature, then CH2Cl2 was removed under reduced 
pressure and the product purified with column chromatography (heptane/EtOAc 6:1) 
to give methyl 1-(4-Fluorophenyl)but-3-enylcarbamate (29, 1.48 g, 50%) as a yellow 
solid. Mp: 39-41 °C; IR (neat, cm–1): 3438, 3321, 3070, 2997, 2954, 2846, 1692, 1511, 
1437, 1217, 1040, 914, 828, 772; 1H NMR (300 MHz, CDCl3): δ = 7.20 (dd, J= 6.0, 9.3 Hz, 
2H, ArH), 6.98 (dd, J= 8.7, 8.7 Hz, 2H, ArH), 5.71-5.57 (m, 1 H, CH2=CH), 5.53 (s, 1 H, 
CF3C=CH), 5.10 (d, J=17.1 Hz, 1H, H2C=CH), 5.08 (d, J=9.3 Hz, 1H, H2C=CH), 5.01 (br 
s, 1H, NH), 4.73 (br s, 1H, PhCH), 3.63 (s, 3H, CH3), 2.52-2.48 (m, 2H, H2CCH=CH2); 
13C NMR (75 MHz, CDCl3): δ = 162.0 (d, J = 243.5 Hz, CF), 156.4, 138.11, 133.7, 127.9, 
127.8, 118.6, 115.5, 115.3, 54.0, 52.2, 41.1; HRMS (EI) calcd for C12H15FNO2 (M + H) + 
224.1087, found 224.1087. To a suspension of NaH (31 mg, 1.3 mmol) in DMF (2 mL) 
was added at rt product 29 (156 mg, 0.71 mmol). After stirring for 15 min, compound 
9 (196 mg, 0.71 mmol) was added dropwise. The reaction was stirred for 12 h, 
quenched with water (2 mL) and extracted with Et2O (3 × 4 mL). The ether layers 
were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 34 (128 mg, 56%) as yellow oil. IR 
(neat, cm–1): 3084, 2950, 2933, 1705, 1610, 1511, 1394, 1321, 1230, 1161, 1113, 914, 836, 
763; 1H NMR (300 MHz, CDCl3): δ = 7.30 (dd, J= 6.0, 9.3 Hz, 2H, ArH), 6.97 (dd, J= 8.7, 
8.7 Hz, 2H, ArH), 5.77-5.64 (m, 1H, CH2=CH), 5.53 (s, 1H, CF3C=CH), 5.42 (br s, 1H, 
CF3C=CH), 5.10 (d, J= 17.1 Hz, 1H, H2C=CH), 5.09 (br, s, 1H, PhCH), 5.08 (d, J= 9.3 Hz, 
1H, H2C=CH), 3.87-3.79 (m, 2H, NCH2), 3.73 (s, 3H, CH3), 2.69 (dd, J= 6.6, 6.6 Hz, 2H, 
H2CCH=CH); 13C NMR (75 MHz, CDCl3, some signals appear as rotamers): δ = 162.1 
(d, J = 244.4 Hz, CF), 156.8, 134.5 + 134.4, 134.1, 129.9 + 129.8, 123.0 (q, J = 271.1 Hz, 
CF3), 123.4(q, J = 5.2 Hz, CCF3), 117.9, 117.6 (br s, C=CCF3), 115.4 (d, J = 21.3 Hz, CCF), 
58.7, 53.2, 41.8, 35.8; HRMS (EI) calcd for C16H17F4NO2 (M+) 331.1195, found 331.1196. 
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1-(4-Fluorophenyl)but-3-enyl-(2-trifluoromethylallyl) carbamic acid tert-butyl 
ester (35):  
To a solution of tert-butyl carbamate 28 (392 mg, 2.97 mmol) in 
CH2Cl2 (6 mL) were added at 0 C 4-fluorobenzaldehyde (0.32 
mL, 2.97 mmol), BF3·OEt2 (0.38 mL, 2.97 mmol) and 
allyltrimethylsilane (0.47 mL, 2.97 mmol). The mixture was 
reacted for 3 h at rt, then CH2Cl2 was removed under reduced pressure and the 
product purified with column chromatography (heptane/EtOAc 6:1) to give tert-
butyl  1-(4-Fluorophenyl)but-3-enylcarbamate (30, 172 mg, 22%) as a white solid. 
Mp: 89-91 °C; IR (neat, cm–1): 3425, 3352, 3071, 3002, 2976, 2928, 1697, 1511, 1359, 1251, 
1225, 1165, 1014, 919, 828; 1H NMR (300 MHz, CDCl3): δ = 7.20 (dd, J= 6.0, 9.3 Hz, 2H, 
ArH), 6.98 (dd, J= 8.7, 8.7 Hz, 2H, ArH), 5.70-5.67 (m, 1H, CH2=CH), 5.10 (d, J= 17.1 
Hz, 1H, H2C=CH), 5.08 (d, J= 9.3 Hz, 1H, H2C=CH), 4.79 (br s, 1H, NH), 4.67 (br s, 1H, 
PhCH), 2.47 (br dd, J= 6.3, 6.6, 2H, H2CCH=CH2), 1.39 (s, 9H, C(CH3)3); 13C NMR (75 
MHz, CDCl3): δ = 162.0 (d, J = 243.5 Hz, CF), 155.3, 138.6, 133.8, 127.9, 127.8, 118.6, 
115.6 (2×CH), 115.3 (2×CH), 53.5, 41.4, 28.5; HRMS (EI) calcd for C15H21FNO2 (M + H)+ 
266.1556, found 266.1555. To a suspension of NaH (31 mg, 1.3 mmol) in DMF (2 mL) 
was added at room temperature product 30 (172 mg, 0.65 mmol). After stirring for 15 
min, compound 9 (182 mg, 0.65 mmol) was added dropwise. The reaction was stirred 
for 12 h, quenched with water (2 mL) and extracted with Et2O (3 × 4 mL). The ether 
layers were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 35 (150 mg, 62%) as colorless oil. IR 
(neat, cm–1): 3071, 2976, 2933, 1697, 1601, 1506, 1398, 1316, 1234, 1161, 1122, 919, 836, 
772; 1H NMR (300 MHz, CDCl3): δ = 7.7(dd, J= 5.7, 8.4 Hz, 2H, ArH), 6.97 (dd, J= 5.7, 
8.4 Hz, 2H, ArH), 5.79-5.66 (m, 1H, CH2=CH), 5.51 (s, 1H, CF3C=CH), 5.47 (br s, 1H, 
CF3C=CH), 5.14-5.02 (m, 3H, H2C=CH, PhCH), 3.76 (br s, 2H, NCH2), 2.66 (dd, J= 7.2, 
2.7 Hz, 2H, H2CCH=CH2), 1.44 (s, 9H, C(CH3)3); 13C NMR (75 MHz, CDCl3, some 
signals appear as rotamers): δ = 162.0 (d, J = 244.1 Hz, CF), 155.3, 135.0, 134.4, 129.7 + 
129.6, 123.1 (q, J = 271.1 Hz, CF3), 119.6 (q, J = 5.5 Hz, CCF3), 117.7, 117.0 (br s, 
C=CCF3), 115.3 (d, J = 21.3 Hz, CCF), 80.7, 57.6, 41.8, 35.9, 28.5; HRMS (EI) calcd for 
C19H23F4NO2 (M+) 373.1665, found 373.1669. 
 
1-(2,4-Dichlorophenyl)but-3-enyl-(2-trifluoromethylallyl) carbamic acid methyl 
ester (36):  
To a solution of methyl carbamate 27 (360 mg, 4.8 mmol) in 
CH2Cl2 (10 mL) were added at 0 °C 2,4-dichlorobenzaldehyde 
(839 mg, 4.81 mmol), BF3·OEt2 (0.61 mL, 4.8 mmol) and 
allyltrimethylsilane (0.76 mL, 4.8 mmol). The mixture was 
reacted for 3 h at room temperature, then CH2Cl2 was removed under reduced 
pressure and the product purified with column chromatography (heptane/EtOAc 
10:1 to 6:1) to give methyl 1-(2,4-Dichlorophenyl)but-3-enylcarbamate (31, 813 mg, 
68%) as a white solid. Mp: 100-104 °C; IR (neat, cm–1): 3425, 3313, 3067, 2980, 2950, 
1692, 1532, 1467, 1264, 1100, 1040, 914, 819; 1H NMR (300 MHz, CDCl3): δ = 7.34 (s, 
1H, ArH), 7.19 (br s, 2H, ArH), 5.71-5.57 (m, 1H, CH2=CH), 5.15-5.10 (m, 4H, NH, 
H2C=CH, PhCH), 3.62 (s, 3H, CH3), 2.58-2.44 (m, 2H, H2CCH=CH2); 13C NMR (75 
MHz, CDCl3): δ = 156.2, 135.0, 133.6, 133.2, 129.8, 128.4, 127.4, 119.3, 52.4, 51.7, 39.2; 
HRMS (EI) calcd for C12H14Cl2NO2 (M + H)+ 274.0402, found 274.0389. To a 
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suspension of NaH (31 mg, 1.3 mmol) in DMF (2 mL) was added at room 
temperature product 31 (174 mg, 0.7 mmol). After stirring for 15 min, compound 9 
(196 mg, 0.7 mmol) was added dropwise. The reaction was stirred for 12 h, quenched 
with water (2 mL) and extracted with Et2O (3 × 4 mL). The ether layers were dried 
(MgSO4), evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 10:1) to give 36 (158 mg, 60%) as colorless oil. IR (neat, cm–1): 3079, 
2954, 1705, 1588, 1472, 1398, 1316, 1165, 1117, 953, 914, 819, 767; 1H NMR (300 MHz, 
CDCl3): δ = 7.36-7.20 (m, 3H, ArH), 5.77-5.61 (m, 2H, CH2=CH, CF3C=CH), 5.50 (s, 1H, 
CF3C=CH), 5.22-5.03 (m, 3H, H2C=CH, PhCH), 3,94 (d, J =17.7 Hz, 1H, NCH), 3.73 (s, 
3H, CH3), 3.7(d, J =18.0 Hz, 1H, NCH), 2.81-2.63 (m, 2H, H2CCH=CH2); 13C NMR (75 
MHz, CDCl3, some signals appear as rotamers, signals of the CCF3 carbon are not 
visible): δ = 156.6, 135.9, 134.4 + 134.2, 133.5 + 133.3, 129.7, 129.5, 127.0 + 126.9, 122.8 
(q, J = 271.1 Hz, CF3) ,118.5 + 118.3, 117.5-117.3 (m, C=CCF3), 53.5, 42.3, 36.1, 32.1; 
HRMS (EI) calcd for C16H16Cl2F3NO2 (M+) 381.051, found 381.0511. 
 
1-(3,5-Dichlorophenyl)but-3-enyl-(2-trifluoromethylallyl) carbamic acid methyl 
ester (37):  
To a solution of methyl carbamate 27 (360 mg, 4.80 mmol), in 
CH2Cl2 (10 mL) were added at 0 °C 3,5-dichlorobenzaldehyde 
(839 mg, 4.8 mmol), BF3·OEt2 (0.61 mL, 4.8 mmol) and 
allyltrimethylsilane (0.76 mL, 4.8 mmol). The mixture was 
reacted for 3 h at rt, then CH2Cl2 was removed under reduced 
pressure and the product purified with column chromatography (heptane/EtOAc 
10:1 to 6:1) to give methyl 1-(3,5-Dichlorophenyl)but-3-enylcarbamate (32, 602 mg, 
51%) as a white solid. Mp: 108-110 °C; IR (neat, cm–1): 3291, 3062, 2976, 2950, 2924, 
1684, 1528, 1264, 1191, 1053, 923, 858, 793, 685; 1H NMR (300 MHz, CDCl3): δ = 7.23 (s, 
1H, ArH), 7.14 (s, 2H, ArH), 5.70-5.57 (m, 1H, CH2=CH), 5.17-5.11 (m, 2H, H2C=CH) 
5.02 (br s, 1H, NH), 4.7 (br s, 1H, PhCH), 3.66 (s, 3H, CH3), 2.57-2.40 (m, 2H, 
H2CCH=CH2); 13C NMR (75 MHz, CDCl3): δ = 156.3, 136.9, 135.3, 132.8, 127.7, 124.9, 
119.6, 53.8, 52.5, 40.9; ; HRMS (EI) calcd for C12H14Cl2NO2 (M+H) + 274.0402, found 
274.0405. To a suspension of NaH (31 mg, 1.31 mmol) in DMF (2 mL) was added at 
room temperature product 32 (174 mg, 0.7 mmol). After stirring for 15 min, 
compound 8 (196 mg, 0.71 mmol) was added dropwise. The reaction was stirred for 
12 h, quenched with water (2 mL) and extracted with Et2O (3 × 4 mL). The ether 
layers were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 37 (186 mg, 70%) as light-yellow oil. IR 
(neat, cm–1): 3079, 2958, 1701, 1571, 1398, 1321, 1264, 1165, 1122, 919, 862, 798, 607; 1H 
NMR (300 MHz, CDCl3): δ = 7.25 (s, 1H, ArH), 7.19 (s, 2H, ArH), 5.76-5.61 (m, 2H, 
CH2=CH, CF3C=CH), 5.32 (br s, 1H, PhCH), 5.15-5.06 (m, 3H, H2C=CH, CF3C=CH), 
3.84 (d, J = 5.4 Hz, 2H, NCH2), 3.74 (s, 3H, CH3), 2.70-2.65 (m, 2H, H2CCH=CH2); 13C 
NMR (75 MHz, CDCl3): δ = 156.6, 142.3, 135.0, 133.2, 128.0, 126.6, 122.9 (q, J = 271.1 
Hz, CF3), 119.8 (q, J = 5.5 Hz, CCF3), 118.4, 118.0 (br s, C=CCF3), 58.7, 53.3, 42.3, 35.5; 
HRMS (EI) calcd for C16H16Cl2F3NO2 (M+) 381.051, found 381.0511. 
 
 
 
N
MeO2C
F3C
Cl
Cl
Chapter 3 
52 
[1-(4-Methoxyphenyl)but-3-enyl]-(2-trifluoromethylallyl) carbamic acid methyl 
ester (38):  
To a solution of methyl carbamate 27 (721 mg, 9.6 mmol), in 
CH2Cl2 (20 mL) were added at 0 °C 4-methoxybenzaldehyde 
(1.16 mL, 9.6 mmol), BF3·OEt2 (1.22 mL, 9.6 mmol) and 
allyltrimethylsilane (1.53 mL, 9.6 mmol). The mixture was 
reacted for 3 h at rt, then CH2Cl2 was removed under reduced pressure and the 
product purified with column chromatography (heptane/EtOAc 6:1) to give methyl 
1-(4-methoxyphenyl)but-3-enylcarbamate (33, 667 mg, 30%) as a yellow solid. Mp: 
82-85 °C; IR (neat, cm–1): 3326, 3075, 3002, 2945, 2902, 2829, 1697, 1506, 1455, 1243, 
1174, 1031, 914, 828; 1H NMR (300 MHz, CDCl3): δ = 7.15 (d, J = 8.4 Hz, 2H, ArH), 6.81 
(d, J = 8.7 Hz, 2H, ArH), 5.72-5.58 (m, 1H, CH2=CH), 5.24 (br s, 1H, NH), 5.09-5.02 (m, 
2H, H2C=CH), 4.70 (br s, 1H, PhCH), 3.74 (s, 3H, OCH3), 3.60 (s, 3H, PhOCH3), 2.51-
2.46 (m, 2H, H2CCH=CH2); 13C NMR (75 MHz, CDCl3): δ = 158.9, 156.4, 134.3, 134.1, 
127.5, 118.4, 114.1, 55.4, 54.1, 52.2, 41.2; HRMS (EI) calcd for C15H21FNO3 (M+H) + 
236.1287, found 236.12842. To a suspension of NaH (31 mg, 1.3 mmol) in DMF (2 mL) 
was added at room temperature product 33 (174.3 mg, 0.7 mmol). After stirring for 
15 min, compound 9 (196 mg, 0.71 mmol) was added dropwise. The reaction was 
stirred for 12 h, quenched with water (2 mL) and extracted with Et2O (3 × 4 mL). The 
ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 10:1) to give 38 (186 mg, 46%) as light-
yellow oil. IR (neat, cm–1): 3075, 3002, 2950, 2833, 1701, 1614, 1515, 1459, 1321, 1251, 
1161, 1113, 1035, 919, 828, 771; 1H NMR (300 MHz, CDCl3): δ = 7.21 (d, J = 10.8 Hz, 2H, 
ArH), 6.80 (d, J = 10.8 Hz, 2H, ArH), 5.78-5.65 (m, 1H, CH2=CH), 5.52 (s, 1H, 
CF3C=CH), 5.50 (br s, 1H, CF3C=CH), 5.12-5.05 (m, 3H, H2C=CH, PhCH), 3.78 (s, 6H, 
2CH3), 3.72 (br s, 2H, H2CN), 2.67-2.65 (m, 2H, H2CCH=CH2); 13C NMR (75 MHz, 
CDCl3, the signals of the CCF3 carbon are not visible): δ = 159.0, 134.5, 130.6, 129.3, 
127.7, 123.1 (q, J = 271.1 Hz, CF3), 117.6, 117.4, 113.8, 58.8, 55.4, 53.1, 41.6, 35.9; HRMS 
(EI) calcd for C17H20F3NO3 (M+) 343.1395, found 343.1394. 
 
2-(4-Fluorophenyl)-5-trifluoromethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 
methyl ester (39): 
 To a solution of 34 (110 mg, 0.33 mmol) in dry toluene (45 mL) 
Grubbs-II (4 mol%) was added at 80 °C in small portions. The 
reaction was complete in 60 min. The solvent was evaporated 
and the residue purified using column chromatography (heptane/EtOAc 10:1) to give 
39 (80 mg, 80%) as a colorless oil. IR (neat, cm–1): 3065, 2954, 2898, 2855, 1705, 1605, 
1515, 1446, 1316, 1247, 1156, 1113, 1022, 966, 858, 767; 1H NMR (300 MHz, CDCl3): δ = 
7.18 (dd, J= 6.0, 9.3 Hz, 2H, ArH), 6.97 (dd, J= 6.9, 8.7 Hz, 2H, ArH), 6.5 (br s, 1H, 
CF3C=CH), 5.62 (d, J= 4.2 Hz, 1H, PhCH), 4.44 (d, J = 18.0 Hz, 1H, NCH), 3.78 (s, 3H, 
CH3) 3.36 (d, J = 20 Hz, 1H, NCH), 2.85-2.64 (m, 2H, H2CCH=CCF3); 13C NMR (75 
MHz, CDCl3): δ = 161.9 (d, J = 244.1 Hz, CF), 155.7, 134.8, 128.4 (d, J = 8.0 Hz, CCHCF), 
127.5 (br s, C=CCF3), 126.2 (q, J = 31 Hz, CCF3), 122.5 (q, J = 269.1 Hz, CF3), 115.5 (d, J = 
21 Hz, CCF), 53.3, 49.9, 37.4, 27.3; HRMS(EI) calcd for C14H13F4NO2 (M+) 303.0882, 
found 303.0883. 
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2-(4-Fluorophenyl)-5-trifluoromethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 
tert-butyl ester (40):  
To a solution of 35 (83 mg, 0.22 mmol) in dry toluene (40 mL) 
Grubbs-II (4 mol%) was added at 80 °C in small portions. The 
reaction was complete in 60 min. The solvent was evaporated 
and the residue purified using column chromatography (heptane/EtOAc 6:1) to give 
40 (75 mg, 99%) as a colorless oil. IR (neat, cm–1): 3065, 2980, 2928, 1705, 1601, 1515, 
1411, 1312, 1238, 1165, 1109, 983, 849, 763; 1H NMR (300 MHz, CDCl3): δ = 7.16 (dd, J= 
6.0, 9.3 Hz, 2H, ArH), 6.97 (dd, J= 8.7, 8.7 Hz, 2H, ArH), 6.5 (br s, 1H, CF3C=CH), 5.56 
(d, J= 5.73 Hz, 1H, PhCH), 4.37 (d, J = 18.0 Hz, 1H, NCH), 3.32 (d, J = 18.3 Hz, 1H, 
NCH), 2.82-2.62 (m, 2H, H2CCH=CCF3), 1.50 (s, 9H, C(CH3)3); 13C NMR (75 MHz, 
CDCl3): δ = 161.9 (d, J = 243.8 Hz, CF), 154.4, 135.3, 128.1 (d, J = 8.0 Hz, CCHCF), 
127.5-127.2 (m, C=CCF3), 126.5 (q, J = 30 Hz, CCF3), 122.6 (q, J = 268.8 Hz, CF3), 115.4 
(d, J = 20.9 Hz, CCF), 81.0, 49.6, 37.4, 28.7, 27.4; HRMS (EI) calcd for C17H19F4NO2 (M+) 
345.1352, found 345.1352. 
 
2-(3,4-Dichlorophenyl)-5-trifluoromethyl-3,6-dihydro-2H-pyridine-1-carboxylic 
acid methyl ester (41):  
To a solution of 36 (142 mg, 0.37 mmol) in dry toluene (40 mL, 
0.02 M solution) in a resealable vial was added Grubbs-II (4.3 
mg, 1 mol%). The mixture was heated at 80 °C in a microwave 
open system for 10 min at 300 W. The reaction was followed by GC and new portions 
of catalyst were added, followed by heating until the reaction was complete (at total 
of 3 mol% of catalyst, 30 min heating). The mixture was evaporated and the residue 
was purified using column chromatography (heptane/EtOAc 10:1) to give 41 (106 
mg, 63%) as a colorless oil. IR (neat, cm–1): 3071, 2958, 2898, 1709, 1585, 1446, 1346, 
1308, 1165, 1113, 1022, 966, 854, 772; 1H NMR (200 MHz, CDCl3): δ = 7.37 (s, 1H, ArH), 
7.16 (d, J = 8.4 Hz, 1H, ArH), 6.98 (d, J = 8.4 Hz, 1H, ArH), 6.47 (br s, 1H, CF3C=CH), 
5.74 (br s, 1H, PhCH), 4.42 (d, J = 18.0 Hz, 1H, NCH), 3.77 (d, J = 18.3 Hz, 1H, NCH), 
3.73 (s, 3H, CH3), 2.87-2.75 (m, 1H, HCCH=CCF3), 2.64-2.56 (m, 1H, HCCH=CCF3); 13C 
NMR (75 MHz, CDCl3): δ = 155.4, 137.0, 134.0, 129.9, 127.8, 127.4 (br s, C=CCF3), 127.0, 
126.4 (q, J = 32 Hz, CCF3), 122.5 (q, J = 269.1 Hz, CF3), 53.4, 49.0, 39.2, 32.2; HRMS (EI) 
calcd for C14H12F3Cl2NO2 (M+) 353.0197, found 353.0197. 
 
2-(3,5-Dichlorophenyl)-5-trifluoromethyl-3,6-dihydro-2H-pyridine-1-carboxylic 
acid methyl ester (42):  
To a solution of 37 (183 mg, 0.48 mmol) in dry toluene (50 mL, 
0.02 M solution) in a resealable vial was added Grubbs-II (6 mg, 
1 mol%). The mixture was heated at 80 °C in a microwave open 
system for 10 min at 300 W. The reaction was followed by GC 
and new portions of catalyst were added, followed by heating until the reaction was 
complete (at total of 3 mol% of catalyst, 30 min heating). The mixture was evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 10:1) to 
give 42 (134 mg, 79%) as a colorless oil. IR (neat, cm–1): 3075, 2954, 2859, 1709, 1572, 
1446, 1321, 1251, 1113, 1031, 966, 798, 768; 1H NMR (200 MHz, CDCl3): δ = 7.28-7.26 
(m, 1H, ArH), 7.10 (s, 2H, ArH), 6.57 (br s, 1H, CF3C=CH), 5.61 (br s, 1H, PhCH), 4.49 
(d, J = 18.1 Hz, 1H, NCH), 3.81 (s, 3H, CH3), 3.47 (d, J = 18.3 Hz, 1H, NCH), 2.77-2.71 
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(m, 2H, H2CCH=CCF3); 13C NMR (75 MHz, CDCl3): δ = 155.6, 142.6, 135.3, 127.9 (br s, 
C=CCF3), 126.4 (q, J = 32 Hz, CCF3), 125.2, 122.3 (q, J = 269.1 Hz, CF3), 53.5, 49.9, 37.7, 
27.0; HRMS (EI) calcd for C14H12NCl2F3O2 (M+) 353.0197, found 353.0197. 
 
2-(4-Methoxyphenyl)-5-trifluoromethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 
methyl ester (43): 
To a solution of 38 (100 mg, 0.29 mmol) in dry toluene (40 
mL) in a resealable vial was added Grubbs-II (2 mg, 0.6 
mol%). The mixture was heated at 80 °C in a microwave 
open system for 10 min at 300 W. The reaction was followed by GC and new portions 
of catalyst were added, followed by heating until the reaction was complete (at total 
of 5 mol% of catalyst, 40 min heating). The mixture was evaporated and the residue 
was purified using column chromatography (heptane/EtOAc 10:1) to give 43 (73 mg, 
80%) as a colorless oil. IR (neat, cm–1): 3002, 2954, 2902, 2837, 1701, 1610, 1515, 1446, 
1316, 1247, 1109, 1035, 966, 832, 767; 1H NMR (300 MHz, CDCl3): δ = 7.13 (d, J = 8.4 
Hz, 2H, ArH), 6.81 (d, J = 9.0 Hz, 2H, ArH), 6.55 (br s, 1H, CF3C=CH), 5.59 (br s, 1H, 
PhCH), 4.42 (d, J = 18.0 Hz, 1H, NCH), 3.77 (s, 6H, 2CH3), 3.35 (d, J = 18.9 Hz, 1H, 
NCH), 2.80-2.63 (m, 2H, H2CCH=CCF3); 13C NMR (75 MHz, CDCl3): δ = 158.8, 155.7, 
131.0, 127.9, 127.8 (br s, C=CCF3), 126.1 (q, J = 31 Hz, CCF3), 122.6 (q, J = 269.1 Hz, CF3), 
113.9, 55.4, 53.2, 49.9, 37.3, 27.3; HRMS (EI) calcd for C15H16F3NO3 (M+) 315.1082, 
found 315.1082. 
 
2-[tert-Butoxycarbonyl-(2-trifluoromethylallyl)amino]pent-4-enoic acid methyl 
ester (50): 
 To a suspension of NaH (34 mg, 1.42 mmol) in DMF (3 mL) was 
added Boc-protected allylglycine methyl ester (164 mg, 0.71 mmol) 
at room temperature. After stirring for 15 min, compound 9 (200 
mg, 0.71 mmol) was added. The reaction was stirred for 12 h, quenched with water (7 
mL) and extracted with Et2O (3 × 10 mL). The ether layer was dried (MgSO4), the 
solvent evaporated and the residue purified using column chromatography 
(heptane/EtOAc 10:1) to give 50 (146 mg, 61%) as a colorless oil. IR (neat, cm–1): 3079, 
2980, 1744, 1705, 1459, 1368, 1321, 1251, 1169, 1117, 1001, 919, 858, 772; 1H NMR (400 
MHz, CDCl3): δ 5.79-5.61 (m, 3H, CH2=CH, F3CC=CH2), 5.15-5.08 (m, 2H, H2C=CH), 
4.55 (s, 1H, COCH), 4.28-3.99 (m, 2H, F3CCH2), 3.72 (s, 3H, CH3), 2.78-2.58 (m, 1H, 
HCCH=CH2), 2.56-2.46 (m, 1H, HCCH=CH2), 1.42 (s, 9H, 3CH3); 13C NMR (75 MHz, 
CDCl3, some signals appear as rotamers, signals of the CCF3 are not visible): δ = 171.1, 
155.0, 133.7, 123.1 (q, J = 271.1 Hz, CF3), 118.93, 118.9-118.2 (m, F3CC=CH2), 81.5 + 81.2, 
59.3, 52.3, 46.6-45.3 (m, F3CCCH2), 35.1 + 34.3, 28.4; HRMS (ESI) calcd for 
C15H22F3NNaO4 (M + Na)+ 360.1398, found 360.1416. 
 
2-[(5-Chloro-2-methoxyphenyl)sulfonyl]amino)pent-4-enoic acid (45): 
To a suspension of allylglycine (44, 2.00 g, 17.4 mmol) in CH2Cl2 (35 
mL) was added Me3SiCl (2.2 mL, 17.4 mmol). The mixture was 
heated at reflux for 2 h, Et3N (4.87 mL, 34.8 mmol) was added, 
followed by a solution of 5-chloro-2-methoxybenzensulfonyl 
chloride (4.20 g, 17.4 mmol) in CH2Cl2 (17.5 mL). The resulting 
mixture was vigorously stirred for 1 h at rt, MeOH (2.78 mL, 20.0 
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mmol) was added and the mixture was evaporated. The residue was dissolved in 
water and brought to pH 8 using aqueous K2CO3. The aqueous layer was washed 
with Et2O (3 × 10 mL), acidified to pH 1 using 1 N hydrochloric acid (1 N) and 
extracted with EtOAc (3 × 20 mL). The combined organic layers were dried (MgSO4) 
and the solvent was evaporated to afford crude 45 (4.41 g, 80%) as a yellow solid. The 
crude acid was used without further purification in the next reactions. 
 
2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]-2-trifluoromethylallyl)amino}- 
N-(2-methoxybenzyl)pent-4-enamide (51):  
A solution of crude acid 45 (500 mg, 1.6 mmol) in CH2Cl2 (33 
mL) was stirred for 1 h at rt with HOBt (233 mg, 1.73 mmol) 
and EDCI (331 mg, 1.73 mmol). 2-Methoxybenzylamine (0.3 
mL, 2.0 mmol) was added, the mixture was stirred for 12 h and the solvent was 
evaporated. The residue was dissolved in EtOAc (20 mL), washed with brine (10 mL) 
and aqueous NaHCO3 (10 mL). The combined water phases were reextracted with 
EtOAc (3 × 10 mL), and the combined organic layers were dried (MgSO4) and 
evaporated. The residue was crystallized (heptane/EtOAc 2:1) to give 2-{[(5-Chloro-
2-methoxyphenyl)sulfonyl]-amino}-N-(2-methoxybenzyl)pent-4-enamide 46 (520 
mg, 76%) as a white solid. Mp = 105–108 °C; IR (neat, cm–1): 3404, 3157, 3066, 2967, 
2932, 2902, 2833, 1653, 1601, 1489, 1463, 1325, 1234, 1156, 1014, 914, 828; 1H NMR (400 
MHz, CDCl3): δ = 7.82 (d, J = 2.4 Hz, 1H, SO2ArH), 7.41-7.38 (m, 1H, ArH), 7.30-7.25 
(m, 1H, ArH), 7.17-7.14 (m, 1H, ArH), 6.92-6.81 (m, 3H, ArH), 6.68 (br s, 1H, NH), 
5.61-5.51 (m, 2H, NHSO2, CH2=CH), 5.08-5.02 (m, 2H, H2C=CH), 4.31-4.29 (m, 2H, 
NCH2Ph), 3.89 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.71-3.68 (m, 1H, CHC=O), 2.58-2.51 
(m, 1H, HCCH=CH2), 2.33-2.26 (m, 1H, HCCH=CH2); 13C NMR (75 MHz, CDCl3): δ = 
169.6, 154.8, 134.4, 133.9, 133.6, 132.3, 131.8, 129.4, 129.3, 128.8, 128.1, 127.4, 125.5, 
120.4, 113.4, 56.6, 56.4, 55.2, 39.4, 37.5; HRMS (EI) calcd for C20H23ClN2O5S (M+) 
438.1016, found 438.1013. To a suspension of NaH (34 mg, 1.43 mmol) in DMF (3 mL) 
was added at rt 46 (304 mg, 0.71 mmol). After stirring for 15 min, compound 9 (200 
mg, 0.71 mmol) was added dropwise. The reaction was stirred for 12 h, quenched 
with water (3 mL) and extracted with Et2O (3 × 6 mL). The ether layers were dried 
(MgSO4), evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 6:1 to 1:1) to give 51 (170 mg, 45%) as a yellow oil. IR (neat, cm–1): 
3384, 3324, 3076, 2945, 2840, 1679, 1588, 1522, 1481, 1437, 1388, 1338, 1319, 1273, 1245, 
1157, 1116, 1067, 1017, 949, 910, 812, 754, 644, 592; 1H NMR (400 MHz, CDCl3): δ = 
7.87 (d, J = 2.4 Hz, 1H, SO2Ph), 7.41-7.38 (m, 1H, SO2Ph), 7.30-7.25 (m, 1 H, SO2Ph), 
7.18-7.16(m, 1H, Ph), 6.91-6.82 (m, 3H, Ph), 6.71 (br s, 1H, NH), 5.57 (d, J = 6.9 Hz, 2H, 
F3CC=CH2), 5.41-5.32 (m, 1H, CH2=CH), 4.96-4.86 (m, 2H, H2C=CH), 4.52 (d, J = 18.4 
Hz, 1H, NCHPh), 4.31-4.21 (m, 2H, NCHPh + F3CCCH), 4.13-4.10 (m, 2H, 
F3CCCH+COCH), 3.87 (s, 6H, 2OCH3), 2.68-2.61 (m, 1H, HCCH=CH2), 2.22-2.15 (m, 
1H, HCCH=CH2); 13C NMR (100 MHz, CDCl3): δ = 167.8, 157.6, 155.3, 134.5 (q, J = 29.1 
Hz, CH2=CCF3), 133.0, 130.8, 129.9, 129.0, 128.6, 125. 3, 122.9 (q, J = 272.3 Hz, CF3), 
120.4, 120.2 (q, J = 5.5 Hz, H2C=CCF3), 118.3, 113.5, 110.2, 59.1, 56.3, 55.2, 43.2, 39.6, 
33.1; HRMS (EI) calcd for C24H27ClF3N2O5S (M + H)+ 547.1281, found 547.1174. 
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2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]-[2-(trifluoromethyl)allyl]amino}-N- 
(4-chloro-3-trifluoromethylbenzyl)pent-4-enamide (52): 
A solution of crude acid 45 (500 mg, 1.6 mmol) in CH2Cl2 
(33 mL) was stirred for 1 h at rt with HOBt (233 mg, 1.73 
mmol) and EDCI (331 mg, 1.73 mmol). 4-Chloro-3-
trifluoromethylbenzylamine (418 mg, 2.0 mmol) was added, the mixture was stirred 
for 12 h and the solvent was evaporated. The residue was dissolved in EtOAc (20 
mL), washed with brine (10 mL) and aqueous NaHCO3 (10 mL). The combined water 
phases were reextracted with EtOAc (3 × 10 mL), and the combined organic layers 
were dried (MgSO4) and evaporated. The residue was crystallized (heptane/EtOAc 
2:1) to give 2-{[(5-Chloro-2-methoxyphenyl)sulfonyl] amino}-N-(4-chloro-3-
trifluoromethylbenzyl) pent-4-enamide 47 (808 mg, 99%) as a white solid. Mp = 140-
143 °C; IR (neat, cm–1): 3300, 3257, 3079, 2945, 2852, 1649, 1554, 1472, 1316, 1161, 1122, 
1022, 897, 810, 646; 1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 3.6 Hz, SO2ArH), 7.57-
7.46 (m, 3H, ArH), 7.38-7.35 (m, 1H, ArH), 6.98-6.94 (m, 2H, ArH, NH), 5.58-5.43 (m, 
2H, NHSO2, CH2=CH), 5.15-5.06 (m, 2H, H2C=CH), 4.49-4.34 (m, 2H, NCH2Ph), 3.96 (s, 
3H, CH3), 3.77-3.71 (m, 1H, COCH), 2.64-2.55 (m, 1H, HCCH=CH2), 2.33-2.24 (m, 1H, 
HCCH=CH2); 13C NMR (75 MHz, CDCl3): δ = 170.4, 154.9, 137.2, 134.9, 132.0, 131.9, 
131.8, 131.3 (q, J = 2.01 Hz, ClC=CCF3), 130.0, 128.5 (q, J = 31.3 Hz, CCF3), 127.9, 126.7 
(q, J = 5.2 Hz, C=CCF3), 126.0, 122.8 (q, J = 271.7 Hz, CF3), 120.2, 113.7, 56.7, 56.6, 42.6, 
36.9; HRMS (EI) calcd for C20H19Cl2F3N2O4S (M+) 510.0395, found 510.0399. To a 
suspension of NaH (34 mg, 1.43 mmol) in DMF (3 mL) was added at room 
temperature 47 (364 mg, 0.71 mmol). After stirring for 15 min, compound 8 (200 mg, 
0.71 mmol) was added dropwise at rt. The reaction was stirred for 12 h, quenched 
with water (3 mL) and extracted with Et2O (3 × 6 mL). The ether layers were dried 
(MgSO4), evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 6:1 to 1:1) to give 52 (190 mg, 44%) as a colorless oil. IR (neat, cm–1): 
3373, 3076, 2945, 2852, 1687, 1588, 1528, 1478, 1437, 1388, 1319, 1275, 1171, 1130, 1067, 
1037, 1015, 946, 908, 842, 817, 740, 647, 589, 524; 1H NMR (400 MHz, CDCl3): δ = 7.85 
(d, J = 2.8 Hz, 1H, SO2Ph), 7.57-7.43 (m, 3H, 1 HSO2Ph+ 2 HPh), 7.37-7.34 (m, 1H, Ph), 
6.95 (d, J = 8.8 Hz, 1H, SO2Ph), 6.88 (br s, 1H, NH), 5.73 (s, 1H, F3CC=CH), 5.61 (s, 1H, 
F3CC=CH), 5.42-5.31 (m, 1H, CH2=CH), 4.99-4.91 (m, 2H, H2C=CH), 4.54-4.40 (m, 2H, 
H2CPh), 4.27-4.08 (m, 3H, F3CCH2+ COCH), 3.92 (s, 3H, CH3), 2.74-2.67 (m, 1H, 
HCCH=CH2), 2.26-2.19 (m, 1H, HCCH=CH2); 13C NMR (100 MHz, CDCl3): δ = 168.8, 
155.4, 136.9, 134.8, 134.2 (q, J = 29.1 Hz, CH2=CCF3), 132.6, 132.2, 131.6, 131.2, 130.7, 
128.5, 128.4 (q, J = 30.5 Hz, CCF3), 126.9 (q, J = 4.5 Hz, C=CCF3), 125.5, 122.8 (q, J = 
274.6 Hz, CF3), 122.6 (q, J = 271.5 Hz, CF3), 121.5 (q, J = 6.1 Hz, H2C=CCF3), 118.6, 
113.6, 59.0, 56.4, 43.4, 42.5, 32.7; HRMS (EI) calcd for C24H23Cl2F6N2O4S (M+H)+ 
619.0660, found 619.0616. 
 
2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]-[2-(trifluoromethyl)allyl]amino}- 
N-3,4-difluorobenzyl)pent-4-enamide (53):  
A solution of crude acid 45 (1.00 g, 3.13 mmol) in CH2Cl2 
(65 mL) was stirred for 1 h at with HOBt (466 mg, 3.45 
mmol) and EDCI (662 mg, 3.45 mmol). 3,4-
Difluorobenzylamine (1.1 mL, 9.39 mmol) was added, the 
mixture was stirred for 12 h and the solvent was evaporated. The residue was 
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dissolved in EtOAc (20 mL), washed with brine (10 mL) and aqueous NaHCO3 (10 
mL). The combined water phases were reextracted with EtOAc (3 × 10 mL), and the 
combined organic layers were dried (MgSO4) and evaporated. The residue was 
crystallized (heptane/Et2O 3:1) to give 2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]-
amino}-N-3,4-difluorobenzyl)pent-4-enamide 48 (1.21 g, 87%) as a white solid. Mp = 
115–118 °C; IR (neat, cm–1): 3309, 3261, 3097, 3075, 2980, 2894, 1653, 1515, 1437, 1329, 
1282, 1156, 1113, 1070, 1014, 897, 815, 646; 1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 
3.2 Hz, 1H, SO2Ph), 7.55-7.52 (m, 1H, SO2Ph), 7.15-6.92 (m, 4H, 1H SO2Ph + 3H Ph), 
6.85 (br s, 1H, C=ONH), 5.57-5.44 (m, 2H, CH2=CH, TsNH), 5.15-5.05 (m, 2H, 
H2C=CH), 4.39-4.25 (m, 2H, NCH2), 3.95 (s, 3H, OCH3), 3.74 (t, J = 8.0 Hz, 1H, COCH), 
2.61-2.53 (m, 1H, HCCH=CH2), 2.34-2.24 (m, 1H, HCCH=CH2); 13C NMR (75 MHz, 
CDCl3) δ = 170.3, 154.9, 150.1 (dd, J = 47.1, FC=CF, J = 247.0 Hz Hz, FC=CF), 149.9 (dd, 
J = 47.1 Hz, FC=CF, J = 247.0 Hz, FC=CF), 135.0-134.9 (m, C=C=CF), 134.8, 132.0, 129.8, 
127.8, 125.8, 123.6-123.4 (m, C=C=CF), 119.9, 117.0 (dd, J = 17.2 Hz, Cmeta=CF=CF, J = 
61.7 Hz, Cmeta=CF=CF), 116.9 (dd, J = 17.2 Hz, Cortho=CF=CF, J = 61.7 Hz, 
Cortho=CF=CF), 113.6, 56.6, 56.5, 42.5, 37.1; HRMS (EI) calcd for C19H19ClF2N2O4S (M+) 
444.0722, found 444.0718. To a suspension of NaH (27 mg, 1.10 mmol) in DMF (2 mL) 
was added at rt 48 (250 mg, 0.56 mmol). After stirring for 15 min, compound 9 (156 
mg, 0.56 mmol) was added dropwise at rt. The reaction was stirred for 12 h, 
quenched with water (2 mL) and extracted with Et2O (3 × 4 mL). The ether layers 
were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 6:1 to 1:1) to give 53 (185 mg, 60%) as a colorless 
oil. IR (neat, cm–1): 3373, 3082, 2978, 2939, 2846, 1890, 1684, 1610, 1588, 1517, 1481, 
1388, 1322, 1278, 1155, 1113, 1067, 952, 817, 740, 642, 589; 1H NMR (400 MHz, CDCl3): 
δ = 7.72 (d, J = 3.5 Hz, 1H, SO2Ph), 7.38-7.34 (m, 1H, SO2Ph), 7.00-6.88 (m, 2H, 1H 
SO2Ph + 1H Ph), 6.81-6.79 (m, 2H, Ph), 6.59 (br s, 1H, NH), 5.59 (s, 1H, F3C=CH), 5.47 
(s, 1H, F3C=CH), 5.28-5.15 (m, 1H, CH2=CH), 4.86-4.76 (m, 2H, H2C=CH), 4.38 (d, J = 
24 Hz, 1H, NCH), 4.26-4.19 (m, 1H, NCH), 4.11-4.06 (m, 1H, F3CCH), 3.98-3.91 (m, 2H, 
F3CCH+ COCH), 3.77 (s, 3H, CH3), 2.61-2.51 (m, 1H, HCCH=CH2), 2.13-2.04 (m, 1H, 
HCCH=CH2); 13C NMR (100 MHz, CDCl3): δ = 168.7, 155.4, 151.2 (dd, J = 12.8, FC=CF, 
J = 53.9 Hz, FC=CF), 148.7 (dd, J = 12.4, FC=CF, J = 52.4 Hz, FC=CF), 134.8, 134.7 (q, J = 
5.3 Hz, C=C=CF), 134.2 (q, J = 29.0 Hz, CCF3), 132.8, 130.9, 128.6, 125.7, 125.6 (q, J = 
272.3 Hz, CF3),124.2, 123.9-123.7 (m, C=C=CF), 121.5 (q, J = 4.4 Hz, C=CCF3 Hz), 117.3 
(d, J = 16.3 Hz, C=CF), 116.9 (d, J = 17.3 Hz, C=CF), 113.7, 59.1, 56.5, 43.5, 42.7, 32.8; 
HRMS (EI) calcd for C23H23ClF5N2O4S (M + H)+ 553.0987, found 553.0972. 
 
2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]-[2-(trifluoromethyl)allyl]amino}- 
N-(2-chlorobenzyl)pent-4-enamide (54):  
A solution of crude acid 45 in CH2Cl2 (35 mL) was stirred for 
1 h with HOBt (233 mg, 1.75 mmol) and EDCI (331 mg, 1.75 
mmol). 2-Chlorobenzylamine (250 µL, 1.75 mmol) was 
added, the mixture was stirred for 12 h and the solvent was evaporated. The residue 
was dissolved in EtOAc (20 mL), washed with brine (10 mL) and aqueous NaHCO3 
(10 mL). The water layer was reextracted with EtOAc (3 × 10 mL), and the combined 
organic layers were dried (MgSO4) and evaporated. The residue was crystallized 
(heptane/Et2O 3:1) to give 2-{[(5-Chloro-2-methoxyphenyl)sulfonyl]amino}-N-(2-
chlorobenzyl)pent-4-enamide 49 (700 mg, 99%) as a white solid. Mp = 97-100 °C; IR 
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(neat, cm–1): 3404, 3114, 3075, 2967, 2933, 2846, 1653, 1528, 1480, 1437, 1325, 1277, 1156, 
1018, 914, 750; 1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 2.4 Hz, 1H, SO2Ph), 7.49-
7.46 (m, 1H, SO2Ph), 7.38-7.35 (m, 1H, Ph), 7.30-7.23(m, 3H, Ph), 6.90 (d, J = 8.8 Hz, 
1H, SO2Ph), 6.66 (br s, 1H, C=ONH), 5.58-5.48 (m, 2H, CH2=CH, TsNH), 5.11-5.04 (m, 
2H, H2C=CH), 4.48-4.37 (m, 2H, CH2Ph), 3.93 (s, 3H, OCH3), 3.77-3.73 (m, 1H, 
C=OCH), 2.61-2.54 (m, 1H, HCCH=CH2), 2.33-2.26 (m, 1H, HCCH=CH2); 13C NMR (75 
MHz, CDCl3): δ = 170.1, 154.9, 134.9, 134.6, 133.6, 133.4, 132.1, 129.7, 129.6, 129.5, 
128.9, 127.9, 127.1, 125.7, 119.7, 113.5, 56.6, 56.5, 41.5, 37.4; HRMS (EI) calcd for 
C19H20Cl2N2O4S (M+) 442.0521, found 442.0514. To a suspension of NaH (34 mg, 1.43 
mmol) in DMF (3 mL) was added at rt 49 (310 mg, 0.71 mmol). After stirring for 15 
min, compound 9 (200 mg, 0.71 mmol) was added dropwise. The reaction was stirred 
for 12 h, quenched with water (3 mL) and extracted with Et2O (3 × 6 mL). The ether 
layers were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 6:1 to 1:1) to give 54 (183 mg, 47%) as a colorless 
oil. IR (neat, cm–1): 3373, 3318, 3071, 2978, 2945, 2846, 1665, 1591, 1572, 1530, 1481, 
1440, 1388, 1338, 1319, 1275, 1248, 1155, 1122, 1067, 1015, 949, 921, 842, 817, 754, 644, 
589; 1H NMR (400 MHz, CDCl3): δ = 7.88 (d, J = 2.8 Hz, 1H, SO2Ph), 7.47-7.44 (m, 1H, 
SO2Ph), 7.37-7.35 (m, 1H, Ph), 7.31-7.29 (m, 1H, Ph), 7.28-7.21 (m, 2H, Ph), 6.88 (d, J = 
8.8 Hz, 1H, SO2Ph), 6.77 (br s, 1H, NH), 5.63 (d, J = 10.8 Hz, 2H, F3CC=CH2), 5.45-5.35 
(m, 1H, CH2=CH), 4.99-4.98 (m, 2H, H2C=CH), 4.54 (d, J = 18 Hz, 1H, HCPh), 4.43-4.38 
(m, 1H, HCPh), 4.28-4.15 (m, 3H, F3CCH2+COCH), 3.88 (s, 3H, OCH3), 2.68-2.61 (m, 
1H, HCCH=CH2), 2.29-2.22 (m, 1H, HCCH=CH2); 13C NMR (100 MHz, CDCl3): δ = 
168.4, 155.3, 134.9, 134.6 (q, J = 29.2 Hz, CCF3), 134.5, 133.7, 132.7, 130.8, 130.4, 129.4, 
128.9, 128.6, 127.2, 125.4, 122.9 (q, J = 272.3 Hz, CF3), 120.5 (q, J = 6.1 Hz, CH2=CCF3), 
118.5, 113.6, 58.9, 56.4, 43.3, 41.4, 33.3; HRMS (EI) calcd for C23H24Cl2F3N2O4S (M+H)+, 
551.0786 found 551.0736. 
 
5-Trifluoromethyl-3,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-tert-butyl ester- 
2-methyl ester (55): 
To a solution of 50 (46 mg, 0.14 mmol) in dry toluene (20 mL) 
Grubbs-II (10 mol%) was added at 100 °C in small portions. The 
reaction was complete in 60 min. The solvent was evaporated 
and the residue purified using column chromatography (heptane/EtOAc 10:1 to 6:1) 
to give 55 (29 mg, 67%) as a colorless oil. IR (neat, cm–1): 2976, 2924, 2872, 1744, 1701, 
1403, 1364, 1308, 1251, 1212, 1161, 1113, 1035, 1001, 823, 607; 1H NMR (300 MHz, 
CDCl3): δ = 6.37 (s, 1H, F3C=CH), 5.11-4.89 (m, 1H, COCH), 4.34-4.17 (m, 1H, F3CCH), 
3.91-3.76 (m, 1H, F3CCH), 3.71 (s, 3H, CH3), 2.84-2.77 (m, 1H, HCCH=CF3), 2.62-2.53 
(m, 1H, HCCH=CF3), 1.50 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3): δ = 171.0, 155.1, 
126.5-126.3 (m, CCF3), 125.9-125.8 (m, C=CCF3), 122.6 (q, J = 267.9 Hz, CF3), 81.4, 52.7, 
50.3, 39.4, 30.0, 28.6; HRMS (EI) calcd for C13H19F3NO4 (M+H)+ 310.1266, found 
310.1260. 
 
1-(5-Chloro-2-methoxybenzenesulfonyl)-5-trifluoromethyl-1,2,3,6 tetrahydro 
pyridine-2-carboxylic acid 2 methoxybenzylamide (56):  
To a solution of 51 (158 mg, 0.29 mmol) in dry toluene (60 
mL) Grubbs-II (10 mol%) was added at 100 °C in small 
portions. The reaction was complete in 60 min. The solvent 
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was evaporated and the residue purified using column chromatography 
(heptane/EtOAc 3:1 to 1:1) to give 56 (105 mg, 70%) as a white solid. Mp = 120-123 °C; 
IR (neat, cm–1): 3384, 3313, 3076, 2923, 2846, 1679, 1591, 1519, 1489, 1478, 1437, 1390, 
1341, 1305, 1273, 1245, 1163, 1116, 1078, 1017, 965, 899, 839, 814, 754, 735, 644, 589; 1H 
NMR (400 MHz, CDCl3): δ = 7.91 (d, J = 2.4 Hz, 1H, SO2Ph), 7.50-7.47 (m, 1H, SO2Ph), 
7.30-7.18 (m, 3H, 1H SO2Ph+2H Ph), 6.92-6.87 (m, 3H, 2H Ph+1H NH), 6.38 (br s, 1H, 
F3C=CH), 4.51-4.35 (m, 4H, NCH2Ph, F3CCH2N), 3.86 (s, 3H, OCH3), 3.76 (s, 3H, 
OCH3), 3.70 (s, 1H, COCH), 2.95-2.89 (m, 1H, HCCH=CF3), 1.87-1.80 (m, 1H, 
HCCH=CF3); 13C NMR (100 MHz, CDCl3): δ=167.5, 157.5, 155.1, 134.9, 134.3, 131.0, 
129.6, 129.1, 127.9 (q, J = 5.3 Hz, CH=CCF3), 127.8, 125.7, 125.5, 124.5, 124.1 (q, J = 30.5 
Hz, CCF3), 122.4 (q, J = 270.9 Hz, CF3), 120.5, 113.5, 110.6, 56.3, 55.2, 52.7, 40.4, 38.9, 
29.6, 22.5; HRMS(EI) calcd for C22H21ClF3N2O5S (M–H)+ 517.0812, found 517.0823. 
 
1-(5-Chloro-2-methoxybenzenesulfonyl)-5-trifluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 4-chloro-3 trifluoromethyl 
benzylamide (57):  
To a solution of 52 (180 mg, 0.29 mmol) in dry toluene 
(68 mL) Grubbs-II (10 mol%) was added at 100 °C in 
small portions. The reaction was complete in 60 min. The solvent was evaporated 
and the residue purified using column chromatography (heptane/EtOAc 3:1 to 1:1) to 
give 57 (167 mg, 98%) as a white solid. Mp = 203-205 °C; IR (neat, cm–1): 3390, 3087, 
2956, 2928, 2851, 1670, 1585, 1522, 1478, 1440, 1396, 1341, 1316, 1305, 1270, 1160, 1113, 
1075, 1031, 1012, 960, 894, 836, 814, 735, 642; 1H NMR (400 MHz, CDCl3): δ = 7.93 (d, J 
= 2.8 Hz, 1H, SO2Ph), 7.57-7.45 (m, 3H, 1H SO2Ph+2H Ph), 7.37-7.34 (m, 1H, Ph), 7.19 
(br s, 1H, NH), 6.95 (d, J = 8.8 Hz, 1H, SO2Ph), 6.45-6.44 (m, 1H, F3C=CH), 4.59-4.40 
(m, 4H, NCH2Ph, F3CCH2N), 3.84 (s, 3H, OCH3), 3.78 (s, 1H, COCH), 2.95-2.84 (m, 1H, 
HCCH=CF3), 1.87-1.81 (m, 1H, HCCH=CF3); 13C NMR (100 MHz, CDCl3): δ = 168.4, 
155.2, 137.1, 135.2, 134.2 (q, J = 29.1 Hz, CH=CCF3), 131.8, 131.7, 131.5, 131.2, 129.8, 
128.8 (q, J = 31.2 Hz, CCF3), 127.8 (q, J = 5.6 Hz, C=CCF3), 127.4, 126.6 (q, J = 5.3 Hz, 
H2C=CCF3), 126.0, 124.6, 124.2, 122.6 (q, J = 274.6 Hz, CF3), 122.4 (q, J = 269.9 Hz, CF3), 
113.7, 52.6, 42.9, 39.3, 22.5; HRMS (EI) calcd for C22H19Cl2F6N2O4S (M+H)+ 591.0347, 
found 591.0402. 
 
1-(5-Chloro-2-methoxybenzenesufonyl)-5-trifluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 3,4-difluorobenzylamide (58):  
To a solution of 53 (110 mg, 0.20 mmol) in dry toluene (40 
mL) Grubbs-II (10 mol%) was added at 100 °C in small 
portions. The reaction was complete in 60 min. The 
solvent was evaporated and the residue purified using column chromatography 
(heptane/EtOAc 3:1 to 1:1) to give 58 (73 mg, 70%) as a white solid. Mp = 148-149 °C; 
IR (neat, cm–1): 3302, 3098, 3054, 2939, 2846, 1657, 1607, 1519, 1481, 1434, 1388, 1338, 
1303, 1273, 1209, 1160, 1111, 1070, 1015, 954, 899, 812, 729, 647, 584, 521; 1H NMR (400 
MHz, CDCl3): δ = 7.92 (d, J = 2.8 Hz, 1H, SO2Ph), 7.52-7.51 (m, 1H, SO2Ph), 7.13-6.94 
(m, 5H, 1H SO2Ph+3H Ph+1H NH), 6.43-6.42 (m, 1H, F3C=CH), 4.58-4.33 (m, 4H, 
NCH2Ph, F3CCH2N), 3.83 (s, 3H, OCH3), 3.78 (s, 1H, COCH), 2.95-2.90 (m, 1H, 
HCCH=CF3), 1.87-1.81 (m, 1H, HCCH=CF3); 13C NMR (100 MHz, CDCl3): δ = 168.2, 
155.2, 151.3 (dd, J = 12.6, FC=CF, J =59.1 Hz, FC=CF), 148.8 (dd, J = 12.8, FC=CF, J = 
N
F3C
O
H
N
ArSO2
CF3
Cl
N
F3C
O
H
N
ArSO2
F
F
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58.1 Hz, FC=CF), 135.2, 134.9 (q, J = 1.2 Hz, C=C=CF), 131.1, 127.9 (q, J = 5.5 Hz, 
C=CCF3), 127.5, 125.9, 124.5 (q, J = 31.1 Hz, CCF3), 123.3 (q, J = 2.7 Hz, C=C=CF), 122.4 
(q, J = 270.3 Hz, CF3), 117.5 (d, J = 17.2 Hz, C=CF), 116.5 (d, J = 17.5 Hz, C=CF), 113.7, 
56.4, 52.6, 42.9, 39.2, 22.6; HRMS (EI) calcd for C21H19Cl F5N2O4S (M+H)+ 525.0674, 
found 525.0678. 
 
1-(5-Chloro-2-methoxy-benzenesulfonyl)-5-trifluoromethyl-1,2,3,6-tetrahydro 
pyridine-2-carboxylic acid 2-chlorobenzylamide (59):  
To a solution of 54 (173 mg, 0.31 mmol) in dry toluene (69 
mL) Grubbs-II (10 mol%) was added at 100 °C in small 
portions. The reaction was complete in 60 min. The solvent 
was evaporated and the residue purified using column chromatography 
(heptane/EtOAc 3:1 to 1:1) to give 59 (145 mg, 90%) as a white solid. Mp = 137-140 °C; 
IR (neat, cm–1): 3384, 3329, 3071, 2939, 2917, 2846, 1676, 1591, 1572, 1522, 1478, 1440, 
1390, 1344, 1305, 1273, 1209, 1163, 1113, 1078, 1015, 960, 897, 839, 814, 751, 644, 589; 1H 
NMR (400 MHz, CDCl3): δ = 7.92 (d, J = 2.8 Hz, 1H, SO2Ph), 7.51-7.48 (m, 1H, SO2Ph), 
7.38-7.35 (m, 1H, Ph), 7.30-7.22 (m, 3H, Ph), 7.12 (br s, 1H, NH), 6.9 (d, J = 8.8 Hz, 1H, 
SO2Ph), 6.41 (br s, 1H, F3C=CH), 4.61-4.45 (m, 4H, NCH2Ph+F3CCH2N), 3.84 (s, 1H, 
COCH), 3.79 (s, 3H, OCH3), 2.95-2.89 (m, 1H, HCCH=CF3), 1.91-1.85 (m, 1H, 
HCCH=CF3); 13C NMR (100 MHz, CDCl3): δ = 168.0, 155.1, 135.0, 134.9, 134.3, 133.5, 
131.0, 129.8, 129.6, 129.1, 127.9 (q, J = 5.3 Hz, CH=CCF3), 127.1, 125.9, 124.4 (q, J = 31.2 
Hz, CCF3), 122.4 (q, J = 271.1 Hz, CF3), 113.9, 56.4, 52.6, 41.9, 39.1, 31.8; HRMS (EI) 
calcd for C21H20Cl2F3N2O4S (M + H)+ 523.0473, found 523.0439. 
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CHAPTER 4 
RCM-MEDIATED SYNTHESIS OF FLUORIDE-CONTAINING NITROGEN 
HETEROCYCLES 
 
 
 
Keywords: Fluoride-substituted diolefins / Ring-closing metathesis / Fluoride-
substituted piperidines 
 
 
Abstract٭ 
The synthesis of highly functionalized fluorinated piperidines is described. The key 
step is a ring-closing metathesis reaction involving fluoride-substituted olefins, 
which leads to the corresponding cyclic vinyl fluorides. Several sequences to arrive at 
differently substituted piperidines have been evaluated.  
 
 
 
 
 
 
 
 
 
 
٭ V. De Matteis, F. L. van Delft, J. Tiebes, F. P. J. T. Rutjes, “A ring-closing metathesis 
pathway to vinyl fluoride-containing nitrogen heterocyles”, Eur. J. Org. Chem. 2006, 1166–
1176. 
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4.1 INTRODUCTION 
 
Owing to the better knowledge of scientists concerning the chemical, 
biological and physical properties of fluorinated compounds,1 their expansion in 
agrochemical and pharmaceutical research is increasing. The relevance of the class of 
fluoride-containing compounds in the agrochemical and pharmaceutical field is 
illustrated in Chart 1. As an example, betamethasone (1) is a representative of a class 
of anti-inflammatory drugs, in which useful modification of the biological activity 
was achieved by the introduction of a carbon-fluoride instead of a carbon-hydrogen 
bond.2 Fluoroneplanocin A (2) acts as an antiviral drug by inhibiting (S)-
adenosylhomocysteine hydrolase (SAN).3 Finally, profluazol (3) is a herbicide that 
inhibits protoporphyrinogen oxidase.4 
 
HO
F
OH
2: fluoroneplamocin A
(antiviral)
O
O
Me
HO
Me
Me
F
OH
1: betamethasone
(anti-inflammatory)
OH
H
H
N
NN
N
NH2
3: profluazol
(herbicide)
OH
N
NF
H
O
O
F
Cl
NH
SO2Cl
 
 
Chart 1. Fluorinated carba- and heterocycles. 
 
Considering the importance of research in fluorine chemistry, we focused our 
study on the synthesis of fluorinated (hetero)cycles. In conjunction with a continuing 
program on ring-closing metathesis in our group,5,6 we decided to study the 
possibility to obtain fluoride-containing heterocycles 4 (Scheme 1) via ring-closing 
metathesis of vinyl fluorides 5. The latter compounds should be accessible from the 
corresponding olefinic amines 6, via reaction with suitable fluorinated alkylating or 
acylating reagents.  
 
N
4
N
5
RCM
R R
R = protective group
HN
R
F
Y
X
XF
X
F
6
X = H2, O
Y = Cl, F
 
Scheme 1. Retrosynthetic approach. 
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Over the years, ring-closing olefin metathesis has become a reliable approach 
for the construction of (hetero)cyclic systems.7 Initially, applications were restricted 
to terminal olefins, but gradually – stimulated by the emergence of more reactive Ru-
carbene and Mo-catalysts – a wide variety of different substituents located at one of 
the participating olefins was reported to successfully undergo a ring-closing 
metathesis process. Substituents other than alkyl include heteroatoms such as 
nitrogen,6g,8 oxygen,9 phosphorus,10 silicon,11 and boron.12 Until recently, however, 
there were no examples where halides were tolerated in this conversion. Considering 
the generally low reactivity of vinyl fluorides in transition metal-mediated reactions, 
we reasoned that such functionalities might well undergo a metathesis process in the 
desired fashion. Despite the fact that Grubbs had shown previously that 1,1-
difluoroethylene forms a stable complex with ruthenium carbenes,13 several other 
groups were working along the same lines. In fact, during the course of our work of 
RCM on vinyl fluorides and trifluoromethylated olefins,6a the Weinreb group 
published the first successful examples of vinyl chloride metathesis14 and soon 
thereafter, the Brown group reported the first examples of vinyl fluoride ring-closing 
metathesis.15 More recently, the Haufe group published examples of fluoroacrylate 
ring-closing metathesis.16 These examples once more emphasize the versatility of the 
RCM technique, giving facile access to potentially useful cyclic vinyl fluoride 
containing heterocycles. 
In this chapter, we provide a detailed account of the synthesis of vinyl fluoride-
containing reagents, a series of successful metathesis examples and elaboration of the 
resulting products into highly functionalized biologically relevant heterocycles. 
 
4.2 SYNTHESIS OF FLUORIDE-CONTAINING NITROGEN HETEROCYCLES 
 
Initially, a preliminary investigation was performed to synthesize fluoride-
containing heterocyclic building blocks 9 via RCM of olefins of type 8 (Scheme 3). 
 
N
F
(  )n
N
F
(  )nRCM
8 9
O O
Bn Bn
HN
(  )n
Bn
F
O
F
7  
Scheme 3. RCM approach to fluorinated heterocyclic systems. 
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The vinyl fluoride-containing precursors 10-12 were synthesized by acylation 
of the corresponding benzylamines with 1.0 equiv of 2-fluoroacryloyl fluoride (12, 
Section 2.3) at –78 °C in diethyl ether. After stirring overnight at rt, the acylated 
products were isolated in satisfactory yields considering the volatility of the acyl 
fluoride (Table 1, entries 1-3). While the first three benzylamines were readily 
available, preparation of the last benzylamine required a few steps. This involved 
condensation of methyl 2-amino-4-pentenoate with benzaldehyde and subsequent 
reduction with NaBH4. These precursors were then subjected to RCM conditions 
using the 2nd generation Grubbs catalyst (Grubbs-II).  
 
Table 1. RCM of vinyl fluorides. 
Entry Precursor Cat (mol%) Time(h) Product(yield) 
 
 
 
1 
2 
3 
 
 
 
10: n = 1 (41%) 
11: n = 2 (30%) 
12: n = 4 (63%) 
 
 
 
7 
7 
7 
 
 
 
4 
4 
72 
 
 
 
14: n = 1 (99%) 
15: n = 2 (80%) 
16: n = 4 (0%) 
 
 
 
4 13 (20%) 
 
 
 
4 
 
 
 
4 
 
 
 
17 (99%) 
 
Optimal results were obtained by heating at 100 °C for the indicated time 
during which the catalyst was added in small portions to the reaction mixture. This 
provided significantly better yields since at elevated temperatures catalyst 
decomposition led to incomplete conversion. As can be seen in Table 1, RCM of 
precursors 10 and 11 proceeded readily under these conditions to form the 
corresponding unsaturated five- and six-membered lactams 14 and 15 in 99 and 80% 
yield, respectively (entries 1 and 2). It appeared that in these cases the benzyl 
protecting group on the nitrogen was essential for cyclization to occur. Without a 
protecting group, subjection to the metathesis catalyst did not lead to cyclization, but 
eventually (upon prolonged reaction times) to decomposition of the amides. The 
identity of the five-membered ring lactam 14 was unambiguously confirmed through 
an X-ray crystallographic determination of the crystal structure (Fig. 1).17 
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Figure 1. X-ray crystal structure of the five-membered ring lactam 14. 
 
Unfortunately, the eight-membered ring precursor 12 did not provide any 
cyclization product at all. Furthermore, the allylglycinol-derived precursor 13 
underwent selective ring closure to the six-membered ring lactam in excellent yield. 
At this point, having realized some successful examples of fluoroacrylate 
metathesis, we adjusted our strategy and aimed for new classes of heterocycles, 
which would allow straightforward variation of substituents at multiple positions. In 
the new strategy, we intended to start from commercially available 2-amino-4-
pentenoic acid, a so-called trifunctional amino acid,18 which allows the use of the 
nitrogen and ester substituent as an attachment point for introduction of new 
substituents in a later stage, and thus generate series of potentially biologically active 
cyclic fluorinated amino acid derivatives. 
The first vinyl fluoride-containing metathesis precursor 20 was obtained via 
standard protection of 2-amino-4-pentenoic acid (18, allylglycine) as the 
corresponding Boc-protected methyl ester (19), followed by alkylation with 2-fluoro-
1-chloro-2-propene using NaH in DMF in 79% overall yield (Scheme 4). 
 
H2N CO2H HN CO2Me
Boc
19 (90%)
NaH
DMF, rt
N
Boc
20 (79%)
CO2Me
F
Cl
F
1) SOCl2
    MeOH
2) Boc2O
    Et3N
    CH2Cl2
18  
Scheme 4. Synthesis of precursor 20. 
 
In addition, other specifically functionalized metathesis precursors were 
synthesized (Table 2). This sequence also commenced with allylglycine (18), which 
was first transformed into the sulfonamides 21-23 (TMSCl, CH2Cl2 reflux, then 
sulfonyl chloride, Et3N) in good yields, followed by introduction of differently 
substituted benzylamines at the carboxylic acid position (HOBt, EDCI, CH2Cl2, rt, 1 
h, then benzylamine, rt, 12 h) to give the amides 24-26. The amide formation also 
proceeded in very good to excellent yields.  
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Table 2. Yields for the synthesis of RCM precursors. 
HN CO2H
PG
HN
O
X
PG
N
O
X
PG
H2N CO2H
F
21-23 24-26 27-2918
1) Me3SiCl, CH2Cl2
reflux, 2 h
2) ArSO2Cl, Et3N
CH2Cl2, rt, 1 h
HOBt, EDCI
CH2Cl2, rt, 1h
benzylamine
rt, 12 h
NaH, DMF
Cl
F
rt  or 50 ºC, 12 h
 
Entry PG Product 
(Yield) 
X Product 
(Yield) 
Product 
(Yield) 
 
1 
 
 
 
21 (86%) 
 
HN
 
 
24 (80%) 
 
27 (9%) 
 
2 O2S
MeO
Cl 
 
22 (80%) 
 
F
F
HN
 
 
25 (87%) 
 
28 (10%) 
 
3 O2S
MeO
Cl 
 
23 (80%) 
  
 
26 (89%) 
 
 
29 (30%) 
 
 
Finally, the 2-fluoro-2-propenyl substituent was introduced at the 
sulfonamide nitrogen. As can be seen from Table 2, this resulted in rather 
disappointing yields of the target products 27 and 28 (entries 1 and 2). A different 
solvent (THF) or base (NaHMDS) and variable amounts of 1-chloro-2-fluoropropene 
(up to 2 equiv) did not give better results. Adding NaI did not improve the reaction 
either, only raising the temperature to 50 °C gave a significant increase in the yield to 
30% for product 29 (entry 3). The lower alkylation yields as compared to 20 might be 
explained by the lower nucleophilicity of the sulfonamides, but these problems could 
also be due to the presence of the amide nitrogen, which may give rise to side 
products. Gratifyingly, all four precursors 20 and 27-29 underwent facile cyclization 
under the previously optimized conditions (Grubbs-II catalyst, added in portions 
during the reaction, toluene, 100 °C, Table 3).  
Compound 20 gave a somewhat faster cyclization reaction, with a lower 
amount of catalyst. This may have to do with the nature of the side chain, where the 
methyl ester interferes less with the cyclization than the amide substituents in 
precursors 27-29. A variety of other conditions (lower temperatures, lower and 
higher catalyst loading (added both in portions and at once), different solvents) was 
also screened. However, no clear difference in yields was observed, the cyclizations 
proceeded smoothly in very good to excellent yields. 
Ts
HN
Cl
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Table 3. RCM to functionalized cyclic amino acid derivatives. 
Entry Precursor Cat 
(mol%) 
Time 
(min) 
Product (yield) 
 
 
 
1 
 
 
 
20 
 
 
 
2.5 
 
 
 
30 
 
 
 
30 (99%) 
 
 
 
2 
 
27 
 
 
 
5 
 
 
 
50 
 
 
 
31 (74%)a 
 
 
 
 
 
3 28 
 
 
 
 
 
5 
 
 
 
 
 
60 32 (99%) 
 
 
 
 
4 29 
 
 
 
 
5 
 
 
 
 
60 
 
33 (90%) 
a The reaction was carried out in a microwave oven: toluene, 100 °C, 300 W, 5 mol% 
Grubbs-II catalyst, 50 min. 
 
The cyclization of 27 (entry 2) was also carried out in a microwave (toluene, 
100 °C, 300 W, 5 mol% catalyst, 50 min) to see if this would lead to a faster and/or 
higher yielding reaction. However, no clear increase of the yield was observed. In 
conclusion, a series of functionalized cyclic vinyl fluoride-containing amino acids 
was obtained in a straightforward manner.  
Clearly, the sequence contains one low-yielding step, which renders the pathway less 
suitable for the production of large libraries of compounds. Therefore, we 
investigated whether building block 30 – readily accessible in good yields – could be 
used as a useful starting point for further functionalization. Initially, we focused on a 
pathway consisting of Boc-deprotection/functionalization, followed by ester 
hydrolysis/amide formation, which is outlined in Scheme 6. 
N
Boc
CO2Me
F
N
F
Boc
CO2Me
N
O
H
N
Ts
F
N
O
H
N
F
Ts
N
O
H
N
SO2
F
F
MeO
Cl
F
N
F
O
H
N
SO2
MeO
Cl
F
F
N
O
H
N
SO2
MeO
Cl
Cl
F
N
F
O
H
N
SO2
MeO
Cl
Cl
Chapter 4 
72 
TFA-mediated Boc-deprotection proceeded in excellent yield, but 
sulfonylation of the nitrogen (Hünig’s base, sulfonyl chloride, CH2Cl2) gave a rather 
disappointing 23% yield of sulfonamide 35. Then, ester hydrolysis (LiOH, THF/H2O) 
followed by amide formation resulted in the target compound 37. However, the low 
yield in the amide formation, combined with the poor sulfonylation reaction 
prompted us to reverse the order of events. 
 
N
F
O
H
N
HOBT, EDCI
CH2Cl2, rt, 1 h
N CO2Me
F
Boc
SO2
MeO
Cl
CF3
Cl
MeO
Cl
ClO2S
N
H
F
CO2Me
34 (99%)
LiOH
THF/H2O
N
F
CO2R
SO2
MeO
Cl
Cl
CF3
H2N
35 R = Me (23%)
36 R = H  (99%)
37 (22%)
30
TFA
CH2Cl2
0 °C to rt
iPr2NEt
 
Scheme 6. Synthesis using a Boc-deprotection/functionalization pathway. 
 
Thus, ester hydrolysis under similar conditions was again followed by amide 
formation with appropriate benzylamines to give 39 and 40 in good overall yields 
(Scheme 7).  
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0 °C to rt
R
41 R = A (99%)
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CH2Cl2
R
43 R = A (33%)
37 R = B (32%)
 
Scheme 7. Synthesis using a functionalization/Boc-deprotection pathway. 
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Boc-deprotection using TFA and subsequent sulfonylation (Hünig’s base, sulfonyl 
chloride, CH2Cl2) provided the target piperidines 43 and 37. Although the final step 
gave a relatively low yield, this sequence gives by far the highest overall yield of all 
the sequences that have been evaluated. Also in terms of ease of functionalization, 
the latter pathway is preferred: the versatile scaffold 30 was prepared in a scalable 
manner and appeared a useful starting point to synthesize series of the desired 
piperidines. 
 
4.3 CONCLUSION 
 
Generally applicable routes were developed for the synthesis of vinyl 
fluoride-containing building blocks, which may be relevant for the agrochemical and 
pharmaceutical industry. Key step in this sequence is ring-closing metathesis of vinyl 
fluorides, which were shown to readily undergo a ruthenium-mediated cyclization 
process in very good yields. Furthermore, different pathways were evaluated to 
probe combinatorial approaches resulting in series of highly functionalized, 
fluorinated and potentially bioactive cyclic amino acid derivatives.  
 
4.4 EXPERIMENTAL SECTION 
 
N-Allyl-N-benzyl-2-fluoroacrylamide (10):19 
 A solution of N-allyl-N-benzylamine (240 mg, 1.63 mmol) and 
triethylamine (0.227 mL, 164.9 mg, 1,63 mmol) in Et2O (1 mL) was added 
dropwise at –78 °C to a solution of 2-fluoroacryloyl fluoride (12, Scheme 
3 Chapter 2, 150 mg, 1.63 mmol) in Et2O (1 mL). The reaction mixture 
was stirred overnight thereby slowly reaching room temperature. The 
mixture was concentrated and the residue was purified using column 
chromatography (heptane/EtOAc 6:1) to give fluoride 10 (145 mg, 41%) as a colorless 
oil. IR (neat, cm–1): 3062, 2987, 2887, 2800, 1726, 1443, 1261, 1174, 1080, 1016, 800; 1H 
NMR (300 MHz, CDCl3) δ = 7.35-7.23 (m, 5H, ArH), 5.83-5.70 (m, 1H, CH2=CH), 5.32 
(dd, J = 3.5, 47.3 Hz, 1H, FC=CHtrans), 5.21 (dd, J = 3.4, 16.8 Hz, 1H, FC=CHcis), 5.28-5.04 
(m, 2H, CH2=CH), 4.57 (s, 2H, CH2Ph), 3.88 (br s, 2H, CHCH2); 13C NMR (75 MHz, 
CDCl3, some signals appear as rotamers) δ = 157.5 (d, J = 271.7 Hz, CF), 132.8, 128.7, 
127.6, 118.5, 99.8 (d, J = 14.4 Hz, CCF), 50.8 + 50.1, 48.4 + 47.9; HRMS calcd for 
C13H14NOF (M+) 219.1059, found 219.1059. 
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N-Benzyl-N-but-3-enyl-2-fluoroacrylamide (11):  
To a suspension of NaH (154 mg, 6.4 mmol) in DMF (20 mL) was added 
at rt but-3-enyl-carbamic acid tert-butyl ester20 (1.0 g, 5.8 mmol). After 
stirring for 15 min, benzylbromide (1.1 g, 6.4 mmol) was added dropwise 
at rt. The reaction was stirred for 12 h, quenched with water (20 mL) and 
extracted with Et2O (3 × 30 mL). The ether layers were dried (MgSO4), 
evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 10:1) to give Benzyl-but-3-enyl-carbamic acid tert-butyl ester (1.49 g, 
99%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ = 7.37-7.29 (m, 5H, ArH), 5.77-
5.73 (m, 1H, CH2=CH), 5.12-5.49 (m, 2H, CH2=CH), 4.56-4.43 (m, 2H CH2Ph), 3.2 (br s, 
2H, NCH2CH2), 2.25-2.22 (m, 2H, NCH2CH2), 1.44 (s, 9H, C(CH3)3).Trifluoro acetic-
acid (3 mL, 38.8 mmol) was added at room temperature to a solution of Benzyl-but-3-
enyl-carbamic acid tert-butyl ester (520 mg, 2.0 mmol) in CH2Cl2 (11 mL). The 
reaction mixture was stirred for 2 hours then AcOEt (10 mL) and a solution of NaOH 
(1M, 10 mL) were introduced. The water layer was then extracted with AcOEt (3 × 10 
mL) and dried over MgSO4. After removal of the solvent, the crude product benzyl-
but-3-enylamine was obtained (161 mg, 50%) as a colorless oil and it was used 
without purification for the next step. A solution of N-benzyl-N-but-3-enylamine (322 
mg, 2.01 mmol) and triethylamine (0.31 mL, 2.23 mmol) in Et2O (2 mL) was added 
dropwise at –78 °C to a solution of 2-fluoroacryloyl fluoride (12, Scheme 3 Chapter 2, 
205 mg, 2.23 mmol) in Et2O (2 mL). The reaction mixture was stirred overnight 
thereby slowly reaching room temperature. The mixture was concentrated and the 
residue was purified using column chromatography (heptane/EtOAc 6:1) to give 11 
(140 mg, 30%) as a colorless oil. IR (neat, cm–1): 3062, 3036, 2924, 2843, 1640, 1424, 
1359, 1178, 996, 919, 884, 728, 689; 1H NMR (300 MHz, CDCl3) δ = 7.32-7.22 (m, 5H, 
ArH), 5.74-5.65 (m, 1H, CH2=CH), 5.38 (br s, 1H, FC=CH), 5.21(br s, 1H, FC=CH), 5.13-
5.0 (m, 2H, CH2=CH), 4.61 (s, 2H CH2Ph), 3.36 (t, J = 7.5 Hz, 2H, NCH2CH2), 2.35-2.28 
(m, 2H, NCH2CH2); 13C NMR (75 MHz, CDCl3, some signals appear as rotamers) δ = 
162.3 (d, J = 30.1 Hz, FCC=O), 157.6 (d, J = 269.2 Hz, CF=C), 136.3, 134.7 + 134.0, 128.6, 
127.6, 126.9, 117.6-116.9 (m, CH2=CH), 99.8-99.1 (m, CH2=CF), 52.2-52.0 + 49.2-49.1 (m, 
NCH2CH2), 47.3-47.2 + 45.5-45.3 (m, CH2Ph), 33.5-33.3 + 31.7-31.5 (m, NCH2CH2); 
HRMS calcd for C14H16NOF (M+) 233.1216, found 233.1209. 
 
N-Benzyl-2-fluoro-N-(hex-5-enyl)acrylamide (12):  
A solution of N-benzylhex-5-en-1-amine21 (359 mg, 1.90 mmol) and 
triethylamine (0.26 mL, 192.3 mg, 1.90 mmol) in Et2O (1 mL) was added 
dropwise at –78 °C to a solution of 2-fluoroacryloyl fluoride (12, 148 mg, 
2.0 mmol) in Et2O (1 mL). The reaction mixture was stirred overnight 
thereby slowly reaching room temperature. The mixture was 
concentrated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give fluoride 12 (313 mg, 63%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ = 7.32-7.23 (m, 5H, ArH), 5.77-5.66 (m, 1H, 
CH2=CH), 5.37-4.91 (m, 4H, FC=CH2, CH2=CH), 4.59 (s, 2H, CH2Ph), 3.28 (t, J = 7.8 Hz, 
2H, NCH2CH2), 2.06-1.99 (m, 2H, N(CH2)3CH2), 1.58 (brs, 2H, NCH2CH2), 1.39-1.25 
(m, 2H, N(CH2)2CH2); 13C NMR (75 MHz, CDCl3) δ = 162.3 (d, J = 29.3 Hz, FCC=O), 
157.5 (d, J = 308.2 Hz, CF=C), 130.5, 128.7, 128.0, 127.6, 114.9, 99.3-99.2 (m, CH2=CF), 
48.9, 47.8, 45.8, 33.5, 26.3. 
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2-Fluoroacrylic acid 2-[benzyl-(2-fluoroacryloyl)amino]pent-4-enyl ester (13):  
To a stirred solution of 2-amino-pent-4-enoic acid methyl ester 
hydrochloride22 (1.0 g, 6 mmol) in CH2Cl2 (15 mL) were added 
MgSO4 (7.5 g, 62 mmol), triethylamine (0.83 mL, 6 mmol) and 
benzaldehyde (0.61 mL, 6 mmol). The reaction mixture was 
stirred under N2 atmospere at rt overnight. The mixture was 
filtered throudh celite and the solvent was evaporated. The crude 
product was taken up with ether, filtered through celite again and the solvent was 
evaporated. Purification is not necessary for the next step. To a stirred solution of the 
imine (1.3 g, 6 mmol) in MeOH (10 mL) at 0 °C, NaBH4 (0.63 g, 16.6 mmol) was 
added in small portions. The reaction mixture was stirred for 6 h, quenched with 
saturated solution of NaHCO3 (10 mL) and extracted with ether (3 × 10 mL), the 
combined organic layers were washed with saturated solution of NaHCO3 (10 mL) 
and NaCl (10 mL), dried with MgSO4. After removal of the solvent the residue was 
purified using column chromatography (heptane/EtOAc from 6:1 to 3:1) to give the 
methyl N-benzyl-2-amino-4-pentenol (573 mg, 50%) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ = 7.28-7.22 (m, 5H, ArH), 5.77-5.68 (m, 1H, CH2=CH), 5.11-5.05 (m, 
2H, CH2=CH), 3.79-3.76 (m, 2H, CH2Ph), 3.66-3.61 (m, 1H, CH2OH), 3.36-3.31 (m, 1H, 
CH2OH), 2.78-2.75 (m, 1H, CHCH2OH), 2.26-2.22 (m, 2H, H2C=CHCH2 ). A solution of 
N-benzyl-2-amino-4-pentenol(425 mg, 2.23 mmol) and triethylamine (0.62 mL, 4.45 
mmol) in Et2O (2 mL) was added dropwise at –78 °C to a solution of 2-fluoroacryloyl 
fluoride (12, Scheme 3 Chapter 2, 409 mg, 4.45 mmol) in ether (2 mL). The reaction 
mixture was stirred overnight reaching slowly room temperature. The mixture was 
concentrated and the residue was purified using column chromatography 
(heptane/EtOAc 6:1) to give 13 (149 mg, 20%) as a colorless oil. IR (neat, cm–1): 3010, 
2919, 1744, 1643, 1446,1424, 1317, 1163, 988, 926, 780, 720, 689; 1H NMR (300 MHz, 
CDCl3) δ = 7.28-7.23 (m, 5H, ArH), 5.70-5.56 (m, 1H, CH2=CH), 5.56 (dd, J = 3.3, 42.9 
Hz, 1H, NCFC=CHtrans), 5.29 (dd, J = 3.3, 13.0 Hz, 1H, NCFC=CHcis), 5.34-5.05 (m, 4H, 
CH2=CF + CH2=CH), 4.68 (br s, 2H, CH2Ph), 4.43 (br s, 2H, CHCH2O), 4.25 (br s, 1H, 
CHCH2O), 2.44 (br s, 2H, NCHCH2); 13C NMR (75 MHz, CDCl3, some signals appear 
as rotamers, the signals of the quarternary carbons are not visible) δ = 135.0, 128.6, 
128.0, 127.4, 118.6 + 118.6, 102.8-102-4 (m, FC=CH2), 99.2-99.8 (m, FC=CH2), 64.8 + 64.8, 
57.1 + 56.9, 56.7 + 56.6, 34.14; HRMS calcd for C18H19NO3F2 (M+) 335.1333, found 
335.1332.  
 
General procedure for the RCM reactions 
To a 0.01 M solution of the diene in dry toluene under an inert atmosphere, Grubbs-II 
catalyst was added at 100 °C. Stirring was continued until the reaction was complete 
(indicated by TLC or GC), followed by concentration of the reaction mixture and 
subsequent purification with column chromatography. 
 
1-Benzyl-3-fluoro-1,5-dihydropyrrol-2-one (14): 
To a solution of N-allyl-N-benzyl-2-fluoroacrylamide (10, 50 mg, 0.23 
mmol) in dry toluene (20 mL) Grubbs-II (7 mol%) was added at 100 °C in 
small portions. The reaction was complete in 4 h. The mixture was 
evaporated and the product was purified using column chromatography 
(heptane/EtOAc 3:1) to give 14 (44 mg, 99%) as a white solid.23 Mp= 37–41 
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°C; IR (neat, cm–1): 3058, 2920, 2854, 1697, 1664, 1452, 1232, 1219, 988, 926, 780, 720, 
689; 1H NMR (300 MHz, CDCl3) δ = 7.35-7.20 (m, 5H, ArH), 6.24-6.21 (m, 1H, FC=CH), 
4.63 (s, 2H, CH2Ph), 3.74-3.72 (m, 2H, CHCH2); 13C NMR (75 MHz, CDCl3) δ = 162.7 
(d, J = 31.2 Hz, FCC=O), 152.7 (d, J = 275.7 Hz, CF), 136.2, 128.8, 128.1, 127.8, 112.7 (d, J 
= 7.4 Hz, HC=CF), 47.1, 45.5 (d, J = 5.4 Hz, CH2CH=CF); HRMS calcd for C11H10NOF 
(M+) 191.0764, found 191.0740. 
 
1-Benzyl-3-fluoro-5,6-dihydro-1H-pyridin-2-one (15):  
To a solution of N-benzyl-N-3-butenyl-2-fluoroacrylamide (11, 34 mg, 0.15 
mmol) in dry toluene (10 mL) Grubbs-II (7 mol%) was added at 100 °C in 
small portions. The reaction was complete in 4 h. The mixture was 
evaporated and the product was purified using column chromatography 
(heptane/EtOAc 3:1) to give 15 (25 mg, 80%) as an amorphous solid. IR 
(neat, cm-1): 3058, 2920, 1640, 1428, 1318, 1155, 910, 730, 690; 1H NMR (300 MHz, 
CDCl3) δ = 7.34-7.25 (m, 5H, ArH), 5.97 (dt, J = 4.5, 10.5 Hz, 1H, FC=CH), 4.61 (s, 2H 
CH2Ph), 3.32 (t, J = 7.3 Hz, 2H, NCH2CH2), 2.39-2.35 (m, 2H, NCH2CH2); 13C NMR (75 
MHz, CDCl3, some signals appear as rotamers) δ = 159.6 (d, J = 30.6 Hz, FCC=O), 
149.7 (d, J = 253.3 Hz, CF), 136.6, 128.6, 128.0, 127.6, 112.7 (d, J = 14.5 Hz, HC=CF), 50.0 
+ 49.9, 44.8, 21.6 (d, J = 5.6 Hz, CH2CH=CF); HRMS calcd for C12H12NOF (M+) 
205.0903, found 205.0910. 
 
2-Fluoroacrylic acid 1-benzyl-5-fluoro-6-oxo-1,2,3,6-tetrahydropyridin-2-ylmethyl 
ester (17):  
To a solution of 2-fluoroacrylic acid 2-[benzyl-(2-fluoroacryloyl) 
amino]pent-4-enyl ester (13, 102 mg, 0.30 mmol) in dry toluene ( 
40 mL) Grubbs-II (4 mol%) was added at 100 °C in small portions. 
The reaction was complete in 4 h. The mixture was evaporated 
and the residue was purified using column chormatography (heptane/EtOAc 3:1) to 
give 17 (91 mg, 99%) as an amorphous white solid. IR (neat, cm–1): 3050, 2915, 2850, 
1744, 1658, 1450, 1260, 1156, 1022, 798, 698; 1H NMR (300 MHz, CDCl3,) δ = 7.33-7.13 
(m, 5H, ArH), 5.87-5.83 (m, 1H, NCFC=CH), 5.65 (dd, J = 3.6, 42.9 Hz, 1H, FC=CH), 
5.38-5.30 (m, 2H, FC=CH + CH2Ph), 4.35-4.21 (m, 2H, CHCH2O), 4.06 (d, J = 14.4, 1H, 
CH2Ph), 3.73-3.67 (m, 1H, NCH), 2.33 (s, 2H, NCHCH2); 13C NMR (75 MHz, CDCl3) δ 
= 159.5 (d, J = 36.5 Hz, FCC=ON), 158.2 (d, J = 30.6 Hz, FCC=OO), 152.2 (d, J = 268.8 
Hz, CH2=CF), 148.8 (d, J = 260.8 Hz, CH=CF) 136.5, 128.6, 127.7, 125.0, 110.0 (d, J = 15.0 
Hz, CH=CF), 103.6 (d, J = 14.6 Hz, CH2=CF), 63.8, 52.3, 48.5, 23.4; HRMS calcd for 
C16H15NO3F2 (M+) 307.1020, found 307.1021. 
 
2-[tert-Butoxycarbonyl-(2-fluoroallyl)amino]pent-4-enoic acid methyl ester (20): 
To a suspension of NaH (155 mg, 6.5 mmol) in DMF (10 mL) was 
added Boc-protected allylglycine methyl ester (19, 740 mg, 3.20 mmol) 
at room temperature. After stirring for 15 min, 3-chloro-2-
fluoropropene (301 mg, 3.20 mmol) was added. The reaction was 
stirred for 12 h, quenched with water (7 mL) and extracted with Et2O (3 × 10 mL). The 
ether layer was dried MgSO4), the solvent evaporated and the residue purified using 
column chromatography (heptane/EtOAc 10:1) to give 20 (726 mg, 79%) as a colorless 
oil. IR (neat, cm–1): 2976, 1744, 1701, 1450, 1368, 1243, 1165, 1001, 932, 862, 780; 1H 
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NMR (300 MHz, CDCl3): δ = 5.84–5.70 (m, 1H, CH2=CH), 5.14–5.05 (m, 2H, HC=CH, 
FC=CH), 4.69–4.39 (m, 3H, HC=CH, FC=CH, COCH), 4.12–3.71 (m, 2H, FCCH2), 3.70 
(s, 3H, CH3), 2.77–2.66 (m, 1H, HCCH=CH2), 2.65–2.53 (m, 1H, HCCH=CH2), 1.44 (s, 
9H, 3CH3); 13C NMR (75 MHz, CDCl3, some signals appear as rotamers): δ = 171.1 + 
170.9, 162.1 (d, J = 259 Hz, CF) + 159.5 (d, J = 255 Hz, CF), 154.8 + 154.3, 133.9 + 131.9, 
119.2 + 117.8, 92.6 (d, J = 16.1 Hz, FC=C), 91.4 (d, J = 17.8 Hz, FC=C), 81.2 + 81.0, 60.1 + 
58.9, 53.0 + 52.1, 48.1 (d, J = 33.0 Hz, FCCH2) + 46 6 (d, J = 35.6 Hz, FCCH2), 35.0 + 34.0, 
28.4; HRMS (EI) calcd for C14H22FNO4 (M+) 287.1533, found 287.1534. 
 
2-[(2-Fluoroallyl)(toluene-4-sulfonyl)amino]-4-pentenoic acid benzylamide (27): 
To a suspension of allylglycine (0.57 g, 5.00 mmol) in CH2Cl2 (10 
mL) was added Me3SiCl (0.54 g, 5.00 mmol). The mixture was 
heated at reflux for 2 h, Et3N (1.4 mL, 10.0 mmol) was added, 
followed by addition of a solution of p-toluenesulfonyl chloride 
(0.95 g, 5.00 mmol) in CH2Cl2 (5 mL).23 The resulting mixture was vigorously stirred 
for 1 h at rt, MeOH (0.81 mL, 20.0 mmol) was added, and the mixture was 
evaporated. The residue was dissolved in water and brought to pH 8 using aqueous 
K2CO3. The aqueous layer was washed with diethyl ether (3 × 10 mL), acidified to pH 
1 using 1 N hydrochloric acid (1 N) and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried (MgSO4) and the solvent was evaporated to 
afford 21 (1.15 g, 86%) as a white solid. The crude acid 21 (1.15 g, 4.29 mmol) was 
dissolved in CH2Cl2 (86 mL) and stirred for 1 h with 1-hydroxybenzotriazole (HOBt, 
0.637 g, 4.72 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDCI, 0.903 g, 4.72 mmol). Benzylamine (1.4 mL, 12.9 mmol) was 
added and the mixture was stirred for 12 h. The solvent was evaporated and the 
residue was purified using column chromatography (heptane/EtOAc 3:1 to 1:1) to 
give 24 (1.18 g, 80%) as a white solid. Mp= 141-144 °C, IR (neat, cm–1): 3322, 3235, 
3067, 3036, 2920, 1645, 1554, 1455, 1338, 1161, 1070, 927, 815, 698; 1H NMR (300 MHz, 
CDCl3, 25 °C, TMS): δ=7.69 (d, J = 8.4 Hz, 2 H, Ph), 7.32-7.17 (m, 7 H, Ph), 6.72 (br s, 1 
H, C=ONH), 5.44-5.30 (m, 1 H, CH2=CH), 5.06-4.95 (m, 3 H, TsNH, H2C=CH), 4.43-
4.30 (m, 2 H, NCH2Ph), 3.78-3.71 (m, 1 H, COCH), 2.54-2.43 (m, 1 H, HCCH=CH2), 
2.43 (s, 3 H, CH3), 2.29-2.20 (m, 1 H, HCCH=CH2); 13C NMR (75 MHz, CDCl3, 25 °C) 
δ=170.2, 144.2, 137.7, 136.3, 132.2, 129.9, 128.7, 127.7, 127.6, 127.4, 120.3, 56.1, 43.7, 37.0, 
21.7; HRMS (EI) calcd for C19H22N2O3S (M+) 358.1351, found 358.1348. To a solution of 
24 (468 mg, 1.31 mmol) in DMF (3.5 mL) was added NaHMDS (135 μL of a 1 M 
solution in THF, 1.36 mmol), 3-chloro-2-fluoropropene (123 mg, 1.36 mmol) and NaI 
(8.5 mg, 0.055 mmol). After stirring at rt for 10 h, water (5 mL) was added and the 
mixture was extracted with EtOAC (3 × 5 mL). The combined organic layers were 
washed with water (3 × 5 mL), brine (3 × 5 mL), dried (Na2SO4) and evaporated. The 
residue was purified using column chromatography (heptane/EtOAc from 3:1 to 1:1) 
to give 27 (55 mg, 9%) as a yellow oil. IR (neat, cm–1): 3378, 3317, 3062, 3032, 2980, 
2924, 1675, 1528, 1338, 1156, 1087, 923, 815, 698, 664, 543; 1H NMR (300 MHz, CDCl3): 
δ = 7.67–7.64 (m, 2H, Ph), 7.32–7.22 (m, 7H, Ph), 6.78 (br s, 1H, NH), 5.37–5.23 (m, 1H, 
CH2=CH), 4.93–4.78 (m, 2H, H2C=CH), 4.66–4.25 (m, 5H, FC=CH2, NCH2Ph, COCH), 
4.15–3.90 (m, 2H, FCCH2), 2.79–2.70 (m, 1H, HCCH=CH2), 2.40 (s, 3H, CH3), 2.23–2.13 
(m, 1H, HCCH=CH2);13C NMR (75 MHz, CDCl3): δ = 168.7, 163.7 (d, J = 249 Hz, CF), 
144.0, 137.6, 136.4, 133.5, 129.6, 128.5, 127.7, 127.4, 118.0, 94.7 (d, J = 17.5 Hz, FC=C), 
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60.1, 44.7 (d, J = 30.2 Hz, FCCH2), 44.1, 33.1, 21.9; HRMS (EI) calcd for C22H25FN2O3S 
(M+) 416.157, found 416.1572. 
 
2-[(5-Chloro-2-methoxybenzenesulfonyl)-(2-fluoroallyl)amino]-4-pentenoic acid 
3,4-difluorobenzylamide (28):  
To a suspension of allylglycine (2.00 g, 17.4 mmol) in 
CH2Cl2 (35 mL) was added Me3SiCl (2.2 mL, 17.4 mmol). 
The mixture was heated at reflux for 2 h, Et3N (4.87 mL, 
34.8 mmol) was added, followed by a solution of 5-chloro-
2-methoxybenzenesulfonyl chloride (4.2 g, 17.4 mmol) in 
CH2Cl2 (17.5 mL). The resulting mixture was vigorously 
stirred for 1 h, MeOH (2.78 mL, 20.0 mmol) was added and the mixture was 
evaporated. The residue was dissolved in water and brought to pH 8 using aqueous 
K2CO3. The aqueous layer was washed with diethyl ether (3 × 10 mL), acidified to pH 
1 using 1 N hydrochloric acid (1 N) and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried (MgSO4) to afford 22 (4.41 g, 80%) as a yellow 
solid. A solution of the crude acid 22 (1.00 g, 3.13 mmol) in CH2Cl2 (65 mL) was 
stirred for 1 h at with HOBt (466 mg, 3.45 mmol) and EDCI (662 mg, 3.45 mmol). 3,4-
Difluorobenzylamine (1.1 mL, 9.39 mmol) was added, the mixture was stirred for 12 
h and the solvent was evaporated. The residue was dissolved in EtOAc (20 mL), 
washed with brine (10 mL) and aqueous NaHCO3 (10 mL). The combined water 
phases were reextracted with EtOAc (3 × 10 mL), and the combined organic layers 
were dried (MgSO4) and evaporated. The residue was crystallized (hepthane/Et2O 
3:1) to give 25 (1.21 g, 87%) as a white solid. Mp = 115–118°C; IR (neat, cm–1): 3309, 
3261, 3097, 3075, 2980, 2894, 1653, 1515, 1437, 1329, 1282, 1156, 1113, 1070, 1014, 897, 
815, 646; 1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 3.2 Hz, 1H, ArH), 7.55–7.52 (m, 
1H, ArH), 7.15–6.92 (m, 4H, 1H, ArH), 6.85 (br s, 1H, C=ONH), 5.57–5.44 (m, 2H, 
CH2=CH, TsNH), 5.15–5.05 (m, 2H, H2C=CH), 4.39–4.25 (m, 2H, NCH2), 3.95 (s, 3H, 
OCH3), 3.74 (t, J = 8.0 Hz, 1 H, COCH), 2.61–2.53 (m, 1H, HCCH=CH2), 2.34–2.24 (m, 
1H, HCCH=CH2); 13C NMR (75 MHz, CDCl3) δ = 170.3, 154.9, 150.1 (dd, J = 47.1, 247.0 
Hz, ArF), 149.9 (dd, J = 47.1, 247.0 Hz, ArF), 135.0–134.9 (m, ArF), 134.8, 132.0, 129.8, 
127.8, 125.8, 123.6–123.4 (m, ArF), 119.9, 117.0 (dd, J = 17.2, 61.7 Hz, ArF), 116.9 (dd, J 
= 17.2, 61.7 Hz, ArF), 113.6, 56.6, 56.5, 42.5, 37.1; HRMS (EI) calcd for C19H19ClF2N2O4S 
(M+) 444.0722, found 444.0718. To a suspension of NaH (70 mg, 2.88 mmol) in DMF (6 
mL) was added at 10 °C 25 (640 mg, 1.44 mmol). After stirring for 15 min, 3-chloro-2-
fluoropropene (135 mg, 1.44 mmol) was added dropwise at rt. The reaction was 
stirred for 12 h, quenched with water (6 mL) and extracted with Et2O (3 × 6 mL). The 
ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 3:1 to 1:1) to give 28 (30 mg, 10%) as a 
colorless oil. IR (neat, cm–1): 3379, 3087, 2950, 2846, 1679, 1607, 1585, 1519, 1478, 1434, 
1390, 1333, 1273, 1155, 1111, 1067, 1015, 913, 877, 817, 735, 647, 584; 1H NMR (400 
MHz, CDCl3): δ = 7.89 (d, J = 2.4 Hz, 1H, ArH), 7.53–7.50 (m, 1H, ArH), 7.15–7.00 (m, 
4H, ArH + NH), 6.92 (d, J = 8.8 Hz, 1H, ArH), 5.37–5.27 (m, 1H, CH2=CH), 4.99 (dd, J = 
1.2, 16.8 Hz, 1H, HHC=CH), 4.88 (dd, J = 0.8, 10.0 Hz, 1H, HHC=CH), 4.62–4.57 (m, 
1.5H, FC=CH2), 4.46–4.25 (m, 4.5H, FC=CH2 + NCH2 + NCH2CF), 3.88 (s, 4H, CH3 + 
COCH), 2.89–2.82 (m, 1H, HCCH=CH2), 2.35–2.27 (m, 1H, HCCH=CH2); 13C NMR 
(100 MHz, CDCl3, some signals appear as rotamers) δ = 169.2, 160.1 (d, J = 259.2 Hz, 
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C=CF), 155.3, 150.0 (dd, J = 58.4, 247.1 Hz, ArF), 149.9 (dd, J = 58.1 Hz, 247.2 Hz, ArF), 
134.9–134.8 (m, ArF), 134.7, 133.5, 131.0, 128.7, 125.7, 123.7 (m, ArF), 118.0, 117.3 (d, J 
= 18.1 Hz, ArF), 116.8 (d, J = 17.7 Hz, ArF), 113.6, 94.9 (d, J = 17.7 Hz, C=CF), 59.3, 56.4, 
44.9 (d, J = 29.9 Hz, CH2CF), 42.9, 32.6; HRMS (EI) calcd for C22H23ClF3N2O4S (M+ + H) 
503.0965, found 503.1019. 
 
2-(5-Chloro-2-methoxybenzenesufonyl)(2-fluoroallyl)amino]-4-pentenoic acid 2-
chlorobenzylamide (29):  
To a suspension of allylglycine (2.00 g, 17.4 mmol) in 
dichloromethane (35 mL) was added Me3SiCl (2.2 mL, 17.4 
mmol). The mixture was heated at reflux for 2 h, Et3N (4.87 
mL, 34.8 mmol) was added, followed by a solution of 5-
chloro-2-methoxybenzensulfonyl chloride (4.20 g, 17.4 mmol) 
in CH2Cl2 (17.5 mL). The resulting mixture was vigorously 
stirred for 1 h, MeOH (2.78 mL, 20.0 mmol) was added and the mixture was 
evaporated. The residue was dissolved in water and brought to pH 8 using aqueous 
K2CO3. The aqueous layer was washed with diethyl ether (3 × 10 mL), acidified to pH 
1 using 1 N hydrochloric acid (1 N) and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried (MgSO4) and the solvent was evaporated to 
afford 23 (4.41 g, 80%) as a yellow solid. A solution of the crude acid 23 in CH2Cl2 (35 
mL) was stirred for 1 h with HOBt (233 mg, 1.75 mmol) and EDCI (331 mg, 1.75 
mmol). 2-Chlorobenzylamine (250 μL, 1.75 mmol) was added, the mixture was 
stirred for 12 h and the solvent was evaporated. The residue was dissolved in EtOAc 
(20 mL), washed with brine (10 mL) and aqueous NaHCO3 (10 mL). The water layer 
was reextracted with EtOAc (3 × 10 mL), and the combined organic layers were dried 
(MgSO4) and evaporated. The residue was crystallized (hepthane/Et2O 3:1) to give 26 
(700 mg, 99%) as a white solid. Mp = 90-100 °C; IR (neat, cm–1): 3404, 3114, 3075, 2967, 
2933, 2846, 1653, 1528, 1480, 1437, 1325, 1277, 1156, 1018, 914, 750; 1H NMR (400 MHz, 
CDCl3, 25 °C, TMS): δ=7.85 (d, J = 2.4 Hz, 1 H, SO2Ph), 7.49-7.46 (m, 1 H, SO2Ph), 7.38-
7.35 (m, 1 H, Ph), 7.30-7.23(m, 3 H Ph), 6.90 (d, J = 8.8 Hz, 1 H, SO2Ph), 6.66 (br s, 1 H, 
C=ONH), 5.58-5.48 (m, 2 H, CH2=CH, TsNH), 5.11-5.04 (m, 2 H, H2C=CH), 4.48-4.37 
(m, 2 H, CH2Ph), 3.93 (s, 3 H, OCH3), 3.77-3.73 (m, 1 H, C=OCH), 2.61-2.54 (m, 1 H, 
HCCH=CH2), 2.33-2.26 (m, 1 H, HCCH=CH2); 13C NMR (75 MHz, CDCl3, 25 °C): 
δ=170.1, 154.9, 134.9, 134.6, 133.6, 133.4, 132.1, 129.7, 129.6, 129.5, 128.9, 127.9, 127.1, 
125.7, 119.7, 113.5, 56.6, 56.5, 41.5, 37.4; HRMS (EI) calcd for C19H20Cl2N2O4S (M+) 
442.0521, found 442.0514. 
To a suspension of NaH (34 mg, 1.43 mmol) in DMF (3 mL) was added 26 (310 mg, 
0.714 mmol). After stirring for 15 min, 1-chloro-2-fluoro-2-propene (67 mg, 0.714 
mmol) was added slowly at 50 °C. The reaction was stirred for 12 h at 50 °C, 
quenched with water (3 mL) and extracted with Et2O (3 × 3 mL). The ether layers 
were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 3:1 to 1:1) to give 29 (90 mg, 30%) as a colorless oil. 
IR (neat, cm–1): 3379, 2961, 2851, 2758, 2642, 2543, 1747, 1720, 1670, 1533, 1478, 1440, 
1390, 1333, 1270, 1198, 1174, 1138, 1070, 1015, 1006, 919, 875, 836, 798, 721, 644, 589; 1H 
NMR (400 MHz, CDCl3): δ = 7.88 (d, J = 2.4 Hz, 1H, ArH), 7.49–7.46 (m, 1H, ArH), 
7.37–7.35 (m, 2H, Ph), 7.27–7.22(m, 2H, ArH), 6.98 (br s, 1H, NH), 6.88 (d, J = 8.8 Hz, 
1H, ArH), 5.44–5.34 (m, 1H, CH2=CH), 4.99 (dd, J = 1.6, 17.2 Hz, 1H, FC=CH), 4.89 
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(dd, J = 1.2, 10.4 Hz, 1H, FC=CH), 4.57–4.51 (m, 3H, H2C=CH + COCH), 4.43–4.34 (m, 
4H, CH2Ph + FCCH2), 3.85 (s, 3H, OCH3), 2.87–2.79 (m, 1H, HCCH=CH2), 2.37–2.29 
(m, 1H, HCCH=CH2); 13C NMR (100 MHz, CDCl3): δ = 168.9, 160.3 (d, J = 259.3 Hz, 
CF), 155.2, 135.1, 134.6, 133.6, 133.4, 130.9, 129.9, 129.4, 128.85, 128.8, 126.9, 125.5, 
117.9, 113.5, 94.8 (d, J = 17.9 Hz, CH2=CF), 59.4, 56.3, 44.9 (d, J = 30.5 Hz, NCH2CF), 
41.5, 32.9; HRMS (EI) calcd for C22H29Cl2FN2O4S (M+ + H) 501.0786, found 501.0818. 
 
5-Fluoro-3,6-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl 
ester (30):  
To a solution of 20 (412 mg, 1.44 mmol) in dry toluene (160 mL) 
Grubbs-II (2.5 mol%) was added at 100 °C in small portions. The 
reaction was finished in 30 min. The solvent was evaporated and the product 
purified using column chromatography (heptane/EtOAc 10:1) to give 30 (369 mg, 
99%) as a colorless oil. IR (neat, cm–1): 2971, 2863, 1740, 1697, 1407, 1368, 1329, 1156, 
1104, 1022, 888, 811; 1H NMR (300 MHz, CDCl3): δ = 5.27–5.22 (m, 1H, FC=CH), 5.00–
4.98 (m, 1H, COCH), 4.09 (d, J = 17.4 Hz, 1H, FCCH), 3.84 (d, J = 18.6 Hz, 1H, FCCH), 
3.71 (s, 3H, CH3), 2.69–2.50 (m, 2H, H2CCH=CF), 1.49+1.46 (s, 9H, 3CH3); 13C NMR (75 
MHz, CDCl3): δ = 171.3, 155.0, 154.9 (d, J = 248.7 Hz, CF), 98.4 (d, J = 13.5 Hz, FC=C), 
81.2, 52.7, 51.1, 41.6 (d, J = 39.6 Hz, FCCH2), 28.6, 24.3; HRMS (technique) calcd for 
C12H18FNO4 (M+) 259.1220, found 259.1220. 
 
5-Fluoro-1-(toluene-4-sulfonyl)-1,2,3,6-tetrahydropyridine-2-carboxylic acid 
benzylamide (31):  
To a solution of 27 (41 mg, 98 μmol) in dry toluene (4 mL) in a 
resealable vial was added Grubbs-II (2.4 mg, 2 mol%). The 
mixture was heated in a microwave for 20 min at 300 W. The reaction was followed 
by GC and new portions of catalyst were added, followed by heating until the 
reaction was complete (at total of 5 mol% of catalyst, 50 min heating). The mixture 
was evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 3:1) to give 31 (35 mg, 74%) as a white solid: Mp = 90–93 °C; IR (neat, 
cm–1): 3378, 3356, 3317, 3062, 3028, 2924, 2863, 1671, 1524, 1342, 1165, 1091, 962, 815, 
698, 569; 1H NMR (300 MHz, CDCl3): δ = 7.66–7.63 (m, 2H, Ph), 7.33–7.20 (m, 7H, Ph), 
6.90 (br s, 1H, NH), 5.16–5.08 (m, 1H, FC=CH), 4.58–4.34 (m, 3H, NCH2Ph, COCH), 
4.17 (d, J = 17.4 Hz, 1H, FCCH), 3.76 (d, J = 18 Hz, 1H, FCCH), 2.84–2.76 (m, 1H, 
HCCH=CF), 2.41 (s, 3H, CH3), 1.87–1.80 (m, 1H, HCCH=CF); 13C NMR (75 MHz, 
CDCl3): δ = 168.1, 152.5 (d, J = 252.2 Hz, CF), 144.4, 137.7, 135.5, 130.0, 128.7, 127.5, 
127.4, 127.0, 100.0 (d, J = 13.5 Hz, FC=C), 54.0, 44.2, 41.1 (d, J = 39.3 Hz, FCCH2), 21.9, 
21.4; HRMS (technique) calcd for C20H21FN2O3S (M+) 388.1257, found 388.1258. 
 
1-(5-Chloro-2-methoxybenzenesufonyl)-5-fluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 3,4-difluorobenzylamide (32:  
To a solution of 28 (30 mg, 0.06 mmol) in dry toluene (12 
mL) Grubbs-II (5 mol%) was added at 100 °C in small 
portions. The reaction was complete in 60 min. The solvent 
was evaporated and the residue purified using column 
chromatography (heptane/EtOAc from 3:1 to 1:1) to give 32 
(28 mg, 99%) as slightly colored solid. Mp = 165–167 °C; IR 
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(neat, cm–1): 3329, 3109, 2956, 2923, 2846, 1714, 1648, 1519, 1484, 1429, 1390, 1333, 1273, 
1209, 1155, 1111, 1015, 949, 814, 647, 592; 1H NMR (400 MHz, CDCl3): δ = 7.92 (d, J = 
2.8 Hz, 1H, ArH), 7.54–7.51 (m, 1H, ArH), 7.16–6.93 (m, 5H, ArH + NH), 5.32–5.26 (m, 
1H, FC=CH), 4.44–4.40 (m, 4H, NCH2Ph, FCCH2N), 3.86 (s, 4H, OCH3 + COCH), 3.78–
3.72 (m, 1H, HCCH=CF), 1.87–1.81 (m, 1H, HCCH=CF); 13C NMR (100 MHz, CDCl3): 
δ = 168.5, 153.7 (d, J = 324.6 Hz, C=CF), 154.6, 150.9, 141.2, 140.1, 135.1, 131.2, 127.6, 
125.9, 123.5–123.4 (m, ArH), 117.7, 113.6, 99.5 (d, J = 13.7 Hz, C=CF), 56.5, 53.6, 43.1, 
41.1 (d, J = 41.1 Hz, CH2CF), 21.2; HRMS (EI) calcd for C20H19ClF3N2O4S (M+ + H) 
475.0660, found 475.0706. 
 
1-(5-Chloro-2-methoxybenzenesulfonyl)-5-fluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 2-chloro-benzylamide (33): 
To a solution of 29 (33 mg, 66 μmol) in dry toluene (15 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. 
The reaction was complete in 60 min. The solvent was 
evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 3:1 to 1:1) to give 33 (28 mg, 
90%) as a light yellow solid. Mp = 145–148 °C; IR (neat, cm–1): 3307, 3104, 2906, 1917, 
1714, 1665, 1514, 1478, 1437, 1388, 1338, 1273, 1245, 1163, 1017, 960, 812, 738, 587; 1H 
NMR (400 MHz, CDCl3): δ = 7.92 (d, J = 3.6 Hz, 1H, SO2Ph), 7.52–7.48 (m, 1H, ArH), 
7.40–7.23 (m, 4H, ArH), 7.03 (br s, 1H, NH), 6.91 (d, J = 12.4 Hz, 1H, ArH), 5.31–5.23 
(m, 1H, FC=CH), 4.61–4.38 (m, 4H, NCH2Ph + FCCH2N), 3.82 (s, 3H, OCH3), 3.74 (s, 
1H, COCH), 2.86–2.79 (m, 1H, HCCH=CF), 1.91–1.84 (m, 1H, HCCH=CF); 13C NMR 
(100 MHz, CDCl3): δ = 168.2, 155.2, 153.4 (d, J = 253.2 Hz, CF), 135.0, 133.6, 131.1, 
130.0, 129.7, 129.1, 127.9, 127.1, 125.9, 113.5, 99.7 (d, J = 13.9 Hz, C=CF), 56.4, 53.5, 42.1, 
41.0 (d, J = 40.4 Hz, NCH2CF), 21.3 (d, J = 6.1 Hz, CH2CH=CF); HRMS calcd for 
C20H20Cl2FN2O4S (M+ + H) 473.0550, found 473.0505. 
 
1-(5-Chloro-2-methoxybenzenesulfonyl)-5-fluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 4-chloro-3-trifluoromethyl 
benzylamide (37) as shown in Scheme 6: 
 Trifluoroacetic acid (5.0 mL, 6.45 mmol) was added to a 
solution of 30 (730 mg, 2.81 mmol) in CH2Cl2 (20 mL) at 0 
°C. The resulting mixture was stirred at rt for 6 h and the 
solvent was evaporated. Residual traces of trifluoroacetic 
acid were azeotropically removed using CH2Cl2 (3 × 10 mL). The crude compound 34 
was redissolved in CH2Cl2 (8 mL) and Hünig’s base (0.98 mL, 5.62 mmol) was added. 
After 15 min, 5-chloro-2-methoxybenzensulfonyl chloride (668 mg, 2.81 mmol) was 
added and the reaction mixture was stirred overnight. The solvent was evaporated 
and the residue was filtered through silica gel (heptane/EtOAc 3:1 to 1:1) to give 
crude 35 (235 mg, 23%) as a yellow oil. Crude 35 (60 mg, 0.17 mmol) was dissolved in 
THF/H2O (4:1 v/v, 1 mL), LiOH (8.2 mg, 0.34 mmol) was added and the reaction 
mixture was stirred at room temperature. Upon completion, the solution was 
acidified to pH 1 with 1 N hydrochloric acid and extracted with EtOAc (3 × 5 mL). 
The combined organic phases were dried (MgSO4) and the solvent evaporated to 
afford 36 (59 mg, 99%) as a yellow oil. This product was directly dissolved in CH2Cl2 
(5 mL) and treated with HOBt (26 mg, 0.189 mmol) and EDCI (36 mg, 0.189 mmol). 
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Then, 4-chloro-3-trifluoromethylbenzylamine (108 mg, 0.516 mmol) was added and 
the mixture was stirred for 12 h. The solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 3:1 to 1:1) to give 37 (20 mg, 
22%) as a white solid. Mp = 180–182 °C; IR (neat, cm–1): 3324, 3104, 3054, 2945, 2906, 
1717, 1657, 1528, 1478, 1322, 1273, 1163, 1144, 1015, 960, 817; 1H NMR (400 MHz, 
CDCl3): δ = 7.87 (d, J = 3.5 Hz, 1H, SO2Ph), 7.53–7.41 (m, 3H, ArH), 7.33 (d, J = 10.7 Hz, 
1H, ArH), 7.09 (br s, 1H, NH), 6.90 (d, J = 12 Hz, 1H, ArH), 5.29–5.21 (m, 1H, FC=CH), 
4.46–4.36 (m, 5H, NCH2Ph, COCH, FCCH2N), 3.83 (s, 3H, OCH3), 3.73 (d, J = 23.2 Hz, 
1H, HCCH=CF), 2.77 (brd, J = 22.7 Hz, 1H, HCCH=CF); 13C NMR (100 MHz, CDCl3): δ 
= 169.2, 155.6, 153.6 (d, J = 337.6 Hz, CF), 137.5, 135.2, 131.9, 131.8, 131.6-131.4 (m, 
ClC=CCF3), 131.2, 130.8, 129.3 (q, J = 92.4 Hz, CCF3), 127.5, 126.6 (q, J = 6.7 Hz, 
C=CCF3), 125.9, 122.9 (q, J = 362.8 Hz, CF3), 113.9, 99.7(d, J = 18.3 Hz, C=CF), 56.7, 53.8, 
43.2, 41.4(d, J = 54.5 Hz, CH2FC=C), 21.4; HRMS (EI) calcd for C21H18F4Cl2N2O4S (M+ + 
H) 541.0450, found 541.0379. 
 
1-(5-Chloro-2-methoxybenzenesufonyl)-5-fluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 2-methoxybenzylamide (43): 
Compound 30 (500 mg, 1.93 mmol) was dissolved in 
THF/H2O (3:1 v/v, 12 mL), LiOH (93 mg, 3.86 mmol) was 
added and the reaction mixture was stirred at room 
temperature until the reaction was complete. The solution 
was acidified to pH 1 with 1 N hydrochloric acid and 
extracted with EtOAc (3 × 10 mL). The combined organic 
phases were dried (MgSO4) and the solvent evaporated to afford 38 (200 mg, 0.82 
mmol, 99%) as a yellow oil. The crude product was dissolved in CH2Cl2 (7 mL) and 
reacted for 1 h with HOBt (122 mg, 0.90 mmol) and EDCI (173 mg, 0.90 mmol). 2-
Methoxybenzylamine (0.32 mL, 2.46 mmol) was added and the mixture was stirred 
for 12 h at rt. The solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 4:1 to 4:2) to give 39 (190 mg, 65%) as a colorless 
oil. IR (neat, cm–1): 3439,3329, 3065, 2972, 2928, 1692, 1602, 1519, 1492, 1459, 1410, 
1363, 1242,1166, 1105, 1026, 973, 888, 809, 751; 1H NMR (400 MHz, CDCl3): δ= 7.29–
7.19 (m, 2H, ArH), 6.92–6.83 (m, 2H, ArH), 6.53 (br s, 1H, NH), 5.34–5.28 (m, 1H, 
FC=CH), 4.89–4.74 (br m, 1H, COCH), 4.51–4.15 (m, 3H, NCH2Ph + FCCH2N), 3.83 (s, 
3H, OCH3), 3.65–3.59 (br m, 1H, FCCH2N), 2.79–2.73 (m, 1H, HCCH=CF), 2.39–2.32 
(m,1H, HCCH=CF); 13C NMR (100 MHz, CDCl3): δ = 169.5, 157.3, 155.4, 153.3 (d, J = 
246.1 Hz, CF), 129.4, 128.8, 125.7, 120.5, 110.1, 99.1–98.9 (m, CH=CF), 81.3, 55.0, 51.1, 
39.6–39.5 (m, CH2CH=CF), 31.6, 28.0, 22.5; HRMS calcd for C19H26FN2O4 (M + H)+, 
365.1803, found 365.1877. To a solution of compound 39 (190 mg, 0.52 mmol) in 
CH2Cl2 (5 mL) at 0 °C was added trifluoroacetic acid (0.48 mL, 6.3 mmol). The 
resulting mixture was stirred at rt for 6 h, the solvent was evaporated and residual 
traces of trifluoroacetic acid were azeotropically removed with dichloromethane (3 × 
10 mL). The crude mixture was redissolved in CH2Cl2 (4 mL) and Hünig’s base (0.29 
mL, 1.56 mmol) was added at room temperature. After 15 min, 5-chloro-2-
methoxybenzenesulfonyl chloride (125 mg, 0.52 mmol) was added and the reaction 
mixture was stirred overnight. The solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 3:1 to 1:1) to give 43 (80 mg, 
33%) as a white solid. Mp = 102–105 °C; IR (neat, cm–1): 3401, 324, 3071, 3005, 2934, 
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2840, 1717, 1676, 1588, 1519, 1481, 1440, 1390, 1338, 1270, 1245, 1160, 1113, 1015, 960, 
812, 735; 1H NMR (400 MHz, CDCl3): δ = 7.91 (d, J = 3.5 Hz, 1H, ArH), 7.51–7.47 (m, 
1H, ArH), 7.32–7.20 (m, 3H, ArH + NH), 6.94–6.88 (m, 3H, ArH), 5.28–5.20 (m, 1H, 
FC=CH), 4.54–4.11 (m, 5H, NCH2Ph + COCH + FCCH2N), 3.87 (s, 3H, OCH3), 3.79 (s, 
3H, OCH3), 3.73–3.67 (m, 1H, HCCH=CF), 2.85–2.78 (m,1H, HCCH=CF); 13C NMR 
(100 MHz, CDCl3): δ = 167.9, 157.8, 155.2, 153.6 (d, J = 347.1 Hz, CF), 135.0, 131.1, 
129.8, 128.2, 125.8, 125.7, 120.7, 113.5, 110.4, 99.5(d, J = 18.0 Hz, C=CF), 56.3, 55.3, 53.7, 
40.7, 31.9, 22.7; HRMS (EI) calcd for C21H21FClN2O5S (M+ – H) 467.0876, found 
467.0844.  
 
1-(5-Chloro-2-methoxybenzenesulfonyl)-5-fluoro-1,2,3,6-tetrahydropyridine- 
2-carboxylic acid 4-chloro-3-trifluoromethyl 
benzylamide (37) via route in Scheme 7:  
Asolution of compound 30 (500 mg, 1.93 mmol) in 
THF/H2O (3:1 v/v, 12 mL), was treated with LiOH (93 mg, 
3.86 mmol) and the mixture was stirred at until the 
reaction was complete (TLC). The solution was acidified 
to pH 1 with 1 N hydrochloric acid and extracted with EtOAc (3 × 10 mL). The 
combined organic phases were dried (MgSO4) and the solvent evaporated to afford 
38 (200 mg, 0.82 mmol, 99%) as a yellow oil. The crude product was dissolved in 
CH2Cl2 (7 mL) and reacted for 1 h with HOBt (122 mg, 0.90 mmol) and EDCI (173 mg, 
0.90 mmol). 2-Methoxybenzylamine (0.32 mL, 2.46 mmol) was added and the 
mixture was stirred for 12 h at rt. The solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 4:1 to 4:2) to give 40 (390 
mg, 84%) as a colorless oil. IR (neat, cm–1): 3324, 3071, 2972, 2934, 2862, 1695, 1665, 
1525, 1478, 1366, 1316, 1256, 1168, 1135, 1111, 1037, 984, 888; 1H NMR (400 MHz, 
CDCl3): δ = 7.54–7.35 (m, 3H, ArH), 6.4 (br s, 1H, NH), 5.44–5.37 (m, 1H, FC=CH), 4.91 
(br s, 1H, COCH), 4.52–4.13 (m, 3H, NCH2Ph, FCCHHN), 3.66–3.62 (m, 1H, 
FCCHHN), 2.78–2.73 (m, 1H, HHCCH=CF), 2.46–2.33 (m, 1H, HHCCH=CF); 13C NMR 
(100 MHz, CDCl3) some signals are not visible: δ = 170.9, 137.8, 132.1, 126.7, 122.9 (q, J 
= 362.8 Hz, CF3), 99.5 (d, J = 18.3 Hz, C=CF), 82.3, 47.4, 42.8, 32.1, 28.5, 22.9; HRMS (EI) 
calcd for C19H20F4ClN2O3 (M – H)– 435.1030, found 435.1099. To a solution of 
compound 40 (320 mg, 0.74 mmol) in CH2Cl2 (5 mL) at 0 °C was added trifluoroacetic 
acid (0.11 mL, 1.48 mmol). The resulting mixture was stirred at rt for 6 h, the solvent 
was evaporated and residual traces of trifluoroacetic acid were azeotropically 
removed with dichloromethane (3 × 10 mL). The crude mixture was redissolved in 
CH2Cl2 (3 mL) and Hünig’s base (0.3 mL, 1.43 mmol) was added at rt. After 15 min, 5-
chloro-2-methoxybenzenesulfonyl chloride (178 mg, 0.74 mmol) was added and the 
reaction mixture was stirred overnight. The solvent was evaporated and the residue 
was purified using column chromatography (heptane/EtOAc 3:1 to 1:1) to give 37 
(127.9 mg, 32%) as a white solid. Mp = 180–182 °C; IR (neat, cm–1): 3324, 3104, 3054, 
2945, 2906, 1717, 1657, 1528, 1478, 1322, 1273, 1163, 1144, 1015, 960, 817; 1H NMR (400 
MHz, CDCl3): δ = 7.87 (d, J = 3.5 Hz, 1H, SO2Ph), 7.53–7.41 (m, 3H, ArH), 7.33 (d, J = 
10.7 Hz, 1H, ArH), 7.09 (br s, 1H, NH), 6.90 (d, J = 12 Hz, 1H, ArH), 5.29–5.21 (m, 1H, 
FC=CH), 4.46–4.36 (m, 5H, NCH2Ph, COCH, FCCH2N), 3.83 (s, 3H, OCH3), 3.73 (d, J = 
23.5 Hz, 1H, HCCH=CF), 2.80-2.75 (m, 1H, HCCH=CF); 13C NMR (100 MHz, CDCl3): δ 
= 169.2, 155.6, 153.6 (d, J = 337 Hz, CF), 137.5, 135.2, 131.9, 131.8, 131.6–131.4 (m, 
N
F
O
H
N
SO2
MeO
Cl
CF3
Cl
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ClC=CCF3), 131.2, 130.8, 129.3 (q, J = 92.4 Hz, CCF3), 127.5, 126.6 (q, J = 6.7 Hz, 
C=CCF3), 125.9, 122.9 (q, J = 362 Hz, CF3), 113.9, 99.7 (d, J = 18.3 Hz, C=CF), 56.7, 53.8, 
43.2, 41.4(d, J = 54.5 Hz, CH2FC=C), 21.4; HRMS (EI) calcd for C21H18F4Cl2N2O4S (M+ + 
H) 541.0450, found 541.0379. 
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CHAPTER 5 
RCM-MEDIATED SYNTHESIS OF FLUORIDE- AND TRIFLUOROMETHYL-
CONTAINING N-SULFONYLATED NITROGEN HETEROCYCLES 
 
 
 
Keywords: Mitsunobu functionalization / Fluorinated RCM precursors / Fluoride- 
and trifluoromethyl-containing N-sulfonylated nitrogen heterocycles / 
Trifluoromethyl-substituted pyrrole 
 
 
Abstract٭ 
The synthesis of fluoride- and trifluoromethyl-containing N-sulfonylated nitrogen 
heterocycles is described. A first crucial step is a Mitsunobu functionalization of 
intermediate sulfonamides using commercially available unsaturated alcohols, which 
gives efficient access to fluorinated RCM precursors. Key step is a ring-closing 
metathesis reaction leading to the corresponding fluoride- and trifluoromethyl-
substituted heterocyclic building blocks. Furthermore, aminopalladation of the same 
sulfonamide intermediates provides access to trifuoromethyl-containing pyrrole 
derivatives. 
 
 
 
 
 
٭ V. De Matteis, O. Dufay, D. C. J. Waalboer, F. L. van Delft, J. Tiebes, F. P. J. T. Rutjes 
“Ring-closing metathesis-mediated synthesis of fluoro- and trifluoromethyl-containing N-
sulfonylated nitrogen heterocycles”, Eur. J. Org. Chem. 2007, 2667–2675. 
 
Chapter 5 
90 
5.1 INTRODUCTION 
 
As discussed in the previous chapters, we envisaged RCM as general 
methodology for the straightforward introduction of fluoride or trifluoromethyl 
substituents in non-aromatic heterocyclic systems.1 Via this RCM approach we were 
able to prepare small libraries of fluorinated2 and trifluoromethylated3 nitrogen 
heterocycles, including the development of a route to a new trifluoromethyl-
containing allylating reagent.4  
Inspired by these successful approaches, we aimed to extend this 
methodology into a complementary pathway, which is retrosynthetically outlined in 
Scheme 1.5 The targeted sulfonylated heterocycles 1 are accessible through RCM 
from the precursors 2, which are now envisaged to be prepared in a different way 
from the alkylating agents 4 and 5 in a Mitsunobu process. While Mitsunobu 
reactions are normally restricted to aromatic sulfonamides containing nitro 
substituents, we hoped that the strongly electron-withdrawing fluorine substituents 
would be beneficial in making this process possible for a wider range of (biologically 
relevant) sulfonyl groups. Besides the fact that this would lead to a general process 
that can be applied on both 4 and 5, the Mitsunobu reaction allows for use of a wide 
range of commercially available unsaturated alcohols as reaction partners, whereas 
alkylation strategies in the previous chapters had to rely on less well accessible 
olefinic halides. In any case, this approach would commence with efficiently 
converting the electrophilic agents 4 and 5 into the nucleophilic Mitsunobu reagent 3. 
 
RCM
1 3
4
5
N
X
( )n
S
Ar
OO
R
N
( )n
S
Ar
OO
2
X
R
Mitsunobu NH
S
Ar
OO
X
R = Me, Ph, OBn
X = F, CF3
n = 1–3
Cl
F
OTs
CF3
 
Scheme 1. Retrosynthetic approach. 
 
Finally, the sulfonamides 3 might also be subjected to aminopalladation with 
alkoxyallenes, a reaction that has been developed in our group,6 which would give 
access to an even greater variety of fluorinated heterocycles. 
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5.2 SYNTHESIS OF N-SULFONYLATED FLUORIDE-CONTAINING NITROGEN 
HETEROCYCLES 
 
The investigation started with exploring the possibility of transforming the 
commercially available chloride 4 in a nucleophilic amine that may then provide the 
sulfonamides 8 and 9 (Scheme 2). 
 
8 X = Me (30%)
9 X = NO2 (14%)
4 6 (99%) 7 (99%)
NaN3
DMSO
rt, 12 h
Cl
F
N3
F PPh3
DMSO
rt, 12 h
N
F
PPh3
1) H2O
2) Et3N, ArSO2Cl
    Et2O, –78 °C to rt
NH
F
SO O
X
 
Scheme 2. Synthesis of vinyl fluoride-containing sulfonamides. 
 
Chloride 4 was reacted with sodium azide in DMSO for 12 h at rt. Initially, 
the reaction was performed in deuterated DMSO to monitor the conversion by 1H-
NMR, which indicated that the reaction was complete in 12 h giving rise to azide 6 as 
a single product. Triphenylphosphine was added and after 12 h at rt 1H-NMR once 
again showed a complete conversion into the aza-ylide 7. The ylide was quenched by 
addition of water, the resulting amine was extracted out of the aqueous layer with 
diethyl ether and the organic layer was dried with MgSO4. After filtration, Et3N was 
added, the mixture was treated at –78 °C with tosyl chloride and stirred at room 
temperature for 12 h. Evaporation and silica gel purification eventually provided the 
sulfonamide 8 in 30% overall yield. Disappointingly, attempts to obtain sulfonamide 
9 via a similar procedure gave the desired product in only 14% yield. Furthermore, 
the scaling up of this sequence led to considerably lower yields. We then decided to 
focus on optimizing the procedure for 8 and see whether the 30% yield could be 
improved. A main concern in this sequence is the volatility of the amine that is 
formed in the Staudinger reduction of azide 6, which may be a reason for the modest 
yield. We therefore searched for a pathway that would circumvent the evaporation of 
a solution of the intermediate amine (Scheme 3).  
In this modified pathway azide 6 was first extracted into diethyl ether, dried 
(MgSO4), filtrated and then directly treated with 4.4 equiv of LiAlH4 added over a 
period of 30 min. The solution was stirred overnight, excess LiAlH4 was reacted with 
a few drops of ethyl acetate, and the aluminum salts were precipitated through the 
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addition of a few drops of saturated aqueous sodium sulfate (a few drops), followed 
by solid sodium sulfate. 
 
8 (30%)
4 6 (99%) 10 (99%)
NaN3
DMSO
rt, 12 h
Cl
F
N3
F
NH3Cl
F
NH
F
Et3N, TsCl
Et2O, –78 °C to rt
1) 4.4 equiv LiAlH4
    Et2O, rt, 12 h
2) 1 M HCl Ts
 
Scheme 3. Improved synthesis of vinyl fluoride-containing sulfonamides. 
 
The mixture was filtrated, the filtrate was extracted with 1 M aqueous HCl 
and the extract was freeze-dried. The resulting HCl salt of 10 was then suspended in 
diethyl ether, treated with excess triethylamine and tosyl chloride at –78 °C and 
stirred for 12 h at room temperature. Although this procedure could be readily scaled 
up to larger quantities, the last step reproducibly proceeded in 30% yield. However, 
the procedure still compares favorably to a literature procedure in which 4 is heated 
in ammonia in a steel bomb to provide 10 in 30%.7 Having sulfonamide 8 in hand, the 
feasibility of the Mitsunobu approach could be probed. To this end, the RCM 
precursors 11-18 (Scheme 4, Table 1) were either prepared via a regular alkylation 
reaction (method A, entries 1, 4 and 5) or via Mitsunobu conditions (method B, 
entries 2, 3 and 6-8). Method A involved addition of sulfonamide 8 to a suspension of 
NaH in DMF and after 30 min treatment with the bromide followed by stirring for 12 
h. Method B comprised the successive treatment of a solution of sulfonamide 8 in 
toluene with triphenylphosphine, the appropriate alcohol and diethyl 
azodicarboxylate. The mixture was then heated at 50 °C for 12 h and worked up. 
Although most of the yields were fairly good, it is obvious that the Mitsunobu 
sequence worked more reliably in case of non-activated substrates (e.g. compare the 
low alkylation yield in entries 4 and 5 with the good Mitsunobu yields in entries 2, 3 
and 6–8). As such, the Mitsunobu approach allows the use of commercially available 
unsaturated alcohols to prepare a variety of RCM precursors in a straightforward 
manner.  
 
toluene
100 °C
NH
F
SO2Ar
method 
A or B
N
F
SO2Ar
(  )n
R Grubbs-II (x mol%)
N
SO2Ar
(  )n
R
F
11–18 19–258  
Scheme 4. Synthesis of RCM precursors and RCM products. 
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Table 1. Yields of RCM precursors and products. 
Entry Reagent Method Precursor Cat 
(mol%) 
Time 
(h) 
Product 
(yield) 
 
 
1 
 
Br 
 
 
A 
 
 
11 (54%) 
 
 
25 
 
 
10 19 (0%) 
 
 
2 
 
OH
Me
 
 
 
B 
 
12 (79%) 
 
 
20 
 
 
3 
 
20 (72%) 
 
 
3 
 
OH
Ph
 
 
 
B 
 
13 (33%) 
 
 
25 
 
 
4 
 
21 (0%) 
 
 
 
4 
 
Br 
 
 
 
A 14 (60%) 
 
 
 
5 
 
 
 
1 
 
22 (97%) 
 
 
 
5 
 
Br 
 
 
 
A 15 (19%) 
 
 
 
5 
 
 
 
1 
 
23 (80%) 
 
 
 
6 
 
Me
OH
 
 
 
 
B 16 (68%) 
 
 
 
5 
 
 
 
1 
 
24 (94%) 
 
 
 
7 
 
Ph
OH
 
 
 
 
B 17 (60%) 
 
 
 
20 
 
 
 
3 
 
25 (72%) 
 
 
8 
 
OH
( )4  
 
 
B 18 (77%) 
 
 
10 
 
 
2 23 (41%) 
Conditions: Method A: (i) NaH, DMF, then add sulfonamide 8, 15 min, rt, (ii) 
alkylating agent, 12 h rt. B: = PPh3, alcohol, diethyl azodicarboxylate, 50 °C, 12 h. 
 
N
Ts
F
N
F
Ts
N
Ts
F
MeN
Ts
Me
F
N
Ts
F
PhN
Ts
Ph
F
N
F
pNsN
pNs
F
N
Ts
F
N
Ts
F
N
Ts
F
Me
N
Ts
Me
F
N
Ts
F
Ph
N
Ts
Ph
F
N
Ts
F
N
Ts
F
( )4
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Precursor molecules 11-18 were then subjected to the RCM conditions: 
Grubbs-II was added portionwise over a period of 2 h to the reaction mixture which 
was heated in toluene at 100 °C. Most of these precursors led to the corresponding 
fluoride-substituted cyclic building blocks in good to excellent yields (Table 1). There 
were some exceptions, however. Compound 11, which lacks a substituent adjacent to 
the nitrogen atom, did not give any cyclization product, even on prolonged heating 
and larger amounts of catalyst (entry 1). This result is consistent with reactions 
carried out by Brown et al., who observed dialkylation rather than ring closure in 
similar cases.8 Introduction of a methyl substituent at the 2-position (12) surprisingly 
led to the five-membered ring 20 in 72% yield, using similar conditions (entry 2). To 
further investigate the influence of a substituent in this position, precursor 13 
containing a phenyl group was synthesized, but unfortunately did not provide any 
cyclized product (entry 3). These results suggest that there is an optimum in the size 
of the 2-substituent with respect to the cyclization. We then moved on to prepare six-
and seven-membered building blocks as shown in entries 4-7. These cyclizations 
proceeded readily in good yields ranging from 72 to 97% to provide rings 22–25, 
although in case of 25 a larger amount of catalyst was required. Remarkably, 
subjection of compound 18 to the metathesis conditions did not provide the eight-
membered ring, but instead gave the corresponding seven-membered system (entry 
8). This must be due to isomerization of the terminal olefin to the internal position, 
possibly as a result of a relatively slow cyclization process, followed by ring closure 
and expulsion of propene.9,10 
We have also briefly investigated the possibility of forming larger rings by 
this process. Precursors 26 and 27 were conveniently prepared via the newly 
developed Mitsunobu sequence in 78 and 99%, respectively. Exposure of 26 to the 
RCM catalyst led to a complex mixture of unidentifiable products rather than the 
desired twelve-membered ring 28 (Scheme 5). Moreover, all attempts to form a 
thirteen-membered vinyl fluoride ring (29) from precursor 27 failed. 
 
OH
Mitsunobu
 conditions
PhMe, 50 ºC
26: n = 8 (78%)
27: n = 9 (99%)
n = 8, 9
RCM
28 (0%)
29 (0%)
RCM
8
NH
F
Ts
(  )n N
F
Ts
(  )n
N
N
Ts
F
Ts
F
n = 8
n = 9
 
Scheme 5. Synthesis of RCM precursors 26 and 27 and RCM results. 
RCM to fluoride- and CF3-containing N-sulfonylated nitrogen heterocycles 
95 
5.3 SYNTHESIS OF N-SULFONYLATED TRIFLUOROMETHYL-CONTAINING 
NITROGEN HETEROCYCLES 
 
Prompted by the successful Mitsunobu reaction and subsequent RCM results, 
we aimed to apply this protocol in a similar fashion on our previously developed 
trifluoromethyl-containing allylating reagent 5 (Section 2.2.1).3,4 The study started 
with the conversion of tosylate 5 into Mitsunobu precursor 31 (Scheme 6). 
 
30 (81%)5 31 (87%)
OTs
CF3
N
Ts
Boc
CF3
Boc
H
N
Ts
K2CO3
MeCN
reflux, 12 h
TFA
CH2Cl2
0 °C     rt
45 min
NH
Ts
CF3
 
Scheme 6. Synthesis of sulfonamide 31 from tosylate 5. 
 
The conversion proceeded via initial alkylation of tert-butyl tosylcarbamate11 
with tosylate 5 in refluxing acetonitrile, followed by TFA-mediated liberation of 
sulfonamide 31 in good overall yield. Compound 31 was alkylated under Mitsunobu 
conditions (triphenylphosphine, diethyl azodicarboxylate, toluene, 50 °C) with 
several unsaturated alcohols in generally good yields to provide the RCM precursors 
32-35, which in turn, were subjected to the aforementioned RCM conditions (Scheme 
7, Table 2). 
toluene
100 °C
NH
CF3
Ts
Mitsunobu
N
CF3
Ts
(  )n
R Grubbs-II (mol %)
N
Ts
(  )n
R
F3C
32–35 36–3931  
Scheme 7. Synthesis of RCM precursors and RCM products. 
 
Starting from 32, pyrroline 36 was obtained in 57% together with isomerized 
product 37 (23%, entry 1). This sharply contrasts with the fluoride-containing 
precursor 11, which failed to cyclize under identical conditions. The homologous six-
membered ring 38 was also readily formed in one hour from precursor 33 in 98% 
yield. Precursors 34 and 35, however, behaved in a different manner. In both cases, 
isomerization took place, which was either followed by cyclization to the 
corresponding six-membered ring 38 in 68% yield (entry 3), or led to the stable 
product 39 (entry 4). In the latter case, we hoped that the phenyl substituent would 
suppress the isomerization process, but instead a good yield of the linear isomerized 
product was obtained. 
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Table 2. Yields of the RCM precursors and products. 
Entry Reagent Precursor Cat (mol%) Time (h) Product (yield) 
 
 
1 
 
OH 
 
32 (99%) 
 
 
5 
 
 
0.45 36 (57%), 37 (23%) 
 
 
2 
 
OH 
 
33 (64%) 
 
 
5 
 
 
1 
 
 
38 (98%) 
 
 
3 
 
  
34 (60%) 
 
 
7 
 
 
1.30 
 
 
38(68%) 
 
 
 
4 
 
Ph
OH
 
35 (74%) 
 
 
 
10 
 
 
 
2 39(68%) 
 
Comparison of Tables 1 and 2 clearly shows that the fluoride and 
trifluoromethyl substituents play an important role in the RCM process. The 
fluorinated precursors readily afford six- and seven-membered ring products 
without any isomerization. The trifluoromethylated precursors on the other hand 
suffered from isomerization processes, which were only absent in the six-membered 
ring precursors. Recently, the Grubbs group reported that addition of benzoquinone 
could efficiently suppress undesired isomerization processes.12 We also applied these 
conditions to precursors 34 and 35 to see if this would be beneficial for the RCM 
process. In case of precursor 34 (20 mol% of Grubbs-II, 0.4 equiv benzoquinone, 
toluene, 100 °C) the isomerization was partially suppressed. GC analysis revealed the 
presence of the seven-membered ring product, together with the isomerized 
precursor and the six-membered ring 38 in a ratio of 1.3:1.1:1, respectively. In 
contrast, precursor 35 was reacted under identical conditions, but solely led to the 
isomerized product 39, which led us to conclude that benzoquinone addition is not 
useful.  
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5.4 SYNTHESIS OF TRIFLUOROMETHYLATED PYRROLE DERIVATIVES 
 
Trifluoromethylated pyrrole derivatives represent an industrially relevant 
compound class, which is rather poorly accessible via published methods.13 Inspired 
by recent work by Donahoe et al.,14 we decided to use our recently developed 
aminopalladation of alkoxyallenes6 to open up new entries to such compounds. This 
is retrosynthetically shown in Scheme 8, where the target compounds 40 should be 
accessible from the N,O-acetals 41 via RCM and subsequent aromatization. The latter 
compounds should be made from sulfonamide 31 via aminopalladation with an 
alkoxyallene. 
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Scheme 8. Retrosynthetic approach to trifluoromethylated pyrrole 40. 
 
Benzyloxyallene (42), synthesized following a known procedure,15 was 
reacted with sulfonamide 31, in the presence of Et3N, Pd(OAc)2 and dppp in 
acetonitrile to provide N,O-acetal 41 in excellent yield (Scheme 9). 
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    100 °C, 1.5 h
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2) TFA, rt
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Scheme 9. Synthesis of trifluoromethylated pyrrole 40. 
 
RCM precursor 41 was subjected to the previously described RCM conditions 
using 6.5 mol% of Grubbs-II in toluene at 100 °C. Once TLC indicated that the 
conversion was complete, TFA was added and after stirring for 30 min the mixture 
was worked up. Concentration and chromatography then provided pyrrole 40 in 
80% yield. Thus, this pathway provides an efficient and straightforward entry into 
the synthesis of trifluoromethylated pyrroles that may be further exploited in a 
general sense. 
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5.5 CONCLUSION 
 
In conclusion, we have shown that sulfonylated fluoro- and trifluoromethyl-
containing RCM precursors can be readily synthesized via a Mitsunobu reaction 
applied on the corresponding fluorinated sulfonamides involving suitable olefins. 
The first class of compounds was obtained from commercially available 1-chloro-2-
fluoro-2-propene, whereas for the second compound class a trifluoromethyl-
containing allylating reagent – previously developed in our group – served as the 
starting material. We also demonstrated that RCM on these olefins led to fluoride- 
and trifluoromethyl-containing five-, six- and seven-membered ring heterocyclic 
building blocks. Finally, a straightforward synthetic pathway has been developed to 
prepare trifluoromethylated pyrrole derivatives. 
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5.7 EXPERIMENTAL SECTION 
 
N-(2-Fluoroallyl)-4-methylbenzenesulfonamide (8):  
To a solution of 1-chloro-2-fluoro-2-propene (252 mg, 2.68 mmol) in DMSO 
(24 mL) sodium azide (720 mg, 11.34 mmol) was added and the resulting 
mixture was vigorously stirred for 12 h at rt. To this gelly mixture 
containing product 6, was then added triphenylphosphine (992 mg, 3.78 
mmol); slowly the gel dissolved and the solution was stirred for 12 h at rt to 
afford 7 in DMSO solution. The reaction was slowly quenched with water 
(24 mL), giving the 2-fluoro-allylamine. Which was extracted with Et2O (5 × 
20 mL). The ether layer was dried (MgSO4), filtered and used directly to react with 
Et3N (0.6 mL, 3.78 mmol) for 15 min at rt. The mixture was cooled to –78 °C and p-
toluenesulfonyl chloride (720.6 mg, 3.78 mmol) was added. The resulting mixture 
was stirred for 12 h slowly reaching room temperature. The solvent was evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 10:1 to 
6:1) to give 8 (185 mg, 30%) as a white solid. Mp = 89-90 °C; IR (neat, cm–1): 3279, 
2927, 2852, 1680, 1593, 1428, 1320, 1154, 1092, 856, 806, 707,661; 1H NMR (300 MHz, 
CDCl3, 25 °C, TMS): δ = 7.73 (d, J = 8.4 Hz, 2H, Ar), 7.27 (d, J = 8.1 Hz, 2H, Ar), 5.31 (br 
s, 1H, NH), 4.56 (dd, 1H, J = 3.6, 33.6 Hz, CH2cis=CF), 4.46 (dd, 1H, J = 3.3, 64.8 Hz, 
CH2trans=CF), 3.70-3.64 (m, 2H, CFCH2NH), 2.41 (s, 3 H, CH3); 13C NMR (75 MHz, 
CDCl3, 25 °C) δ=160.5 (d, J = 255.3 Hz, CF), 143.6, 136.6, 129.6, 127.9, 92.6 (d, J = 16.9 
Hz, C=CF), 43.4 (d, J = 33.9 Hz, CH2CF), 21.8; HRMS (EI) calcd for C10H12FNO2S (M+) 
229.0573, found 229.0580. 
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N-(2-Fluoroallyl)-4-nitrobenzenesulfonamide (9):  
To a solution of 1-chloro-2-fluoro-2-propene (252 mg, 2.68 mmol) in DMSO 
(24 mL) sodium azide (720 mg, 11.3 mmol) was added and the resulting 
mixture was vigorously stirred for 12 h at rt. To this gelly mixture 
containing product 6, was then added triphenylphosphine (992 mg, 3.78 
mmol). The gel dissolved slowly and the solution was stirred for an other 12 
h at rt to afford 7 in DMSO solution. The reaction was quenched with water 
(24 mL), giving the 2-fluoro-allylamine, which was extracted with Et2O (5 × 20 mL). 
The ether layer was dried (MgSO4), filtered and used directly to react with Et3N (0.60 
mL, 3.78 mmol) for 15 min at rt. The mixture was cooled to -78 °C and 4-
nitrobenzenesulfonyl chloride (838 mg, 3.78 mmol) was added; the resulting mixture 
was stirred for 12 h slowly reaching room temperature. The solvent was evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 10:1 to 
3:1) to give 9 (100 mg, 14%) as a yellow solid. IR (neat, cm–1): 3291, 3105, 2924, 2867, 
1688, 1528, 1437, 1346, 1156, 1091, 849, 737; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ 
= 8.33 (d, J = 9.0 Hz, 2H, Ar), 8.04 (d, J = 9.0 Hz, 2H, Ar), 5.28 (br t, J = 6.0 Hz, 1H, NH), 
4.57 (dd, 1H, J = 3.3, 28.5 Hz CH2cis=CF), 4.47 (dd, 1H, J = 3.6, 60.1 Hz, CH2trans=CF), 
3.86-3.79 (m, 2H, CFCH2NH); 13C NMR (75 MHz, CDCl3, 25 °C) δ=159.7 (d, J = 256.2 
Hz, CF), 150.0, 145.8, 128.3, 124.3, 93.7 (d, J = 17.2 Hz, C=CF), 43.8 (d, J = 32.2 Hz, 
CH2CF); HRMS (EI) calcd for C9H9FN2O4S (M+) 260.0267, found 260.0274. 
 
2-Fluoroallylammonium chloride salt (10):  
To a solution of 1-chloro-2-fluoro-2-propene (252 mg, 2.68 mmol) in 
DMSO (24 mL) sodium azide (720 mg, 11.34 mmol) was added and the 
resulting mixture was vigorously stirred for 12 h at rt. In the gelly 
mixture containing product 6 was introduced water (10 mL), the solution was then 
extracted with Et2O (3 × 20 mL), dried with MgSO4, and filtered. To this ether 
solution was added LiAlH4 (458 mg, 12.06 mmol) at room temperature. Strong 
evolution of gas started after a few minutes. The reaction mixture was stirred 
overnight and the next day the excess of LiAlH4 was eliminated by slow addition of a 
few drops of EtOAc, followed by saturated aqueous Na2SO4 (a few drops) and solid 
Na2SO4. After stirring for a few minutes, the mixture was filtrated. The ether layer 
containing the 2-fluoroallylamine was then extracted with 1 M HCl (3 × 20 mL) and 
freeze-dried. Crude product 10 was then obtained (297 mg, 99%) and used directly 
for the next step without further purification. IR (neat, cm–1): 2876, 2625, 1692, 1593, 
1502, 1403, 1251, 1100, 927, 879; 1H NMR (300 MHz, D2O, 25 °C, TMS): δ = 5.0 (dd, J = 
4.2, 16.8 Hz, 1H, CH2cis=CF), 4.87 (dd, 1H, J = 3.9, 49 Hz, CH2trans=CF), 3.8 (d, 2H, J = 
16.2 Hz, CFCH2N); 13C NMR (75 MHz, D2O, 25 °C) δ = 157.8 (d, J = 252.5 Hz, CF), 97.4 
(d, J = 15.8 Hz, C=CF), 39.9 (d, J = 31.3 Hz, CH2CF). 
 
N-Allyl-N-(2-fluoroallyl)-4-methylbenzenesulfonamide (11):  
To a suspension of NaH (25 mg, 1.05 mmol) in DMF (6 mL) was added at 
rt compound 8 (162 mg, 0.70 mmol). After stirring for 30 min, 3-bromo-
propene (72.7 μl, 0.84 mmol) was added dropwise at rt. The reaction was 
stirred for 12 h, quenched with water (6 mL) and extracted with Et2O (3 × 6 
mL). The ether layers were dried (MgSO4), evaporated and the residue was purified 
using column chromatography (heptane/EtOAc 10:1 to 6:1) to give 11 (152 mg, 54%) 
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as a colorless oil. IR (neat, cm–1): 3071, 3015, 2954, 2920, 1679, 1597, 1346, 1161, 1096, 
927, 798, 659; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.68 (d, J = 8.1 Hz, 2H, Ar), 
7.27 (d, J = 7.8 Hz, 2H, Ar), 5.68-5.55 (m, 1H, CH2=CH), 5.19-5.13 (m, 2H, CH2=CH), 
4.61 (dd, 1H, J = 3.0, 51.7 Hz, CH2cis=CF), 4.51 (dd, 1H, J = 3.0, 82.9 Hz, CH2trans=CF), 
3.91 (d, J = 13.5 Hz, 2H, CFCH2N), 3.83 (d, J = 6.3 Hz, 2H, NCH2CH), 2.41 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3, 25 °C) δ=160.3 (d, J = 258.5 Hz, CF), 143.3, 136.9, 132.0, 
129.5, 127.1, 119.6, 93.9 (d, J = 17.2 Hz, C=CF), 49.9, 46.4 (d, J = 31.9 Hz, CH2CF), 21.7; 
HRMS (EI) calcd for C13H16FNO2S (M+) 269.08857, found 269.08946. 
 
N-(2-fluoroallyl)-4-methyl-N-(1-methylallyl)benzenesulfonamide (12):16  
Under an argon atmosphere, to a solution of compound 8 (100 mg, 0.38 
mmol) in toluene (5 mL) was added triphenylphosphine (202 mg, 0.77 
mmol), 3-buten-1-ol (39.9 μl, 0.46 mmol) and diethyl azodicarboxylate 
(79.8 μl, 0.61 mmol) at ambient temperature. The mixture was heated at 50 °C for 12 
h, then the solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 20:1) to give 12 (86 mg, 79%) as a pink oil. IR (neat, 
cm–1): 3088, 3023, 2980, 2924, 1675, 1593, 1338, 1152, 1092, 1014, 901, 845, 815, 659, 547; 
1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.71 (d, J = 8.1 Hz, 2H, Ar), 7.27 (d, J = 8.1 
Hz, 2H, Ar), 5.68-5.57 (m, 1H, CH2=CH), 5.14-5.5 (m, 2H, CH2=CH), 4.71-4.48 (m, 3H, 
NCHCH3, CH2=CF), 3.89 (dd, 1H, J = 11.7, 16.8 Hz, CFCH2N), 3.73 (dd, 1H, J = 11.7, 
16.8 Hz, CFCH2N), 2.42 (s, 3H, ArCH3), 1.25 (d, J = 6.9 Hz, 3H, CH3); 13C NMR (75 
MHz, CDCl3, 25 °C) δ=162.1 (d, J = 257.6 Hz, CF), 143.3, 136.9, 129.5, 127.13, 127.12, 
117.3, 93.0 (d, J = 17.5 Hz, C=CF), 55.13, 43.5 (d, J = 34.5 Hz, CH2CF), 21.8, 17.5; HRMS 
(EI) calcd for C14H18FNO2S (M+) 283.1042, found 283.1034. 
 
N-(2-Fluoroallyl)-4-methyl-N-(1-phenylallyl)benzenesulfonamide (13):  
Under an argon atmosphere, to a solution of compound 8 (158 mg, 0.60 
mmol) in toluene (8 mL) was added triphenylphosphine (315 mg, 1.20 
mmol), vinyl benzyl alchol (95.0 μl, 0.72 mmol) and diethyl 
azodicarboxylate (0.13 mL, 0.96 mmol) at ambient temperature. The 
mixture was heated at 50 °C for 12 h, then the solvent was evaporated and the 
residue was purified using column chromatography (heptane/EtOAc 20:1) to give 13 
(68 mg, 33%) as a colorless oil. IR (neat, cm–1): 3019, 2963, 2920, 2868, 1679, 1593, 1493, 
1446, 1342, 1260, 1156, 1096, 1018, 914, 811, 741, 664, 616, 543; 1H NMR (300 MHz, 
CDCl3, 25 °C, TMS): δ = 7.74 (d, J = 8.1 Hz, 2H, SO2Ar), 7.30-7.20 (m, 7H, 2H SO2Ar + 
5H Ph), 6.45 (d, J = 15.9 Hz, 1H, CH2=CH); 6.02-5.92 (m, 1H, CH2=CH), 4.65 (dd, 1H, J 
= 3.0, 53.1 Hz, CH2cis=CF), 4.55 (dd, 1H, J = 3.0, 84.7 Hz, CH2trans=CF), 4.00-3.95 (m, 4H, 
1H CHH=CH + CFCH2N + NCHPh), 2.42 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3, 25 
°C) δ = 160.7 (d, J = 259.9 Hz, CF), 143.6, 137.2, 136.1, 134.8, 129.8, 128.7, 128.2, 127.4, 
126.6, 123.3, 94.1 (d, J = 17.2 Hz, C=CF), 49.5, 46.5 (d, J = 31.9 Hz, CH2CF), 21.6; HRMS 
(EI) calcd for C19H20FNO2S (M+) 345.1199, found 345.1210. 
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N-But-3-enyl-N-(2-fluoroallyl)-4-nitrobenzenesulfonamide (14):  
To a suspension of NaH (13 mg, 0.52 mmol) in DMF (4 mL) was added at 
rt compound 8 (90 mg, 0.35 mmol). After stirring for 30 min, 4-bromo-1-
butene (42 μl, 0.42 mmol) was added dropwise at rt. The reaction was 
stirred for 12 h, quenched with water (4 mL) and extracted with Et2O (3 × 4 
mL). The ether layers were dried (MgSO4), evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 10:1 to 6:1) to 
give 14 (65 mg, 60%) as a white solid. Mp = 77-79 °C; IR (neat, cm–1): 3110, 
3071, 2928, 2868, 1718, 1679, 1528, 1346, 1165, 1091, 923, 858; 1H NMR (300 
MHz, CDCl3, 25 °C, TMS): δ = 8.32 (d, J = 9.0 Hz, 2H, Ar), 7.98 (d, J = 8.7 Hz, 2H, Ar), 
5.76-5.63 (m, 1H, CH2=CH), 5.11-5.04 (m, 2H, CH2=CH), 4.66 (dd, 1H, J = 3.6, 44.1 Hz, 
CH2cis=CF), 4.56 (dd, 1H, J = 3.6, 75.4 Hz, CH2trans=CF), 4.05 (d, J = 15.9 Hz, 2H, 
CFCH2N), 3.30 (t, J = 7.5 Hz, 2H, NCH2CH2), 2.39-2.32 (m, 2H, NCH2CH2); 13C NMR 
(75 MHz, CDCl3, 25 °C) δ = 159.5 (d, J = 259.0 Hz, CF), 149.8, 145.6, 133.7, 128.4, 124.1, 
117.7, 95.2 (d, J = 17.2 Hz, C=CF), 47.7 (d, J = 30.2 Hz, CH2CF), 46.9, 32.9; HRMS (EI) 
calcd for C13H15FN2O4S (M+) 314.0737, found 314.0733. 
 
N-(2-Fluoroallyl)-4-methyl-N-pent-4-enylbenzenesulfonamide (15):  
To a suspension of NaH (33 mg, 1.38 mmol) in DMF (10 mL) was added 
at rt compound 8 (210 mg, 0.92 mmol). After stirring for 30 min, 5-
bromo-1-pentene (0.13 mL, 1.10 mmol) was added dropwise at rt. The 
reaction was stirred for 12 h, quenched with water (10 mL) and extracted 
with Et2O (3 × 10 mL). The ether layers were dried (MgSO4), evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 10:1 to 
6:1) to give 15 (53 mg, 19%) as a yellow oil. IR (neat, cm–1): 3075, 2963, 2924, 2863, 
1679, 1597, 1442, 1342, 1156, 1087, 914, 811; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ 
= 7.67 (d, J = 8.4 Hz, 2H, Ar), 7.28 (d, J = 8.7 Hz, 2H, Ar), 5.80-5.66 (m, 1H, CH2=CH), 
5.02-4.93 (m, 2H, CH2=CH), 4.63 (dd, 1H, J = 3.3, 44.1 Hz, CH2cis=CF), 4.53 (dd, 1H, J = 
3.3, 75.7 Hz, CH2trans=CF), 3.91 (d, J = 13.8 Hz, 2H, CFCH2N), 3.16 (t, J = 7.5 Hz, 2H, 
NCH2CH2), 2.41 (s, 3H, CH3), 2.06-1.99 (m, 2H, NCH2CH2CH2), 1.70-1.60 (m, 2H, 
NCH2CH2CH2); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 160.7 (d, J = 258.8 Hz, CF), 143.2, 
137.2, 136.7, 129.5, 127.2, 115.3, 94.0 (d, J = 17.2 Hz, C=CF), 47.8 (d, J = 31.9 Hz, 
CH2CF), 47.6, 30.9, 27.5, 21.8; HRMS (EI) calcd for C15H20FNO2S (M+) 297.1199, found 
297.1203. 
 
N-(2-Fluoro-allyl)-4-methyl-N-(3-methyl-pent-4-enyl)-benzenesulfonamide (16): 
Under an argon atmosphere, to a solution of compound 8 (90 mg, 
0.40 mmol) in toluene (4 mL) was added triphenylphosphine (210 
mg, 0.80 mmol), 3-methyl-pent-4-en-1-ol (48.1 mg, 0.48 mmol) and 
diethyl azodicarboxylate (0.12 mL, 0.64 mmol) at ambient 
temperature. The mixture was heated at 50 °C for 12 h, then the 
solvent was evaporated and the residue was purified using column chromatography 
(heptane/EtOAc 20:1) to give 16 (85 mg, 68%) as a colorless oil. IR (neat, cm–1): 3075, 
2958, 2928, 2863, 1679, 1593, 1450, 1346, 1156, 1091, 923, 849, 815, 664; 1H NMR (300 
MHz, CDCl3, 25 °C, TMS): δ = 7.69 (d, J = 8.4 Hz, 2H, Ar), 7.29 (d, J = 9.3 Hz, 2H, Ar), 
5.68-5.56 (m, 1H, CH2=CH), 5.99-4.91 (m, 2H, CH2=CH), 4.65 (dd, 1H, J = 3.3, 43.5 Hz, 
CH2cis=CF), 4.55 (dd, 1H, J = 3.3, 75.4 Hz, CH2trans=CF), 3.99-3.83 (m, 2H, CFCH2N), 
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3.23-3.07 (m, 2H, NCH2CH2), 2.41 (s, 3H, CH3), 2.16-2.07 (m, 1H, CHCH3), 1.59-1.51 
(m, 2H, NCH2CH2), 0.98 (d, J = 6.6 Hz, 3H, CHCH3); 13C NMR (75 MHz, CDCl3, 25 °C) 
δ = 161.0 (d, J = 259.6 Hz, CF), 143.4, 143.3, 136.8, 129.7, 127.3, 113.6, 94.0 (d, J = 17.2 
Hz, C=CF), 47.7 (d, J = 32.2 Hz, CH2CF), 46.2, 35.6, 34.6, 21.6, 20.3; HRMS (EI) calcd for 
C16H22FNO2S (M+) 311.1355, found 311.1349. 
 
N-(2-Fluoroallyl)-4-methyl-N-(3-phenylpent-4-enyl)-benzenesulfonamide (17):  
Under an argon atmosphere, to a solution of compound 8 (90 mg, 0.40 
mmol) in toluene (4 mL) was added triphenylphosphine (210 mg, 0.80 
mmol), 3-phenylpent-4-en-1-ol (77.9 mg, 0.48 mmol) and diethyl 
azodicarboxylate (0.12 mL, 0.64 mmol) at ambient temperature. The 
mixture was heated at 50 °C for 12 h, then the solvent was evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 20:1) to 
give 17 (90 mg, 60%) as a pink oil. IR (neat, cm–1): 3084, 3058, 3028, 2976, 2928, 2863, 
1675, 1597, 1489, 1455, 1342, 1156, 1087, 927, 810, 759, 707, 664, 547; 1H NMR (300 
MHz, CDCl3, 25 °C, TMS): δ = 7.63 (d, J = 8.4 Hz, 2H, SO2Ar), 7.31-7.13 (m, 7H, 2H 
SO2Ar + 5H Ph), 5.94-5.83 (m, 1H, CH2=CH), 5.05-4.99 (m, 2H, CH2=CH), 4.58 (dd, 1H, 
J = 3.3, 57.9 Hz, CH2cis=CF), 4.47 (dd, 1H, J = 3.3, 89.5 Hz, CH2trans=CF), 3.88 (d, J = 14.4 
Hz, 2H, CFCH2N), 3.26-3.12 (m, 2H, 1H NCH2CH2 + CHPh), 3.06-2.96 (m, 1H, 
NCH2CH2), 2.40 (s, 3H, CH3), 2.04-1.96 (m, 2H, NCH2CH2); 13C NMR (75 MHz, CDCl3, 
25 °C) δ = 160.8 (d, J = 259.6 Hz, CF), 143.5, 143.1, 141.2, 136.7, 129.7, 128.7, 127.6, 
127.4, 126.6, 114.8, 94.2 (d, J = 17.2 Hz, C=CF), 48.0 (d, J = 31.9 Hz, CH2CF), 47.3, 46.4, 
33.6, 21.6; HRMS (EI) calcd for C21H24FNO2S (M+) 373.1512, found 373.1497. 
 
N-(2-Fluoroallyl)-N-hex-5-enyl-4-methylbenzenesulfonamide (18):  
Under an argon atmosphere, to a solution of compound 8 (70 mg, 0.27 
mmol) in toluene (3 mL) was added triphenylphosphine (141 mg, 0.54 
mmol), 5-hexenol (38.9 μl, 0.33 mmol) and diethyl azodicarboxylate (78.7 
μl, 0.43 mmol) at ambient temperature. The mixture was heated at 50 °C for 12 h, 
then the solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 18 (65 mg, 77%) as a colorless oil. IR 
(neat, cm–1): 3071, 2971, 2924, 2863, 1675, 1593, 1442, 1338, 1161, 1091, 909, 810, 664, 
547; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.67 (d, J = 8.4 Hz, 2H, Ar), 7.26 (d, J 
= 8.4 Hz, 2H, Ar), 5.79-5.66 (m, 1H, CH2=CH), 4.99-4.91 (m, 2H, CH2=CH), 4.63 (dd, 
1H, J = 3.3, 44.2 Hz, CH2cis=CF), 4.52 (dd, 1H, J = 3.3, 75.7 Hz, CH2trans=CF), 3.91 (d, J = 
14.1 Hz, 2H, CFCH2N), 3.16 (t, J = 7.5 Hz, 2H, NCH2CH2), 2.41 (s, 3H, CH3), 2.05-1.99 
(m, 2H, CH2=CHCH2), 1.66-1.50 (m, 2H, NCH2CH2CH2), 1.42-1.25 (m, 2H, 
NCH2CH2CH2); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 160.7 (d, J = 258.8 Hz, CF), 143.2, 
138.1, 136.7, 129.5, 127.2, 114.8, 93.9 (d, J = 17.5 Hz, C=CF), 47.9, 47.6 (d, J = 27.3 Hz, 
CH2CF), 33.4, 27.6, 26.0, 21.8; HRMS (EI) calcd for C16H23FNO2S (M+ + H) 312.1433, 
found 312.1437. 
 
General procedure for the RCM reactions 
To a 0.01 M solution of the diene in dry toluene under an inert atmosphere, Grubbs-II 
was added at 100 °C. Stirring was continued until the reaction was complete 
(indicated by TLC or GC), followed by concentration of the reaction mixture and 
subsequent purification with column chromatography. 
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4-Fluoro-2-methyl-1-(toluene-4-sulfonyl)-2,5-dihydro-1H-pyrrole (20):  
To a solution of compound 12 (76 mg, 0.27 mmol) in dry toluene (30 mL) 
Grubbs-II (20 mol%) was added at 100 °C in small portions. The reaction 
was complete in 3 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 20 
(50 mg, 72%) as a yellow oil. IR (neat, cm–1): 3101, 3062, 3028, 2963, 2920, 2872, 1701, 
1597, 1450, 1351, 1161, 1091, 1035, 936, 815, 664, 577, 547; 1H NMR (300 MHz, CDCl3, 
25 °C, TMS): δ = 7.69 (d, J = 8.4 Hz, 2H, Ar), 7.31 (d, J = 8.7 Hz, 2H, Ar), 4.92-4.89 (m, 
1H, FC=CHCH), 4.46-4.44 (m, 1H, NCHCH3), 4.16-3.98 (m, 2H, NCH2CF), 2.42 (s, 3H, 
ArCH3), 1.44 (d, J = 6.3 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 153.7 (d, J = 
273.4 Hz, CF), 143.7, 143.1, 129.8, 127.4, 104.4 (d, J = 7.5 Hz, C=CF), 59.9 (d, J = 6.9 Hz, 
CHCH=CF), 50.0 (d, J = 30.7 Hz, CH2CH=CF), 23.6, 21.8; HRMS (CI) calcd for 
C12H15FNO2S (M+H+) 256.0807, found 256.0809. 
 
5-Fluoro-1-(4-nitrobenzenesulfonyl)-1,2,3,6-tetrahydropyridine (22):  
To a solution of compound 14 (40 mg, 0.13 mmol) in dry toluene (20 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction was 
complete in 1 h. The mixture was evaporated and the product was purified 
using column chromatography (heptane/EtOAc 10:1) to give 22 (36 mg, 
97%) as a white solid. Mp= 116-118 °C; IR (neat, cm–1): 3101, 2963, 2920, 
2859, 2790, 1713, 1576, 1528, 1455, 1351, 1260, 1169, 1091, 1009, 824, 798; 1H 
NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 8.37 (d, J = 8.7 Hz, 2H, Ar), 7.97 (d, 
J = 8.4 Hz, 2H, Ar), 5.31 (dt, J = 5.7, 17.1 Hz, 1H, FC=CHCH2), 3.75-3.73 (m, 2H, 
CFCH2N), 3.25 (t, J = 5.7 Hz, 2H, NCH2CH2), 2.25-2.19 (m, 2H, NCH2CH2); 13C NMR 
(75 MHz, CDCl3, 25 °C) δ = 153.4 (d, J = 251.6 Hz, CF), 150.5, 142.6, 128.6, 124.5, 100.9 
(d, J = 13.2 Hz, C=CF), 43.9 (d, J = 39.9 Hz, CH2CF), 42.8 (d, J = 1.4 Hz, CH2CH=CF), 
22.7; HRMS (EI) calcd for C11H11FN2O4S (M+) 286.0424, found 286.0417. 
 
6-Fluoro-1-(toluene-4-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine (23): 
 To a solution of compound 15 (46 mg, 0.15 mmol) in dry toluene (20 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction 
was complete in 1 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 23 
(32 mg, 80%) as a colorless oil. IR (neat, cm–1): 3058, 2980, 2933, 2872, 2846, 1701, 1597, 
1450, 1342, 1161, 1091, 1044, 914, 811, 664, 551; 1H NMR (300 MHz, CDCl3, 25 °C, 
TMS): δ = 7.65 (d, J = 8.1 Hz, 2H, Ar), 7.27 (d, J = 8.1 Hz, 2H, Ar), 5.28 (dt, J = 5.7, 19.8 
Hz, 1H, FC=CHCH2), 4.00 (d, J = 6.6 Hz, 2H, CFCH2N), 3.38 (t, J = 6.0 Hz, 2H, 
NCH2CH2), 2.42 (s, 3H, CH3), 2.04-1.97 (m, 2H, NCH2CH2CH2), 1.85-1.77 (m, 2H, 
NCH2CH2CH2); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 157.2 (d, J = 251.0 Hz, CF), 143.4, 
135.9, 128.6, 127.1, 106.9 (d, J = 18.7 Hz, C=CF), 49.0, 47.4 (d, J = 43.9 Hz, CH2CF), 27.2, 
21.8, 21.4 (d, J = 9.8 Hz, CH2CH=CF); HRMS (EI) calcd for C13H16FNO2S (M+) 269.0886, 
found 269.0889. 
 
 
 
 
 
N
Ts
F
Me
N
S OO
NO2
F
N
Ts
F
Chapter 5 
104 
6-Fluoro-4-methyl-1-(toluene-4-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine (24):  
To a solution of compound 16 (73 mg, 0.23 mmol) in dry toluene (30 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction 
was complete in 1 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 24 
(62 mg, 94%) as a colorless oil. IR (neat, cm–1): 3028, 2963, 2924, 2872, 1692, 
1597, 1489, 1446, 1342, 1161, 1100, 923, 879, 815, 754, 655, 590, 547; 1H NMR (300 MHz, 
CDCl3, 25 °C, TMS): δ = 7.67 (d, J = 8.4 Hz, 2H, Ar), 7.31 (d, J = 7.8 Hz, 2H, Ar), 5.13 
(dd, J = 3.9, 21.0 Hz, 1H, FC=CHCHPh), 4.16-4.07 (m, 1H, CFCH2N), 3.91-3.83 (m, 1H, 
CFCH2N), 3.44-3.28 (m, 2H, NCH2CH2), 2.42 (s, 3H, ArCH3), 2.39-2.37 (br m, 1H, 
CHCH3), 1.87-1.77 (m, 1H, NCH2CH2), 1.69-1.56 (m, 1H, NCH2CH2), 1.01 (d, J = 7.2 
Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 156.2 (d, J = 252.3 Hz, CF), 143.7, 
135.9, 129.8, 127.3, 113.4 (d, J = 16.9 Hz, C=CF), 47.3, 47.1 (d, J = 44.5 Hz, CH2CF), 34.9 
9 (d, J = 0.6 Hz, NCH2CH2), 27.7 (d, J = 9.2 Hz, CF=CHCHCH3), 22.1, 21.6; HRMS (EI) 
calcd for C14H18FNO2S (M+) 283.1042, found 283.1036. 
 
6-Fluoro-4-phenyl-1-(toluene-4-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine (25): 
To a solution of compound 17 (60 mg, 0.16 mmol) in dry toluene (25 mL) 
Grubbs-II (20 mol%) was added at 100 °C in small portions. The reaction 
was complete in 3 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 25 
(40 mg, 72%) as a colorless oil. IR (neat, cm–1): 3062, 3028, 2924, 2859, 1697, 1593, 1489, 
1446, 1338, 1161, 1091, 936, 815, 754, 698, 659, 547; 1H NMR (300 MHz, CDCl3, 25 °C, 
TMS): δ = 7.70 (d, J = 8.4 Hz, 2H, SO2Ar), 7.34-7.11 (m, 5H, 2H SO2Ar + 3H Ph), 7.10 (d, 
J = 6.9 Hz, 2H, Ph), 5.38 (dd, J = 3.6, 21.0 Hz, 1H, FC=CHCHPh), 4.29-4.20 (m, 1H, 
CFCH2N), 4.05-3.96 (m, 1H, CFCH2N), 3.51-3.49 (m, 1H, CHPh), 3.43-3.28 (m, 2H, 
NCH2CH2), 2.44 (s, 3H, CH3), 2.07-1.99 (m, 2H, NCH2CH2); 13C NMR (75 MHz, CDCl3, 
25 °C) δ = 157.1 (d, J = 253.3 Hz, CF), 144.4, 143.8, 135.8, 129.9, 128.8, 127.36, 127.35, 
126.8, 111.7 (d, J = 19.8 Hz, C=CF), 46.9 (d, J = 44.2 Hz, CH2CF), 46.8, 39.6 (d, J = 9.5 Hz, 
CF=CHCHPh), 35.6, 21.6; HRMS (EI) calcd for C19H20FNO2S (M+) 345.1199, found 
345.1190. 
 
6-Fluoro-1-(toluene-4-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine (23): 
To a solution of compound 18 (57 mg, 0.18 mmol) in dry toluene (20 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction 
was complete in 1 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 23 
(20 mg, 41%) as a colorless oil. 
 
N-Decyl-N-(2-fluoroallyl)-4-methylbenzenesulfonamide (26): 
 Under an argon atmosphere, to a solution of compound 8 (110 mg, 0.42 
mmol) in toluene (5 mL) was added triphenylphosphine (222 mg, 0.85 
mmol), 9-decen-1-ol (90.5 μl, 0.51 mmol) and diethyl azodicarboxylate 
(0.13 mL, 0.67 mmol) at ambient temperature. The mixture was heated at 50 °C for 12 
h, then the solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 20:1) to give 26 (121 mg, 78%) as a yellow oil. IR 
(neat, cm–1): 3071, 2971, 2928, 2855, 1779, 1675, 1636, 1593, 1467, 1342, 1234, 1156, 1087, 
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914, 815, 659, 547; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.67 (d, J = 8.4 Hz, 2H, 
Ar), 7.26 (d, J = 8.7 Hz, 2H, Ar), 5.85-5.71 (m, 1H, CH2=CH), 5.00-4.88 (m, 2H, 
CH2=CH), 4.63 (dd, 1H, J = 3.0, 41.2 Hz, CH2cis=CF), 4.52 (dd, 1H, J = 3.0, 72.7 Hz, 
CH2trans=CF), 3.90 (d, J = 13.5 Hz, 2H, CFCH2N), 3.14 (t, J = 7.5 Hz, 2H, NCH2CH2), 2.40 
(s, 3H, CH3), 2.06-1.99 (m, 2H, CH2=CHCH2), 1.54-1.24 (m, 12H, NCH2(CH2)6CH2CH); 
13C NMR (75 MHz, CDCl3, 25 °C) δ = 160.7 (d, J = 258.8 Hz, CF), 143.1, 138.9, 136.7, 
129.4, 127.1, 114.1, 93.8 (d, J = 17.2 Hz, C=CF), 47.9, 47.6 (d, J = 31.8 Hz, CH2CF), 33.9, 
29.5, 29.3, 29.2, 29.1, 28.2, 26.8; HRMS (EI) calcd for C20H30FNO2S (M+) 367.1981, found 
367.1967. 
 
N-(2-Fluoroallyl)-4-methyl-N-undec-10-enylbenzenesulfonamide (27):  
Under an argon atmosphere, to a solution of compound 8 (90 mg, 0.35 
mmol) in toluene (4 mL) was added triphenylphosphine (181 mg, 0.69 
mmol), 10-decen-1-ol (83.1 μl, 0.42 mmol) and diethyl azodicarboxylate 
(71.8 μl, 0.55 mmol) at ambient temperature. The mixture was heated at 50 °C for 12 
h, then the solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 20:1) to give 27 (130 mg, 99%) as a yellow oil. IR 
(neat, cm–1): 3075, 2924, 2855, 1779, 1675, 1636, 1593, 1463, 1342, 1156, 1087, 919, 811, 
664, 543; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.69 (d, J = 8.4 Hz, 2H, Ar), 7.28 
(d, J = 7.8 Hz, 2H, Ar), 5.87-5.74 (m, 1H, CH2=CH), 5.02-4.90 (m, 2H, CH2=CH), 4.65 
(dd, 1H, J = 3.0, 41.4 Hz, CH2cis=CF), 4.54 (dd, 1H, J = 3.0, 73.3 Hz, CH2trans=CF), 3.92 (d, 
J = 13.5 Hz, 2H, CFCH2N), 3.15 (t, J = 7.5 Hz, 2H, NCH2CH2), 2.41 (s, 3H, CH3), 2.07-
1.99 (m, 2H, CH2=CHCH2), 1.32-1.24 (m, 14H, NCH2(CH2)7CH2CH); 13C NMR (75 
MHz, CDCl3, 25 °C) δ = 161.0 (d, J = 259.9 Hz, CF), 143.3, 139.2, 136.9, 129.6, 127.3, 
114.2, 93.8 (d, J = 17.5 Hz, C=CF), 47.8, 47.5 (d, J = 32.2 Hz, CH2CF), 33.8, 29.5, 29.4, 
29.2, 29.1, 28.9, 28.0, 26.8; HRMS (EI) calcd for C21H32FNO2S (M+) 381.2138, found 
381.2133. 
 
tert-Butyl tosyl-2-(trifluoromethyl)allylcarbamate (30):  
To a solution of compound 5 (0.461 g, 1.64 mmol) and tert-butyl 
tosylcarbamate11 (0.536 g, 1.98mmol) in acetonitrile (70ml) was added 
potassium carbonate (2.76 g, 2.0 mmol) and the suspension refluxed for 18 
h. After cooling to rt the potassium carbonate was filtered off and the 
solvent evaporated. The crude product was purified by flash 
chromatography (1:25-1:15 ethyl acetate-heptane) to give 30 (0.505 g, 81%) 
as a white solid. Mp= 89-91 °C; IR (neat, cm–1): 2981, 2933, 1734, 1597, 1144; 1H NMR 
(300 MHz, CDCl3, 25 °C, TMS): δ = 7.79-7.83 (m, 1H), 7.30-7.33 (m, 1H), 5.87-5.88 (m, 
1H), 5.61-5.62 (m, 1H), 4.61-4.62 (m, 2H), 2.45 (s, 3H), 1.36 (s, 9H); 13C NMR (75 MHz, 
CDCl3, 25 °C) δ = 150.4, 144.8, 136.7, 134.6 (q, J = 29.5 Hz, CCF3), 129.5, 128.4, 123.0 (q, 
J = 273.7 Hz, CF3), 119.2 (q, J = 5.2 Hz, C=CCF3) 85.1, 45.3, 27.9, 21.8; HRMS (ESI) calcd 
for C16H20F3NNaO4S (M+Na+) 402.09628, found 402.09598. 
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4-Methyl-N-(2-(trifluoromethyl)allyl)benzenesulfonamide (31): 
TFA (10ml) was added to a solution of compound 30 (0.445 g, 1.17 mmol) in 
DCM (10 mL) at 0 °C. After 5 min the reaction was warmed to rt and stirred 
for 40min. Subsequently, the reaction mixture was evaporated to dryness 
and the crude product purified by column chromatography to give 31 
(0.285 g, 87%) as a white solid. Mp= 69 °C; IR (neat, cm–1): 3280, 2925, 2856, 
1672, 1598, 1321;1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.77-7.74 (m, 
1H), 7.74-7.71 (m, 1H), 7.33-7.32 (m, 1H), 7.31-7.29 (m, 1H), 5.78-5.75 (m, 
1H), 5.63 (dd, J = 2.8, 1.4 Hz, 1H), 4.87-4.77 (m, 1H), 3.74 (d, J = 6.6 Hz, 2H), 2.43 (s, 
3H); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 143.9, 136.6, 134.1 (q, J = 29.0 Hz, CCF3), 
129.8, 127.1, 122.7 (q, J = 273.5 Hz, CF3), 120.6 (q, J = 5.2 Hz, C=CCF3), 41.7, 21.5; HRMS 
(EI) calcd for C11H12F3NO2S (M+) 279.0541 found 279.05379. 
 
N-Allyl-4-methyl-N-[2-(trifluoromethyl)allyl]benzenesulfonamide (32):  
Under an argon atmosphere, to a solution of compound 31 (50 mg, 0.179 
mmol) in toluene (4 mL) was added triphenylphosphine (94 mg, 0.36 
mmol), prop-2-en-1-ol (12.5 mg, 0.214 mmol) and diethyl azodicarboxylate 
(49.8 mg, 0.286 mmol) at ambient temperature. The mixture was heated at 50 °C for 
40 min, then the solvent was evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 20:1) to give 32 (56.9 mg, 99%) as a colorless oil. IR 
(neat, cm–1): 2985, 2924, 2858, 1347, 1321; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 
7.68-7.72 (m, 2H, Ar), 7.29-7.32 (m, 2H, Ar), 5.85-5.87 (m, 1H, CH=CCF3), 5.66-5.68 (m, 
1H, , CH=CCF3), 5.50 (ddt, J = 6.7, 6.7, 10.1 Hz, 1H, CH=CH2), 5.06-5.15 (m, 1H, 
CH=CH2), 5.10-5.13 (m, 1H, CH=CH2), 3.90 (s, 2H, NCH2CH), 3.78-3.81 (m, 2H, 
NCH2CCF3), 2.42 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 143.9, 136.9, 133.9 
(q, J = 29.1 Hz, CCF3), 131.8, 130.0, 127.4, 123.1 (q, J = 273.6 Hz, CF3), 120.6, (q, J = 5.3 
Hz, C=CCF3), 120.5, 50.6, 44.9, 21.7; HRMS (EI) calcd for C14H16F3NO2S (M+) 319.08538, 
found 319.08542. 
 
N-But-3-enyl-4-methyl-N-(2-trifluoromethylallyl)benzenesulfonamide (33):  
Under an argon atmosphere, to a solution of compound 31 (50 mg, 0.179 
mmol) in toluene (4 mL) was added triphenylphosphine (94 mg, 0.36 
mmol), 3-buten-1-ol (18.4 μl, 0.214 mmol) and diethyl azodicarboxylate 
(52.2 μl, 0.286 mmol) at ambient temperature. The mixture was heated at 
50 °C for 40 min, then the solvent was evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 20:1) to give 33 (38 mg, 64%) as a colorless 
oil. IR (neat, cm–1): 3071, 2976, 2855, 1455, 1407, 1346, 1321, 1156, 1122, 1091, 953, 919, 
811, 754, 664, 543; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.70 (d, J = 8.1 Hz, 2H, 
Ar), 7.32 (d, J = 8.1 Hz, 2H, Ar), 5.88-5.87 (m, 1H, F3CC=CH), 5.73-5.70 (m, 1H, 
F3CC=CH) 5.68-5.56 (m, 1H, CH2=CH), 5.05-4.97 (m, 2H, CH2=CH), 3.93 (s, 2H, 
NCH2CCF3), 3.22 (t, J = 7.7 Hz, 2H, NCH2CH2), 2.43 (s, 3H, CH3), 2.25-2.17 (m, 2H, 
NCH2CH2); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 143.9, 136.6, 134.3, 134.2 (q, J = 29 
Hz, CCF3), 129.9, 127.3, 123.1 (q, J = 272 Hz, CF3), 120.7 (q, J = 5.2 Hz, C=CCF3), 117.6, 
48.3, 46.5, 32.6, 21.6. HRMS (EI) calcd for C15H18F3NO2S (M+H+) 334.10886, found 
334.10772. 
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4-Methyl-N-pent-4-enyl-N-(2-trifluoromethylallyl)benzenesulfonamide (34):  
Under an argon atmosphere, to a solution of compound 31 (50 mg, 0.179 
mmol) in toluene (4 mL) was added triphenylphosphine (94 mg, 0.36 
mmol), 4-penten-1-ol (22.2 μl, 0.214 mmol) and diethyl azodicarboxylate 
(52.2 μl, 0.286 mmol) at ambient temperature. The mixture was heated at 
50 °C for 40 min, then the solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 20:1) to give 34 (37.3 mg, 
60%) as a colorless oil. IR (neat, cm–1): 3067, 2963, 2924, 2855, 1645, 1597, 1455, 1346, 
1325, 1161, 1117, 1091, 1048, 949, 910, 811, 664, 551; 1H NMR (300 MHz, CDCl3, 25 °C, 
TMS): δ = 7.70 (d, J = 8.4 Hz, 2H, Ar), 7.32 (d, J = 8.4 Hz, 2H, Ar), 5.88 (s, 1H, 
F3CC=CH), 5.73 (s, 1H, F3CC=CH), 5.77-5.64 (m, 1H, CH2=CH), 5.02-4.95 (m, 2H, 
CH2=CH), 3.90 (s, 2H, F3CCCH2N), 3.13 (t, J = 7.7 Hz, 2H, NCH2CH2), 2.43 (s, 3H, 
CH3), 2.02-1.95 (m, 2H, NCH2CH2CH2), 1.61-1.51 (m, 2H, NCH2CH2CH2); 13C NMR (75 
MHz, CDCl3, 25 °C) δ = 143.8, 137.2, 136.6, 134.4 (q, J = 28.7 Hz, CCF3), 129.9, 127.3, 
123.1 (q, J = 272 Hz, CF3), 120.6 (q, J = 5.2 Hz, C=CCF3), 115.7, 48.8, 46.5, 30.9, 27.2, 21.7; 
HRMS (EI) calcd for C16H20F3NO2S (M+) 347.1167, found 347.1169. 
 
4-Methyl-N-(3-phenylpent-4-enyl)-N-(2-(trifluoromethyl)allyl) 
benzenesulfonamide (35):  
Under an argon atmosphere, to a solution of compound 31 (28 mg, 0.1 
mmol) in toluene (3 mL) was added triphenylphosphine (52.6 mg, 0.20 
mmol), 3-phenylpent-4-en-1-ol (19.5 mg, 0.12 mmol) and diethyl 
azodicarboxylate (27.9 mg, 0.16 mmol) at ambient temperature. The mixture was 
heated at 50 °C for 40 min, then the solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 20:1) to give 35 (31.2 mg, 
74%) as a colorless oil. IR (neat, cm–1): 3060, 3027, 2924, 2867, 1637, 1598, 1492, 1452, 
1341, 1321, 1158, 1121, 955, 701; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.61 (d, J 
= 8.2 Hz, Ar), 7.08-7.31 (m, 7H, Ar), 5.84 (ddd, J = 17.1, 10.3, 7.5 Hz CH=CH2), 5.83 (dd, 
J = 2.8, 1.4 Hz, 1H, CH=CCF3), 5.64 (dd, J = 2.8, 1.4 Hz, CH=CCF3), 5.00 (dt, J = 25.5, 1.4 
Hz, 1H, CH=CH2), 5.00-5.02 (m, 1H, CH=CH2), 3.87 (br s, 2H, NCH2), 3.09-3.20 (m, 2H, 
NCH2CCF3), 2.91-3.01 (m, 1H, CHPh), 2.42 (s, 3H, CH3), 1.85-1.93 (m, 2H, NCH2CH2); 
13C NMR (75 MHz, CDCl3, 25 °C) δ = 146.0, 142.9, 141.7, 136.4, 134.3 (q, J = 30.0 Hz, 
CCF3), 129.9, 128.8, 127.6, 127.4, 126.8, 123.1 (q, J = 277 Hz, CF3), 120.8 (q, J = 7.5 Hz, 
C=CCF3), 115.0, 47.6, 47.5, 46.8, 33.4, 21.7. 
 
1-Tosyl-3-(trifluoromethyl)-2,5-dihydro-1H-pyrrole (36):  
To a solution of compound 32 (40 mg, 0.125 mmol) in dry toluene (30 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction was 
complete in 45 min. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 36 
(20.7 mg, 57%) as a white solid and 37 (9.1 mg, 23%) as an amorphous solid. 36: Mp = 
63-64 °C. IR (neat, cm–1): 2956, 2923, 2856, 1679, 1597, 1379. 1H NMR (300 MHz, 
CDCl3, 25 °C, TMS): δ= 7.73 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.0 Hz), 6.19-6.20 (m, 1H), 
4.26 (s, 4H), 2.44 (s, 3H). 13C NMR (75 MHz, CDCl3, 25 °C) δ = 144.3, 133.8, 130.2, 129.8 
(q, J = 4.8 Hz), 129.3 (q, J = 35.5 Hz), 127.6, 120.8 (q, J = 269.3 Hz), 54.9, 52.2, 21.7; 
HRMS (EI) calcd for C12H12F3NO2S (M+) 291.05408, found 291.05392. 37: IR (neat, cm-
1): 3060, 3027, 2959, 2924, 2860, 1662, 1597, 1360, 1322, 1165, 1121, 1051, 972, 943; 1H 
N
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NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.69 (d, J = 7.8 Hz, 2H, Ar), 7.31 (d, J = 7.8 
Hz, 2H, Ar), 6.56 (d, J = 14.1 Hz, 1H, NCH=CH), 5.79 (m, 1H, CH=CCF3), 5.55 (m, 1H, 
CH=CCF3), 4.72 (m, 1H, NCH=CHCH3), 4.02 (s, 2H, NCH2), 2.42 (s, 3H, ArCH3), 1.64 
(dd, J = 6.6 ,1.5, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ = 144.1, 135.7, 131.8 (q, J = 29.3 
Hz, CCF3), 129.9, 126.9, 125.5, 122.9 (q, J = 271.8 Hz, CF3), 119.2, 107.8, 44.2, 21.6, 15.2. 
 
1-Tosyl-5-trifluoromethyl-1,2,3,6-tetrahydro-pyridine (38): 
To a solution of compound 33 (30 mg, 0.09 mmol) in dry toluene (12 mL) 
Grubbs-II (5 mol%) was added at 100 °C in small portions. The reaction 
was complete in 1 h. The mixture was evaporated and the product was 
purified using column chromatography (heptane/EtOAc 10:1) to give 38 
(27 mg, 98%) as a colorless oil. Mp = 90-93 °C; IR (neat, cm–1): 3036, 2954, 2920, 2846, 
1459, 1394, 1342, 1316, 1169, 1117, 1091, 966, 879, 746; 1H NMR (300 MHz, CDCl3, 25 
°C, TMS): δ = 7.69 (d, J = 8.1 Hz, 2H, Ar), 7.35 (d, J = 8.1 Hz, 2H, Ar), 5.39 (t, J = 1.8 Hz, 
1H, F3CC=CHCH2), 3.72 (s, 2H, F3CCCH2N), 3.21 (t, J = 5.7 Hz, 2H, NCH2CH2), 2.44 (s, 
3H, CH3), 2.35-2.32 (m, 2H, NCH2CH2); 13C NMR (75 MHz, CDCl3, 25 °C) δ = 144.2, 
133.3, 130.0, 129.1 (q, J = 5.4 Hz, C=CCF3), 127.8, 125.5 (q, J = 31.0 Hz, CCF3), 122.7 (q, J 
= 270.3 Hz, CF3), 42.1, 41.9, 24.5, 21.7; HRMS (EI) calcd 305.06973532 for C13H14F3NO2S 
(M+), found 305.06963. 
 
1-Tosyl-5-trifluoromethyl-1,2,3,6-tetrahydropyridine (38): 
 The RCM was carried out following the general procedure with 
compound 34 (20 mg, 0.06 mmol) and the reaction was completed in 1 h. 
The mixture was purified using column chromatography (heptane/EtOAc 
10:1) to give 38 (12 mg, 65%) as a colorless oil. 
 
4-Methyl-N-(3-phenylpent-3-enyl)-N-(2-trifluoromethylallyl) 
benzenesulfonamide (39): 
 The RCM was carried out following the general procedure with 
compound 35 (21.8 mg, 0.05 mmol) and the reaction was completed 
in 2 h. The mixture was purified using column chromatography 
(heptane/EtOAc 10:1) to give 39 (14.8 mg, 68%) as a colorless oil. 39 (major isomer): 
1H NMR (300 MHz, CDCl3): δ = 7.67 (d, J = 8.4 Hz, Ar), 7.34-7.18 (m, 7H, Ar), 5.88-5.86 
(m, 1H, CH=CCF3), 5.83-5.81 (m, 1H, CH=CCF3), 5.66 (q, J = 1.2 Hz, 1H, PhC=CHCH3), 
3.99 (s, 2H, NCH2CCF3), 3.12-3.05 (m, 2H, NCH2), 2.74-2.69 (m, 2H, NCH2CH2), 2.45 
(s, 3H, CH3), 1.76 (d, J = 7.2 Hz, 3H, =CH3). 
 
N-(1-(Benzyloxy)allyl)-4-methyl-N-(2-(trifluoromethyl)allyl) 
benzenesulfonamide (41):  
Compound 41 was prepared according to a general literature procedure 
for the amidopalladation of tosylamides.6c To a 0.1 M solution in 
acetonitrile of compound 31 (103 mg, 0.36 mmol) was added Et3N (54 mg, 
0.54 mmol), Pd(OAc)2 (4 mg, 5 mol%), dppp (7.4 mg, 5 mol%) and 
benzyloxyallene 40 (57.6 mg, 0.39 mmol). After stirring at room temperature for one 
hour, the solvent was removed in vacuo and the crude residue purified by column 
chromatography (heptane/EtOAc 6:1 to 4:1) to give product 41 (0.144 g, 92%) as a 
colorless oil. IR (neat, cm–1): 3066, 3031, 2926, 2868, 1347, 1321, 1160; 1H NMR (300 
N
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MHz, CDCl3, 25 °C, TMS): δ = 7.73-7.68 (m, 2H, Ar), 7.36-7.18 (m, 7H, Ar), 5.80 (dd, J = 
2.9, 1.5 Hz, 1H, CH=CCF3), 5.73 (dd, J = 3.0, 1.5 Hz, 1H, CH=CCF3), 5.67 (dd, J = 3.1, 1.3 
Hz, 1H, CH=CH), 5.50-5.45 (m, 2H, HC=CH2), 5.28 (ddd, J = 6.7, 2.6, 1.1 Hz, 1H, 
HC=CH2), 4.52 (dd, J = 11.8, 3.8 Hz, 2H, OCH2), 3.94 (q, J = 18.2 Hz, 2H, NCH2), 2.42 (s, 
3H, CH3) 13C NMR (75 MHz, CDCl3, 25 °C) δ = 144.1, 137.2, 137.0, 135.0 (q, J = 28.8 Hz, 
CCF3), 133.0, 129.9, 128.5, 127.9, 127.7, 127.6, 123.2 (q, J = 273.8 Hz, CF3), 120.3 (q, J = 
5.2 Hz, C=CCF3), 119.9, 87.0, 70.0, 41.4, 21.7; HRMS (EI) calcd for C21H22F3NO3S (M+) 
426.1351 found 426.13521. 
 
1-Tosyl-3-(trifluoromethyl)-1H-pyrrole (40): 
 To a stirred solution of 41 (0.358 g, 0.842 mmol) in toluene (150 ml) at 100 
°C was added Grubbs-II (6.5 mol%) in two portions with an interval of 30 
min. After 1.5 h the reaction was cooled to rt and TFA (5.5 ml) was added. 
After stirring for 30 min the solvent was evaporated and the crude product 
purified by flash chromatography (1:40 ethyl acetate–heptane) to give 40 (0.195 g, 
80%) as a white solid. Mp = 57 °C; IR (neat, cm–1): 3066, 3031, 2957, 2922, 2852, 1583, 
1479, 1378, 1122, 1057; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ= 7.80-7.81 (m, 1H, 
Ar), 7.77-7.78 (m, 1H, Ts), 7.45-7.49 (m, 1H, Ts), 7.35-7.36 (m, 1H, Ar), 7.32-7.33 (m, 
1H, Ts), 7.16-7.18 (m, 1H, Ts), 6.43-6.44 (m, 1H, Ar), 2,43 (s, 3H, CH3); 13C NMR (75 
MHz, CDCl3, 25 °C) δ = 146.0, 135.1, 130.3, 127.2, 126.0 (q, J = 267.1 Hz, CF3), 121.6, 
119.9 (q, J = 5.0 Hz, C=CCF3), 119.4 (q, J = 37.5 Hz, CCF3), 110.2 (m F3CCH=C), 21.7. 
HRMS (EI) calcd for C12H10F3NO2S (M+) 289.0384 found 289.0387. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
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CHAPTER 6 
RCM-MEDIATED SYNTHESIS OF FLUORIDE- AND TRIFLUOROMETHYL-
CONTAINING CYCLIC HYDRAZINES 
 
 
 
Keywords: Fluorinated- and trifluoromethylated olefins / Ring-closing metathesis / 
Fluorinated cyclic hydrazine derivatives 
 
 
Abstract٭ 
A series of fluorinated cyclic hydrazine derivatives have been prepared in a 
straightforward manner using ring-closing metathesis (RCM) of fluorinated- and 
trifluoromethylated olefins as the key step. 
 
 
 
 
 
 
 
 
 
 
 
 
٭ V. De Matteis, F. L. van Delft, J. Tiebes, F. P. J. T. Rutjes “RCM-Mediated synthesis of 
fluorinated cyclic hydrazines”, Synlett 2008, in press. 
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6.1 INTRODUCTION 
 
A main characteristic of hydrazine molecules is the N-N bond, which is 
relatively weak and slightly shorter compared to the C-C bond. On a chemical level 
the weakness of this bond opens up the possibility to further transformations such as 
oxidation to the N=N double bond, cleavage or rearrangement to the corresponding 
amides or medium-sized lactams. On a biological level, this moiety is a structural 
element of several natural and unnatural biologically active compounds (Chart 1). 
An important example of an unnatural bioactive compound with a cyclic hydrazine 
skeleton is LY 186826 (1),1 which is part of a new class of antibiotics where the β-
lactam ring system has been replaced by a chemically activated γ-lactam ring system. 
Piperazic acid (2) is a key component of the biologically active class of peptides 
sanglifehrins.2 A recent example comprises hydrazine 3, which was shown to possess 
promising activity against type 2 diabetes.3  
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3: DPP-IV inhibitor
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Ph
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O
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F F
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Chart 1. Natural and unnatural compounds containing a cyclic hydrazine skeleton. 
 
Examples of drugs currently on the market are phenazone (4)4 and 
dimethylaminophenazone (5),5 which possess antipyretic and analgesic properties. 
Furthermore, benzpiperilone (6)6 and azapropazone (7)7 are anti-inflammatory and 
analgesic drugs, respectively. 
In addition to existing methods to synthesize cyclic hydrazine derivatives8 
such as the Diels-Alder reaction between azo diesters and 1,3-dienes,9 it was recently 
demonstrated that Ring-Closing Metathesis (RCM) can also be applied for this 
purpose.10 Although the latter approach gives potentially rise to a choice of cyclic 
hydrazines of different ring sizes and with various substitution patterns, so far no 
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examples exist in which fluoride or trifluoromethyl is incorporated in the hydrazine 
ring. Given the fact that the introduction of fluoride or fluoride-containing 
substituents often favorably contributes to the pharmacokinetic profile of bioactive 
compounds, an awareness that has led to a tremendous increase of new 
organofluorine compounds and their application in pharmaceutical research,11 we 
became interested in fluorinated cyclic hydrazine derivatives. 
 Inspired by previous experience in our group with preparing cyclic 
hydrazines, 12 the application of RCM in the synthesis of nitrogen heterocyclic 
building blocks,13 in particular of fluorinated and trifluoromethylated nitrogen 
heterocycles,14 we set out to apply RCM as a potential tool to synthesize fluoro- and 
trifluoromethyl-containing cyclic hydrazines. Despite the fact that RCM examples to 
form heterocyclic fluorinated olefins exist,15 it has never been applied for the 
synthesis of this particular class of hydrazines with potentially unique properties. 
Retrosynthetically, readily available fluoride- and trifluoromethylated olefins of type 
9 (Scheme 1) might serve as suitable precursors for the preparation of the 
corresponding target cyclic hydrazines 8 using RCM. 
 
8 9
N
N
PG1
PG2 X
( )1,2 N
N
PG1
PG2
( )1,2
XX = F, CF3
RCM
 
Scheme 1. Retrosynthetic approach. 
 
6.2 SYNTHESIS OF SIX-MEMBERED FLUORIDE- AND TRIFLUOROMETHYL-
CONTAINING CYCLIC HYDRAZINES VIA RCM 
 
 To initially probe the viability of RCM to synthesize fluoride- and 
trifluoromethyl-containing cyclic hydrazines, we first aimed to prepare a simple six-
membered trifluoromethylated cyclic hydrazine bearing the same protective group 
on both nitrogens. The required RCM precursor 12 was synthesized through two 
alkylation steps, starting from diethyl azodicarboxylate (10, Scheme 2). 
The first alkylation of azodicarboxylate 10 with allylmagnesium chloride 
(THF, –78 °C, work up with NH4Cl) provided the monoalkylated hydrazo ester 11 in 
61% yield. Subsequently a second alkylation with the 2-(trifluoromethyl)allylating 
reagent (see: Section 2.2.1) provided the RCM precursor 12 in excellent yield (99%). 
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Grubbs-II
 (20 mol %)
toluene
100 °C
60 min
N
N
EtO2C
EtO2C
N
N
CO2Et
EtO2C
CF3
THF, –78 ºC
11 (61%)
1) NaH, rt
2)
12 (99%)
N
N
EtO2C
EtO2C
CF3
13 (58%)
CF3
OTs
10
1)
2) NH4Cl
MgCl
N
EtO2C
NH
EtO2C DMF, rt
12 h
Scheme 2. Synthesis of the six-membered trifluoromethylated cyclic hydrazine 13. 
 
This precursor molecule 12 was then subjected to RCM using Grubbs-II 
catalyst (20 mol%) added in portions to the reaction mixture in toluene at 100 °C. As 
anticipated, the cyclization proceeded smoothly to produce the desired cyclic 
hydrazine 13 in 58%, along with a minor amount of the isomerized product.16 
Although this first example proved the viability of the RCM strategy, it also made 
clear that isomerization of the precursor 13 could be a potential problem. 
 To avoid the side reaction and to be able to introduce additional substituents 
a somewhat different route was developed for the synthesis of RCM precursors 
(scheme 3). 
PhMe, rt THF, –78 ºC
b
N
N
Ph
Boc
PG
X = CF3, F
a14  15 (93%) 20-2416: X = H (94%)
17-19: X = PG
NH2
NH
Boc
Ph H
O
N
NH
Boc
Ph
MgBr N
NH
Boc
Ph
X
X
 
Scheme 3. Synthesis of differentially protected hydrazines 20-24. 
 
The hydrazines 20-24 were prepared starting from the tert-butyl carbazate 14, 
which was first condensed with benzaldehyde in toluene at room temperature and 
then alkylated with vinylmagnesium bromide to give the Boc-protected hydrazine 
16. Advantage of this route is that different (aromatic) groups can be readily 
introduced, which as a bonus will significantly slow down the undesired 
isomerization process. In order to orthogonally protect the hydrazine moiety, at this 
stage a number of different protecting groups were introduced on the second 
nitrogen atom which required extensive experimentation to reach reasonable 
selectivity and yields. Conditions (a) were used to provide the products 17-19 with 
different substitution patterns. The second alkylation (b) with the 2-
(trifluoromethyl)allylating reagent or 1-fluoro-2-chloro-2-propene provided the 
fluoride- and trifluoromethyl-containing hydrazine precursors 20-24. In Table 1 the 
conditions and yields for these last two steps are described. 
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Table 1. Synthesis and yield of the RCM precursors. 
Entry Step (a) 
conditions 
Monoalkylated 
hydrazo (yield) 
Step (b) conditions RCM  
precursors (yield) 
 
 
 
 
1 
2 
 
NaH, THF
-78 ºC to rt
O
OPh Cl 
 
 
N
NH
PhO
OPh
Boc  
 
17 (50%) 
 
NaH, solvent(S)
0 ºC to rt
Y
X  
S = THF, Y = OTs, X = CF3 
S = DMF, Y = Cl, X = F 
 
N
N
PhO
OPh
Boc
X  
20 (40%) X = CF3 
21 (70%) X = F 
 
 
 
 
3 
 
K2CO3 (1eq), 
0 ºC to rt, 12 h, 
BzBr, 0 ºC to rt
KHMDS (1eq), 
0 ºC to rt,12 h,
THF
 
 
N
NH
Ph
Boc
Ph
 
 
18 (36%) 
 
NaH, DMF
Cl
F
0 ºC to rt
 
 
 
N
N
Ph
Boc
F
Ph
 
22 (70%) 
 
 
 
 
4 
5 
 
O
Cl
Ph
  Et3N, 0 ºC, 
  30 min
THF, 0 ºC to rt
 
 
N
NH
Ph
Boc
O
Ph
 
 
19 (67%) 
 
NaH, DMF
0 ºC to rt
Y
X  
Y = OTs, X = CF3 
Y = Cl, X = F 
 
N
N
Ph
Boc
X
O
Ph
 
23 (76%) X = CF3 
24 (70%) X = F 
 
 Going through the conditions for step (a) in Table 1, it is clear that different 
reagents were required under different conditions. In entry 1 and 2 for example, the 
Cbz group was introduced on hydrazine 16 in 50% yield via deprotonation (NaH, –
78 °C), followed by treatment with benzyl chloroformate and slowly warming to rt. 
Applying similar deprotonation conditions to the reaction with benzyl bromide 
(entry 3) led to mixtures of regioisomers. In this case, however, introducing K2CO3 at 
0 °C together with the Boc-protected hydrazine 16 in THF followed by allowing the 
reaction to warm to rt in 12 hours and subsequent introduction of benzyl bromide at 
0 °C, followed by KHMDS (one equivalent) at 0 °C and slowly warming to room 
temperature in 12 hours provided the desired product 18 in 36%. It appeared that the 
presence of K2CO3 was very important; in fact using the same conditions without 
K2CO3 did not work at all. Finally, acylation of 16 (entry 4 and 5) with phenylacetyl 
chloride (PhAcCl) proceeded in acceptable yield (67%). In this case, PhAcCl was first 
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reacted with Et3N at 0 °C in THF for 30 min to form the corresponding ketene, which 
was then further reacted with 16 and slowly allowed to warm to rt overnight. 
 In contrast, functionalization of the second nitrogen proceeded uneventfully, 
starting with deprotonation of 17 (NaH, THF, 0 °C to rt), followed by alkylation with 
the 2-(trifluoromethyl)allylating reagent to give precursor 20 in 40% yield (entry 1, 
Table 1). The other alkylations, however, were carried out in DMF, which 
consistently gave higher yields. For example, deprotonation of 17 with NaH in DMF, 
followed by alkylation with commercially available 1-chloro-2-fluoro-2-propene 
provided compound 21 in 70% yield (entry 2). Similar yields were obtained for 
precursors 22-24 using identical conditions (entries 3-5). 
 All diolefinic hydrazines 20-24 were then subjected to the previously used 
RCM conditions (Grubbs-II catalyst, toluene, 100 °C) (Scheme 4). 
 
N
N
Ph
Boc
PG
Grubbs-II catalyst 
toluene, 100 °C N
N
Boc
PG
X
Ph
X = F, CF320-24 25-29
X
 
Scheme 4. RCM of the fluoride and trifluoromethyl-containing hydrazine precursors. 
 
This led to the corresponding trifluoromethyl- and fluoride-substituted cyclic 
hydrazine building blocks 25-29 in resonable to good yields (Table 2). In almost all 
cases, 20 mol% of catalyst had to be added over a period of approximately 60 
minutes in order to reach full conversion. Only in case of entry 3 somewhat less of 
the catalyst (15 mol%) appeared sufficient.  
This new synthetic pathway clearly establishes that RCM represents a viable 
pathway to obtain a novel class of cyclic hydrazine derivatives of potential biological 
relevance. Logically, removal of the Boc and the PhAc protecting groups offer useful 
possibilities for further functionalization of these building blocks via paralle 
synthesis techniques. 
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Table 2. RCM results. 
Entry Precursors Cat 
(mol%) 
Time 
(min) 
Product (yield) 
 
 
 
1 
2 
N
N
PhO
OPh
Boc
X  
20 (X = CF3) 
21 (X = F) 
 
 
 
 
20 
 
 
 
 
60 
 
 
 
25 (74%) X = CF3 
26 (66%) X = F 
 
 
 
3 
N
N
Ph
Boc
F
Ph
 
22 
 
 
 
 
15 
 
 
 
 
60 
 
 
 
27 (83%) 
 
 
 
4 
5 
N
N
Ph
Boc
X
O
Ph
 
23 (X = CF3) 
24 (X = F) 
 
 
 
 
20 
 
 
 
 
120 
 
 
 
28 (52%) X = CF3 
29 (62%) X = F 
 
 In order to show that the orthogonally protected nitrogens can indeed be 
exploited in this way, the Boc-group was replaced in compound 29 through a two-
step procedure with a benzyl substituent (Scheme 5).  
 
N
N
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Ph
N
HN
F
Ph
N
N
F
Ph
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O
Ph
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O
Ph
30 (99%) 31 (77%)
CH2Cl2
 0 ºC to rt
1) NaH, DMF
    0 ºC to rt
   15 min
2) BnBr
29
Boc
 
Scheme 5. Replacement of Boc with a benzyl substituent. 
 
This was realized via standard Boc-deprotection of 29 with TFA, followed by 
benzylation of the resulting amine 30 (NaH in DMF at 0 °C, followed by BnBr) to 
give hydrazine 31 in 76% overall yield. 
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6.3 SYNTHESIS OF A FLUORIDE-CONTAINING SEVEN-MEMBERED RING 
HYDRAZINE VIA RCM 
 
Having successfully demonstrated that RCM readily leads to fluoride- and 
trifluoromethyl-substituted six-membered ring hydrazines, we decided to apply the 
same technique for the synthesis of a fluoride-containing seven-membered ring 
hydrazine. The investigation started by exploring the possibility of applying the 
previous successful pathway to reach this goal (Scheme 6). 
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Scheme 6. Synthesis of the fluorinated seven-membered ring hydrazine 35. 
 
Tert-Butyl carbazate 14 was first condensed with benzaldehyde in toluene at 
room temperature providing hydrazone 15 in 93% yield. Subsequent alkylation with 
allylmagnesium bromide produced the Boc-protected hydrazine 32 in 40% yield. The 
synthesis then proceeded as described previously, first selective acylation with 
PhAcCl via the intermediate ketene in 89% yield, followed by alkylation of the 
resulting 33 with NaH and 1-chloro-2-fluoro-2-propene to give RCM precursor 34 in 
54% yield. The compound was then subjected to the standard RCM conditions (20 
mol % Grubbs-II catalyst added over a period of 2 h, toluene, 100 °C) to afford the 
seven-membered ring hydrazine 35 in in a satisfactory yield of 64% along with a 
small amount of an unidentified side product. After chromatographic separation and 
subsequent crystallization, the identity of 35, however, could be unambiguously 
established via X-ray crystallographic determination of the crystal structure (Figure 
1).17  
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Figure 1. Chem3D representation of the crystal structure of 35. 
 
This important result shows again the applicability of RCM and gave the 
opportunity to obtain the first example of a fluoride-containing seven-membered 
ring hydrazine. 
 
6.4 CONCLUSION 
 
In summary, an efficient and straightforward pathway for the synthesis of 
orthogonally protected fluorinated cyclic hydrazines has been developed. Key step is 
the RCM-mediated ring closure of trifluoromethyl- and fluoride-substituted olefins 
that lead to the corresponding cyclic products in reasonable to good yields. 
Considering the biological activity of cyclic hydrazines in general and the increasing 
role of fluorine in pharmaceutical products, this provides a potentially useful entry 
into a promising class of products. 
 
6.5 EXPERIMENTAL SECTION 
 
Diethyl 1-allylhydrazine-1,2-dicarboxylate (11):  
Allylmagnesium chloride (15.1 mL of a 2.0 M solution in THF, 30.1 
mmol) was added at –78 °C to a stirred solution of diethyl 
azodicarboxylate (4.33 mL, 27.5 mmol) in THF (10 mL). The mixture 
was stirred at –78 °C for 1 h and then for 12 h reaching slowly room temperature. It 
was poured into aqueous saturated NH4Cl solution and the aqueous layer was 
extracted with ether (3 × 10 mL). The ether layers were dried (MgSO4), evaporated 
and the residue was purified using column chromatography (heptane/EtOAc 10:1) to 
give 11 (3.63 g, 61%) as a colorless oil. IR (neat, cm–1): 3296, 2976, 2924, 1709, 1519, 
1416, 1264, 1221, 1057, 927, 754; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 6.59 (br s, 
1H, NH), 5.89-5.75 (m, 1H, CH2=CH), 5.21-5.15 (m, 2H, H2C=CH), 4.18 (q, J = 7.2 Hz, 
4H, 2CH2CH3), 4.10 (d, J = 5.4 Hz, 2H, NCH2), 1.27 (t, J = 7.2 Hz, 6H, 2 CH3); 13C NMR 
(75 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 156.3, 156.2, 132.6 + 
132.5, 118.4 + 118.3, 62.7, 62.1, 53.0, 14.6, 14.5; HRMS (CI) calcd for C9H17N2O4 (M++H) 
217.1188, found 217.1190. 
N
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EtO2C
EtO2C
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Diethyl 1-allyl-2-(2-(trifluoromethyl)allyl)hydrazine-1,2-dicarboxylate (12): 
To a suspension of NaH (36 mg, 1.48 mmol) in DMF (2 mL) was added 
at room temperature product 11 (160 mg, 0.74 mmol). After stirring for 
15 min, 2-(trifluoromethyl)allylating reagent (see: Section 2.2.1) (208 
mg, 0.74 mmol) was added dropwise at rt. The reaction was stirred for 
12 h, quenched with water (2 mL) and extracted with Et2O (3 × 2 mL). The ether 
layers were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1 to 6:1) to give 12 (237 mg, 99%) as a colorless 
oil. IR (neat, cm–1): 2984, 2937, 1723, 1407, 1381, 1325, 1238, 1169, 1122, 1027, 932, 772; 
1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 5.84 (br s, 2H, CH2=CH, CF3C=CH), 5.66 
(d, J = 4.6 Hz 1H, CF3C=CH), 5.20-5.11(m, 2H, H2C=CH), 4.63-3.96(m, 8H, 4 CH2), 1.28-
1.23 (m, 6H, 2 CH3); 13C NMR (75 MHz, CDCl3, 25 °C, some signals appear as 
rotamers ad isomers): δ = 155.6, 155.3, 133.5 (q, J = 29.6 Hz, CCF3), 132.7, 122.8(q, J = 
270.8 Hz, CF3), 122.0-121.3 (m, C=CCF3), 118.3-117.6 (m, H2C=CH), 62.9-62.5 (m, 
OCH2), 54.6-53.3 (m, H2CCH=CH2), 50.5 + 49.6; HRMS (EI) calcd for C13H19N2O4F3 
(M+) 324.1297, found 324.1301. 
 
General procedure for the RCM reactions 
To a 0.01 M solution of the diene in dry toluene under an inert atmosphere, Grubbs-II 
catalyst was added at 100 °C. Stirring was continued until the reaction was complete 
(indicated by TLC or GC), followed by concentration of the reaction mixture and 
subsequent purification with column chromatography. 
 
4-Trifluoromethyl-3,6-dihydropyridazine-1,2-dicarboxylic acid diethyl ester (13):  
To a solution of 12 (69 mg, 0.21 mmol) in dry toluene (28 mL) the 
Grubbs-II catalyst (20 mol%) was added at 100 °C in small 
portions. The reaction was complete in 5 h. The mixture was 
evaporated and the product was purified using column 
chromatography (heptane/EtOAc 10:1, 6:1) to give 13 (34 mg, 58%) 
as a yellow oil. IR (neat, cm–1): 2984, 2920,2855, 1718, 1420, 1381, 1346, 1217, 1169, 
1117, 1074, 1027, 884, 759; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 6.40 (s, 1H, 
CF3C=CH), 4.57 (br s, 2H, NCH2CH), 4.23-4.21 (m, 4H, 2 CH2), 3.88 (br s, 2H, 
NCH2CCF3), 1.31-1.26 (m, 6H, 2 CH3); 13C NMR (75 MHz, CDCl3, 25 °C, the signals of 
the quaternary carbons are not visible): δ = 154.9, 127.0, 122.2 (q, J = 268.8 Hz, CF3), 
63.0, 42.9-41.3 (m, H2CCCF3), 30.0; HRMS (EI) calcd for C11H15N2O4F3 (M+) 296.0984, 
found 296.0984 
 
N’-Benzylidenehydrazine carboxylic acid tert-butyl ester (15):  
To a solution of tert-butyl carbazate (5.7 g, 43.1 mmol) in toluene (85 
mL) was added benzaldehyde (4.5 mL, 45.3 mmol) and the mixture 
was stirred at room temperature for 18 h. Filtration and 
recrystallization (ethyl acetate/hexane/methanol 5:10:1) afforded 
product 15 (8.8 g, 94%) as white crystals. Mp = 188–190 °C; IR (neat, 
cm–1): 3244, 3058, 3028, 2967, 2924, 2859, 1688, 1528, 1368, 1251, 1161, 
1057, 1022, 862, 759, 689; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 8.14 (s, 1H, 
N=CH), 7.86 (s, 1H, NH), 7.68-7.65 (m, 2H, Ph), 7.35-7.33 (m, 3H, Ph), 1.54 (s, 9H, 
N
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3CH3); 13C NMR (75 MHz, CDCl3, 25 °C): δ = 152.7, 143.8, 134.1, 129.9, 128.6, 127.3, 
81.5, 28.4; HRMS (EI) calcd for C12H16N2O2 (M+) 220.1212, found 220.1210. 
 
N’-(1-Phenylallyl)hydrazinecarboxylic acid tert-butyl ester (16):  
Vinylmagnesium bromide (62 mL of a 1.0 M solution in THF, 62 
mmol) was added at -78 °C to a stirred solution of compound 15 
(4.50 g, 20.5 mmol) in THF (63 mL). The mixture was stirred at –78 
°C for 1 h and then for 12 h reaching slowly the room temperature. It 
was poured into aqueous saturated NH4Cl solution and the aqueous 
layer was extracted with ether (3 × 50 mL). The ether layers were 
dried (MgSO4), evaporated and the crude product 16 (4.8 g, 94%) was obtained as a 
white crystals. Mp = 62–65 °C; IR (neat, cm–1): 3317, 3296, 3058, 3028, 2984, 2963, 2859, 
1679, 1532, 1467, 1364, 1290, 1152, 932, 798, 750, 698; 1H NMR (300 MHz, CDCl3, 25 
°C, TMS): δ = 7.35-7.23 (m, 5H, Ph), 6.03, (s, 1H, BocNH), 5.97-5.86 (m, 1H, CH=CH2), 
5.23-5.13 (m, 2H, CH=CH2), 4.6 (br s, 1H, PhCH), 4.21 (br s, 1H, BocNHNH), 1.44 (s, 
9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C): δ = 156.8, 138.5, 128.7, 128.1, 127.9, 
127.8, 117.4, 80.6, 67.3, 28.5. 
 
1-Benzyl 2-tert-butyl 1-(1-phenylallyl)hydrazine-1,2-dicarboxylate (17): 
To a suspension of NaH (22 mg, 0.88 mmol) in THF (3 mL) was 
added at –78 °C compound 16 (200 mg, 0.81 mmol). After stirring 
for 15 min, benzyl chloroformate (0.12 mL, 0.81 mmol) was added 
dropwise at ‒78 °C. The reaction was stirred at –78 °C for 1 h, then 
for 12 h reaching slowly room temperature. The solvent was 
evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 6:1) to give 17 (155 mg, 50%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3, 25 °C, TMS): δ = 7.31-7.28 (m, 10H, Ar), 6.41 (br s, 1H, NH), 
6.18-6.15 (m, 1H, CH2=CH), 5.87 (br s, 1H, CHPh), 5.31-5.12 (m, 4H, H2C=CH, CH2Ph), 
1.35 (s, 9H, 3CH3); 13C NMR (100 MHz, DMSO, 25 °C): δ = 155.3, 155.1, 139.4, 137.1, 
136.5, 128.4-127.3 (m, Ar), 127.1, 127.0, 117.35, 80.4, 66.9, 64.9, 27.9. 
 
1-Benzyl-1-(1-phenylallyl)hydrazinecarboxylic acid tert-butyl ester (18): 
To a solution of compound 16 (200 mg, 0.81 mmol) in THF (4 mL) 
was added at 0 °C K2CO3 (111 mg, 0.8 mmol) and the mixture was 
stirred for 12 h reaching slowly room temperature. Then the reaction 
mixture was cooled again at 0 °C and benzyl bromide (95 μl, 0.8 
mmol) was added. After stirring for 1 h at 0 °C, KHMDS (1.6 mL, 0.8 
mmol) was added and the mixture was stirred for 12 h reaching 
slowly the room temperature. The solvent was evaporated and the residue was 
purified using column chromatography (heptane/EtOAc 20:1) to give 18 (105 mg, 
36%) as white crystals. Mp = 101–104 °C; IR (neat, cm–1): 3309, 3084, 3028, 2976, 2924, 
2812, 1709, 1506, 1450, 1359, 1238, 1161, 988, 914, 759, 703; 1H NMR (300 MHz, CDCl3, 
25 °C, TMS): δ = 7.48-7.22 (m, 10H, Ar), 6.11-5.99 (m, 1H, CH2=CH), 5.60 (br s, 1H, 
NH), 5.36-5.14 (m, 2H, CHPh, HC=CH), 4.83-4.79 (m, 1H, HC=CH), 4.04-3.82 (m, 2H, 
CH2Ph), 1.33 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C): δ = 167.8, 136.1, 132.5, 
129.9, 129.3, 128.7, 128.4, 128.2, 128.0, 127.6, 127.2, 126.6, 117.1, 81.1, 68.2, 56.5, 28.3; 
HRMS (CI) calcd for C21H26N2O2 (M+) 338.1994, found 338.2006. 
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1-Phenylacetyl-1-(1-phenylallyl)hydrazinecarboxylic acid tert-butyl ester (19): 
 In a THF (4 mL) solution at 0 °C phenylacetylchloride (0.12 mL, 
0.8 mmol) and Et3N (0.11 mL, 0.8 mmol) were added and the 
mixture was stirred at 0 °C for 30 min. After compound 16 (200 
mg, 0.8 mmol) was added, the mixture was stirred for 12 h thereby 
slowly reaching room temperature. The solvent was evaporated 
and the residue was purified using column chromatography 
(heptane/EtOAc 10:1) to give 19 (196 mg, 67%) as a white solid. Mp = 85–88 °C; IR 
(neat, cm–1): 3239, 3062, 3028, 2976, 2924, 1735, 1645, 1519, 1394, 1256, 1156, 923, 754, 
698, 582; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some signals appear as rotamers): δ 
= 7.30-7.17 (m, 10H, Ar), 6.47-5.91 (m, 3H, NH, CHPh, CH2=CH), 5.35-4.89 (m, 2H, 
H2C=CH), 3.72 (s, 2H, CH2Ph), 1.47 + 1.26 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 
°C): δ = 167.8, 153.6, 137.9, 134.0, 130.1, 129.4, 129.3, 129.2, 128.5, 127.8, 126.8, 119.9, 
82.1, 62.2, 41.1, 31.9; HRMS (ESI) calcd for C22H26N2NaO3 (M++Na) 389.18411, found 
389.18252. 
 
1-Benzyl 2-tert-butyl 1-(1-phenylallyl)-2-(2-(trifluoromethyl)allyl)hydrazine- 
1,2-dicarboxylate (20): 
To a suspension of NaH (10 mg, 0.40 mmol) in THF (3 mL) was 
added at 0 °C compound 17 (140 mg, 0.37 mmol). After stirring for 
1 h at room temperature, 2-(trifluoromethyl)allylating reagent 
(see: Section 2.2.1) (112 mg, 0.40 mmol) was added dropwise. The 
reaction was stirred for 12 h. The solvent was evaporated and the 
residue was purified using column chromatography (heptane/EtOAc 10:1) to give 20 
(71 mg, 40%) as a colorless oil. IR (neat, cm–1): 3065, 3032, 2972, 2934, 1717, 1492, 1451, 
1390, 1363, 1303, 1253, 1168, 1149, 1122, 1023, 932, 853, 751, 696; 1H NMR (400 MHz, 
CDCl3, 25 °C, TMS, some signals appear as rotamers): δ = 7.29 (s, 10H, Ar), 6.36-
6.21+6.20-6.05 (m, 1H, CH2=CH), 5.68-5.44 (m, 3H, CF3C=CH2, CHPh), 5.27-4.96 (m, 
4H, H2C=CH, CH2Ph,), 4.51-3.93 (m, 2H, NCH2), 1.38+1.30 (s, 9H, 3CH3); 13C NMR 
(100 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 156.1, 155.6+154.9, 
139.8, 138.3, 135.7+135.6, 134.7+134.6, 133.6+133.3 (q, J = 39 Hz, CCF3), 128.9-127.6 (m, 
Ar), 122.9(q, J = 363.8 Hz, CF3), 120.7-120.6 + 120.1-119.9 (m, H2C=CH), 82.3, 82.0, 68.2, 
67.8 + 67.0, 52.1-51.6 + 50.9-50.6 (m, NCH2), 27.8+27.6; HRMS (EI) calcd for 
C26H30F3N2O4 (M++H) 491.2158, found 491.2127. 
 
1-Benzyl 2-tert-butyl 2-(2-fluoroallyl)-1-(1-phenylallyl)hydrazine- 
1,2-dicarboxylate (21):  
To a suspension of NaH (19 mg, 0.78 mmol) in DMF (6 mL) was 
added at 0 °C compound 17 (230 mg, 0.60 mmol). After stirring for 
1 h at room temperature, 1-chloro-2-fluoro-2-propene (57 mg, 0.60 
mmol) was slowly added. The reaction was stirred for 12 h, 
quenched with water (6 mL) and extracted with Et2O (3 × 6 mL). 
The ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 10:1 to 6:1) to give 21 (180 mg, 70%) as a 
colorless oil. IR (neat, cm–1): 3065, 3032, 2978, 2923, 1717, 1495, 1454, 1393, 1369, 1297, 
1253, 1215, 1160, 1023, 932, 861, 754, 696; 1H NMR (400 MHz, CDCl3, 25 °C, TMS, 
some signals appear as rotamers): δ = 7.30 (s, 10H, Ar), 6.36-6.30+6.20-6.05 (m, 1H, 
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CH2=CH), 5.62-5.50 (m, 1H, CHPh), 5.26-4.96 (m, 4H, H2C=CH, CH2Ph,), 4.61-3.91 (m, 
4H, CF3C=CH2, NCH2), 1.42 + 1.29 (s, 9H, 3CH3); 13C NMR (100 MHz, CDCl3, 25 °C, 
some signals appear as rotamers): δ = 161.1 (d, J = 254.7 Hz, CF), 155.7, 154.7, 136.2, 
135.5, 134.7, 129.0 (br s, CH=CH2), 128.3-127.4 (m, Ar), 117.8, 94.5+93.8, 81.8 (d, J = 23.6 
Hz, CH2=CF), 67.9, 67.7, 52.9-52.5 + 51.8-50.9 (m, H2CCF), 27.8 + 27.5; HRMS (EI) calcd 
for C25H30FN2O4 (M++H) 441.2190, found 441.2224. 
 
1-Benzyl-2-(2-fluoroallyl)-1-(1-phenylallyl)hydrazinecarboxylic acid tert-butyl 
ester (22):  
To a suspension of NaH (19.4 mg, 0.81 mmol) in DMF (6 mL) was 
added at 0 °C compound 18 (209 mg, 0.62 mmol). After stirring for 1 
h at room temperature, 1-chloro-2-fluoro-2-propene (58.3 mg, 0.62 
mmol) was slowly added. The reaction was stirred for 12 h, 
quenched with water (6 mL) and extracted with Et2O (3 × 6 mL). The 
ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 20:1) to give 22 (172 mg, 70%) as a colorless 
oil. IR (neat, cm–1): 3084, 3058, 3032, 2976, 2928, 2868, 1701, 1454, 1364, 1230, 1161, 
1113, 1022, 923, 858, 763, 703; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some signals 
appear as rotamers): δ = 7.52-7.50 (m, 10H, Ar), 6.04-5.88 (m, 1H, CH2=CH), 5.31-4.96 
(m, 2H, H2C=CH), 4.594.44 (m, 1H, CHPh), 4.31-4.10 (m, 2H, FC=CH2) 4.04-3.60 (m, 
3H, 1H CH2Ph, NCH2), 3.12-2.89 (m, 1H, CH2Ph), 1.63 + 1.46 (s, 9H, 3CH3); 13C NMR 
(75 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 162.3 (d, J = 259.9 Hz, 
CF), 154.5, 139.1, 138.3, 130.1, 128.8, 128.3, 128.2, 127.9, 127.5+127.4, 126.9, 116.9 + 
116.4, 93.9 + 93.1 (d, J = 18.1 Hz, CH2=CF), 81.3 + 80.5, 74.5 + 73.2, 54.9 + 54.5, 52.9 (d, J 
= 29.6 Hz, H2CCF), 28.8 + 28.4; HRMS (EI) calcd for C24H30FN2O2 (M++H) 397.2291, 
found 397.2287. 
 
tert-Butyl 2-(2-phenylacetyl)-2-(1-phenylallyl)-1-(2-(trifluoromethyl)allyl) 
hydrazinecarboxylate (23): 
To a suspension of NaH (6.9 mg, 0.29 mmol) in DMF (3 mL) was 
added at 0 °C compound 19 (88 mg, 0.24 mmol). After stirring for 
15 min at 0 °C, the ice-bath was removed and at room 
temperature 2-(trifluoromethyl)allylating reagent (see: Section 
2.2.1) (67.3 mg, 0.24 mmol) was slowly added. The reaction was 
stirred for 12 h, quenched with water (3 mL) and extracted with Et2O (3 × 4 mL). The 
ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc from 10:1 to 6:1) to give 23 (86 mg, 76%) as 
a colorless oil. IR (neat, cm–1): 3062, 3028, 2980, 2924, 1722, 1679, 1498, 1368, 1333, 
1251, 1178, 1156, 1126, 979, 815, 703, 547. 1H NMR (300 MHz, CDCl3, 25 °C, TMS, 
some signals appear as rotamers): δ = 7.37-7.19 (m, 10H, Ar), 6.38-6.07 (m, 1H, 
CH2=CH), 5.91-5.74 (m, 2H, CH2=CCF3), 5.47-5.14 (m, 3H, CH2=CH, CHPh), 4.36-3.74 
(m, 2H, NCH2), 3.73-3.63 (m, 2H, CH2Ph), 1.45 + 1.27 (s, 9H, 3CH3); 13C NMR (75 MHz, 
CDCl3, 25 °C, some signals appear as rotamers): 154.4, 153.8, 139.1, 135.1, 132.9 (q, J = 
44 Hz, CCF3), 130.1, 130.0, 129.9, 128.5, 128.1, 127.8, 126.6 (q, J = 274.3 Hz, CF3), 123.6 
(q, J = 5.2 Hz, CH2CF3),83.3, 65.5, 47.7-47.5 (m, NCH2), 41.8, 28.0; HRMS (ESI) calcd for 
C26H29F3N2NaO3 (M++Na) 497.2028, found 497.1991. 
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tert-Butyl 1-(2-fluoroallyl)-2-(2-phenylacetyl)-2-(1phenylallyl) 
hydrazinecarboxylate (24): 
 To a suspension of NaH (16.7 mg, 0.69 mmol) in DMF (6 mL) was 
added at 0 °C compound 19 (196 mg, 0.54 mmol). After stirring for 
1 h at room temperature, 1-chloro-2-fluoro-2-propene (50.8 mg, 
0.54 mmol) was added slowly. The reaction was stirred for 12 h, 
quenched with water (6 mL) and extracted with Et2O (3 × 6 mL). 
The ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 10:1) to give 24 (160 mg, 70%) as a colorless 
oil. IR (neat, cm–1): 3088, 3062, 3032, 2980, 2928, 1718, 1675, 1493, 1455, 1368, 1251, 
1152, 932, 845, 759, 703; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some signals appear 
as rotamers): δ = 7.37-7.22 (m, 10H, Ar), 6.26-5.81 (m, 2H, 1H CH2=CH, CH2=CH), 
5.33-5.23 (m, 2H, NCH2), 4.79-4.29 (m, 3H, 1H CH2=CH, 1H FC=CH2, CHPh), 3.80-3.48 
(m, 3H, 1H FC=CH2, CH2Ph), 1.44 + 1.27 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 
°C, some signals appear as rotamers): δ = 160.2 (d, J = 259.3 Hz, CF), 154.4, 153.8, 
139.8, 134.0, 129.8+129.4, 128.5, 128.3, 128.1, 127.6, 126.7, 120.5, 117.5, 96.1-95.9 (m, 
CH2=CF), 83.0+82.8, 66.0+65.4, 52.1-51.8+50.5-50.1 (m, H2CCF), 38.7+38.6, 28.1+28.0; 
HRMS (EI) calcd for C25H30FN2O3 (M++H) 425.2241, found 425.2234. 
 
3-Phenyl-5-Trifluoromethyl-3,6-dihydropyridazine-1,2-dicarboxylic acid-2-benzyl 
ester 1-tert-butyl ester (25) : 
 To a solution of compound 20 (50 mg, 0.10 mmol) in dry 
toluene (20 mL) the Grubbs-II catalyst (20 mol%) was added 
at 100 °C in small portions. The reaction was complete in 1 h. 
The mixture was evaporated and the product was purified 
using column chromatography (heptane/EtOAc 10:1) to give 
25 (34 mg, 74%) as a colorless oil. IR (neat, cm–1): 3032, 2978, 2855, 1709, 1495, 1451, 
1401, 1325, 1231, 1174, 1124, 1078, 1023, 856, 749, 696, 584; 1H NMR (400 MHz, DMSO, 
25 °C, TMS): δ= 7.34 (s, 10H, Ar), 6.61 (s, 1H, CF3C=CH), 5.99 (br s, 1H, CHPh), 5.35-
5.10 (m, 2H, CH2Ph), 4.81 (d, J = 23.6 Hz, 1H, NCH2), 3.86 (d, J = 23.6 Hz, 1H, NCH2), 
0.92 (s, 9H, 3CH3); 13C NMR (100 MHz, DMSO, 25 °C): δ = 154.7, 153.6, 136.3, 135.7, 
130.1, 127.9, 127.8, 127.7, 127.65, 127.6, 127.2, 127.0-126.8 (m, CCF3), 122.1 (q, J = 270.8 
Hz, CF3), 80.2, 67.1, 55.1, 26.6; HRMS (EI) calcd for C24H26F3N2O4 (M+ + H) 463.1845, 
found 463.1837. 
 
5-Fluoro-3-Phenyl-3,6-dihydropyridazine-1,2-dicarboxylic acid-2-benzyl ester- 
1-tert-butyl ester (26) :  
To a solution of 21 (170 mg, 0.39 mmol) in dry toluene (20 mL) 
the Grubbs-II catalyst (20 mol%) was added at 100 °C in small 
portions. The reaction was complete in 1 h. The mixture was 
evaporated and the product was purified using column 
chromatography (heptane/EtOAc 10:1, 6:1) to give 26 (106 mg, 
66%) as a yellow oil. IR (neat, cm–1): 3065, 3032, 2972, 2928, 2857, 1703, 1495, 1451, 
1399, 1366, 1300, 1286, 1256, 1166, 1116, 1056, 1023, 858, 787, 749, 696; 1H NMR (400 
MHz, DMSO, 25 °C, TMS): δ= 7.40-7.31 (m, 10H, Ar), 5.99 (br s, 1H, CF=CH), 5.56 (dd, 
J = 4.0, 14.8 Hz, 1H, CHPh), 5.34-5.08 (m, 2H, CH2Ph), 4.67 (d, J = 16.8 Hz, 1H, NCH2), 
3.99-3.82 (m, 1H, NCH2), 0.92 (s, 9H, 3CH3); 13C NMR (100 MHz, DMSO, 25 °C): δ = 
N
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167.7, 157.6, 156.1 (d, J = 222 Hz, CF), 153.4, 137.7, 135.8, 128.7, 128.5, 128.3, 128.1, 
127.9, 126.4, 102.0 (d, J = 13.8 Hz, C=CF), 81.1, 68.2-67.9 (m, CH2Ph), 54.9 (d, J = 5.7 Hz, 
CHPh), 42.0 (d, J = 36.5 Hz, NCH2), 27.9; HRMS (EI) calcd for C23H26FN2O4 (M+ + H) 
413.1877, found 413.1873. 
 
2-Benzyl-5-fluoro-3-phenyl-3,6-dihydro-2H-pyridazine-1-carboxylic acid tert-butyl 
ester (27) :  
To a solution of 22 (120 mg, 0.30 mmol) in dry toluene (40 mL) the 
Grubbs-II catalyst (15 mol%) was added at 100 °C in small portions. 
The reaction was complete in 1 h. The mixture was evaporated and 
the product was purified using column chromatography 
(heptane/EtOAc 10:1) to give 27 (91 mg, 83%) as a yellow oil. IR (neat, 
cm–1): 3088, 3058, 3028, 2976, 2924, 2850, 1688, 1493, 1450, 1407, 1364, 1161, 1117, 862, 
793, 741, 694; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.51-7.17 (m, 10H, Ar), 5.56 
(dd, J = 5.4, 16.8 Hz, 1H, CF=CH), 4.52 (d, J = 17.4 Hz, 1H, CH2Ph), 4.40 (s, 1H, CHPh), 
4.07-3.96 (m, 2H, NCH2), 3.79 (d, J = 17.4 Hz, 1H, CH2Ph), 1.10 (s, 9H, 3CH3); 13C NMR 
(75 MHz, CDCl3, 25 °C): δ= 155.6 (d, J = 257 Hz, CF), 155.2, 140.2, 137.4, 129.5, 128.7, 
128.4, 127.9, 127.7, 127.4, 99.8 (d, J = 8.6 Hz, C=CF), 79.9, 60.3 (d, J = 5.5 Hz, CHPh), 
58.8, 37.1 (d, J = 35.3 Hz, NCH2), 27.9; HRMS (EI) calcd for C23H27FNO2 (M+ + H) 
368.2026, found 368.2029. 
 
3-Phenyl-2-phenylacetyl-5-trifluoromethyl-3,6-dihydro-2H-pyridazine-1-carboxylic 
acid tert-butyl ester (28): 
To a solution of compound 23 (75 mg, 0.16 mmol) in dry toluene 
(30 mL) the Grubbs-II (20 mol%) was added at 100 °C in small 
portions. The reaction was complete in 2 h. The mixture was 
evaporated and the product was purified using column 
chromatography (heptane/EtOAc 10:1) to give 28 (36 mg, 52%) 
as a yellow oil. IR (neat, cm–1): 3058, 3028, 2976, 2928, 2859, 1722, 1671, 1493, 1368, 108, 
1256, 1169, 1117, 1031, 862, 763, 698, 590. 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 
7.34-7.20 (m, 10H, Ar), 6.53 (br s, 1H, CF3C=CH), 6.31 (br s, 1H, CHPh), 4.76 (d, J = 
17.4 Hz, 1H, NCH2), 3.75-3.62 (m, 2H, CH2Ph), 3.05 (d, J = 17.7 Hz, 1H, NCH2), 1.01 (s, 
9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 
172.3, 153.9, 136.7, 134.1, 130.1, 129.7 (q, J = 36.7 Hz, CCF3), 129.3, 129.2, 128.9, 128.7, 
128.6, 127.2, 122.3 (q, J = 270.5 Hz, CF3), 82.7, 52.2, 40.4-39.6 (m, BocNCH2), 28.1+27.6; 
HRMS (ESI) calcd for C24H25F3N2NaO3 (M+ + Na) 469.1715, found 469.1703. 
 
5-Fluoro-3-phenyl-2-phenylacetyl-3,6-dihydro-2H-pyridazine-1-carboxylic acid 
tert-butyl ester (29):  
To a solution of 24, 146 mg, 0.34 mmol) in dry toluene (58 mL) the 
Grubbs-II catalyst (20 mol%) was added at 100 °C in small 
portions. The reaction was complete in 2 h. The mixture was 
evaporated and the product was purified using column 
chromatography (heptane/EtOAc 20:1, 10:1) to give 29 (84 mg, 
62%) as a white solid. Mp = 113–116 °C; IR (neat, cm–1): 3088, 3062, 3032, 2976, 2933, 
2855, 1705, 1671, 1489, 1455, 1398, 1355, 1251, 1161, 1031, 858, 733, 703; 1H NMR (300 
MHz, CDCl3, 25 °C, TMS): δ = 7.46-7.21 (m, 10H, Ar), 6.34 (br s, 1H, CHPh), 5.47 (dd, J 
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= 5.0, 15.6 Hz, 1H, CF=CH), 4.63 (dd, J = 3.6, 17.1 Hz, 1H, NCH2), 3.74-3.61 (m, 2H, 
CH2Ph), 3.04 (dd, J = 2.0, 18.6 Hz, 1H, NCH2), 1.01 (s, 9H, 3CH3); 13C NMR (75 MHz, 
CDCl3, 25 °C): δ = 172.1, 155.7 (d, J = 260 Hz, CF), 154.1, 134.2, 130.9, 129.2, 129.1, 
128.8, 128.6, 128.4, 127.2, 101.8 (d, J = 13.8 Hz, C=CF), 82.6, 52.2 (d, J = 6.9 Hz, CHPh), 
42.5 (d, J = 36.8 Hz, NCH2), 40.7, 27.5; HRMS (EI) calcd for C23H25FN2O3 (M+) 396.459, 
found 396.186. 
 
1-(2-Benzyl-4-fluoro-6-phenyl-3,6-dihydro-2H-pyridazin-1-yl)- 
2-phenylethanone (31):  
Compound 5-Fluoro-3-phenyl-2-phenylacetyl-3,6-dihydro-2H-  
pyridazine-1-carboxylic acid tert-butyl ester (29, 37 mg, 0.09 
mmol) was dissolved in CH2Cl2 (2 mL) and at 0 °C TFA (3 μL, 
0.04 mmol) was slowly added. The reaction mixture was stirred 
at room temperature for 3 h and later the TFA in excess and the 
solvent were eliminated under vacuum. The crude product 30 was used without 
farther purification. 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.43-7.21 (m, 10H, 
Ar), 6.30 (br s, 1H, CHPh), 5.52 (dd, J = 5.1, 17.1 Hz, 1H, CF=CH), 3.96 (br s, 1H, NH), 
3.95-3.78 (m, 2H, NCH2), 3.32-3.27 (m, 2H, CH2Ph). It was first reacted with NaH (3.3 
mg, 0.13 mmol) in DMF (2 mL) at 0 °C for 15 minutes and after reaching room 
temperature benzyl bromide was added (11 μL, 0.09 mmol). The reaction was stirred 
for 12 h, quenched with water (2 mL) and extracted with Et2O (3 × 3 mL). The ether 
layers were dried (MgSO4), evaporated and the residue was purified using column 
chromatography (heptane/EtOAc 10:1) to give 31 (27 mg, 77%) as an amorphous 
solid. IR (neat, cm–1): 3079, 3062, 3023, 2958, 2924, 2855, 1714, 1649, 1493, 1381, 1256, 
1152, 1027, 914, 802, 750, 698; 1H NMR (300 MHz, CDCl3, 25 °C, TMS): δ = 7.37-7.05 
(m, 15H, Ar), 6.25 (br s, 1H, CHPh), 5.50-5.42 (m, 1H, CF=CH), 4.76-4.56 (m, 1H, 
NCH2), 3.73-3.14 (m, 2H, NCH2Ph), 2.78-2.76 (m, 3H, 1H NCH2, 2H C=OCH2Ph); 13C 
NMR (75 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 173.92+173.9, 
158.1+157.9 (d, J = 265.4 Hz, CF), 140.5+140.4, 140.3+140.1, 138.8+138.7, 129.2, 128.9, 
128.8, 128.7, 128.4, 128.2, 127.8, 127.0+126.7, 126.4+126.0, 101.9+101.8 (d, J = 13.5 Hz, 
C=CF), 52.1 (d, J = 12 Hz, CHPh), 49.6+49.5, 45.7+45.5 (d, J = 27 Hz, NCH2), 40.5+40.4; 
HRMS (CI) calcd for C25H24FN2O (M+ + H) 387.1873, found 387.1875. 
 
N'-(1-Phenylbut-3-enyl)-hydrazinecarboxylic acid tert-butyl ester (32): 
 Allylmagnesium bromide (4.57 mL of a 1.0 M solution in Et2O, 
4.57 mmol) was added at ‒78 °C to a well-stirred solution of 15 
(336 mg, 1.53 mmol) in THF (2 mL). The mixture was stirred at ‒78 
°C for 1 h and then for 12 h thereby slowly reaching room 
temperature. It was poured into aqueous saturated NH4Cl solution 
and the aqueous layer was extracted with ether (3 × 6 mL). The 
ether layers were dried (MgSO4), evaporated and the crude product 32 (135 mg, 40%) 
was obtained as a colorless oil. IR (neat, cm–1): 3403, 3283, 3067, 3028, 2980, 2928, 1709, 
1455, 1368, 1282, 1243, 1156, 1022, 919, 759, 698; 1H NMR (300 MHz, CDCl3, 25 °C, 
TMS): δ = 7.31-7.24 (m, 5H, Ph), 6.22, (s, 1H, BocNH), 5.83-5.69 (m, 1H, CH=CH2), 
5.13-5.03 (m, 2H, CH=CH2), 4.32 (br s, 1H, PhCH), 4.11 (br s, 1H, BocNHNH), 2.42-
2.37 (m, 2H, PhCHCH2), 1.41 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C): δ = 
N
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156.6, 141.9, 134.7, 128.4, 127.8, 127.5, 117.9, 80.3, 63.3, 40.3, 28.4; HRMS (ESI) calcd for 
C15H22N2O2Na (M+ + Na) 285.1579, found 285.15766. 
 
N'-Phenylacetyl-N'-(1-phenylbut-3-enyl)hydrazinecarboxylic acid tert-butyl ester 
(33):  
In a THF (2 mL) solution at 0 °C phenylacetylchloride (64.8 μl, 0.5 
mmol) and Et3N (69.7 μl, 0.5 mmol) were added and the mixture 
was stirred at 0 °C for 30’. After at the same temperature 
compound 32 (130 mg, 0.5 mmol) was added and the mixture was 
stirred for 12 h reaching slowly room temperature. The solvent 
was evaporated and the residue was purified using column chromatography 
(heptane/EtOAc from 10:1 to 6:1) to give 33 (166 mg, 89%) as a white solid. Mp = 107–
109 °C; IR ( neat, cm–1): 3278, 3028, 2980, 2933, 1705, 1658, 1493, 1455, 1394, 1368, 1251, 
1156, 707, 607; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some signals appear as 
rotamers ad isomers): δ = 7.40-7.14 (m, 10H, Ar), 6.1 (br s, 1H, NH), 5.88-5.52 (m, 2H, 
CHPh, CH2=CH), 5.14-5.85 (m, 2H, H2C=CH), 3.72-3.63 (m, 2H, CH2Ph), 2.73-2.50 (m, 
2H, PhCHCH2), 1.50+1.30 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C): δ = 165.2, 
150.6, 145.2, 134.7, 130.8, 129.3, 129.1, 128.0, 127.8, 127.3, 126.9, 117.4, 81.9, 58.8, 49.2, 
40.6, 28.4; HRMS (CI) calcd for C23H29N2O3 (M+ + H) 381.2178, found 381.2188. 
 
N-(2-Fluoroallyl)-N'-phenylacetyl-N'-(1-phenylbut-3-enyl)- 
hydrazinecarboxylic acid tert-butyl ester (34): 
To a suspension of NaH (14 mg, 0.57 mmol) in DMF (5 mL) was 
added at 0 °C product 33 (166 mg, 0.44 mmol). After stirring for 15 
minutes at room temperature, 1-chloro-2-fluoro-2-propene (42 mg, 
0.44 mmol) was slowly added. The reaction was stirred for 12 h, 
quenched with water (5 mL) and extracted with Et2O (3 × 5 mL). 
The ether layers were dried (MgSO4), evaporated and the residue was purified using 
column chromatography (heptane/EtOAc 10:1) to give 34 (104 mg, 54%) as a colorless 
oil. IR (neat, cm–1): 3062, 3032, 2976, 2928, 1718, 1679, 1497, 1450, 1364, 1251, 1156, 
1031, 914, 854, 763, 698; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some signals appear 
as rotamers): δ = 7.41-7.25 (m, 10H, Ar), 5.65-5.43 (m, 2H, 1H CH2=CH, CH2=CH), 
5.07-4.35 (m, 5H, 1H CH2=CH, 2H FC=CH2, CHPh, 1H NCH2), 4.00-3.91 (m, 1H, 1H 
NCH2), 3.72-3.54 (m, 2H, CH2Ph), 2.92 (br s, 2H, PhCHCH2), 1.42+1.22 (s, 9H, 3CH3); 
13C NMR (75 MHz, CDCl3, 25 °C, some signals appear as rotamers): δ = 173.8, 160.3 
(d, J = 260.1 Hz, CF), 169.0, 134.3, 134.2, 133.8, 129.2, 129.1, 128.2, 127.8, 127.2, 126.3, 
122.9, 95.5-95.2 (m, CH2=CF), 82.2, 62.8, 39.8, 38.5, 37.5 (d, J = 48.8 Hz, CH2CF), 
27.8+27.3, HRMS (CI) calcd for C26H32N2O3F (M+ + H) 439.2397, found 439.2389. 
 
6-Fluoro-3-phenyl-2-phenylacetyl-2,3,4,7-tetrahydro-[1,2]diazepine-1-carboxylic 
acid tert-butyl ester (35):  
To a solution of compound 34 (90 mg, 0.2 mmol) in dry toluene (40 
mL) the Grubbs-II catalyst (20 mol%) was added at 100 °C in small 
portions. The reaction was complete in 2 h. The mixture was 
evaporated and the product was purified using column chromatography 
(heptane/EtOAc 10:1) to give 35 (52 mg, 64%) as a white solid. Mp = 110–113°C; IR 
(neat, cm–1): 3058, 3028, 2967, 2898, 2859, 1722, 1689, 1493, 1450, 1368, 1260, 1230, 1161, 
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1117, 1096, 1027, 858, 806, 698, 659, 517; 1H NMR (300 MHz, CDCl3, 25 °C, TMS, some 
signals appear as rotamers): δ = 7.37-7.08 (m, 10H, Ar), 5.48+5.30 (br s, 1H, CHPh), 
5.30-4.86 (m, 1H, CF=CH), 4.74+4.41 (d, J = 18.3, 1H, NCH2), 3.74-3.61 (m, 2H, CH2Ph), 
3.22-3.12 (m, 1H, NCH2), 2.74-2.65 (m, 1H, CH2CHPh), 2.19-2.10 (m, 1H, CH2CHPh), 
1.56+1.51 (s, 9H, 3CH3); 13C NMR (75 MHz, CDCl3, 25 °C, some signals appear as 
rotamers): δ = 173.7+173.4, 156.3+155.9 (d, J = 254.7 Hz, CF), 155.5+154.6, 
141.5+141.3,134.9+134.4, 129.2, 128.8, 128.7, 128.4, 127.3, 127.1, 126.9, 125.7, 101.2+100.6 
(d, J = 18.9 Hz, C=CF), 83.5, 65.3+64.8, 50.2+48.6 (d, J = 42.8 Hz, NCH2), 42.2+41.9, 28.3; 
HRMS (CI) calcd for C24H28FN2O3 (M+ + H) 411.2084, found 411.2075. 
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SUMMARY 
 
Over the past decade or so, it has become increasingly clear that fluorine 
substituents often display a positive effect on the pharmacokinetics and 
pharmacodynamic properties of potential drugs. As a result, the introduction of 
fluorinated substituents has become an important tool to modulate the properties of 
biologically active substances. Most of the biologically active fluorinated compounds 
up to date possess either a fluoride- or trifluoromethyl-substituted aromatic system 
due to the relative facile access to these structural units. Such (hetero)aromatics are 
either commercially available or can be readily prepared via well-established 
synthetic methodology. Inversely, until now the synthesis of fluorinated non-
aromatic (hetero)cycles is much less established. We identified the Ring-Closing 
Metathesis (RCM) of fluoroolefins and trifluoromethylolefins as a possible method 
for the synthesis of fluorine-containing molecules.  
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This thesis deals with investigating the scope and limitations of application of 
RCM to synthesize fluorinated heterocyclic building blocks 1. Hence, several types 
of, thus far unexplored, fluoro- and trifluoromethyl-functionalized olefins 2 are 
required, which in turn rely on the availability of fluorinated allylating agents of type 
3. 
Chapter 1 provides a brief historical overview on the importance of fluorine 
chemistry from the 1980s to nowadays and describes the various reagents available 
for introducing fluoro and/or trifluoromethyl substituents in organic molecules. In 
addition a short introduction on the Ring-Closing Metathesis (RCM) technique is 
provided. 
Chapter 2 describes the synthesis of the trifluoromethyl-containing allylating 
agent 9 via a novel, reliable and efficient pathway. 
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Additionally, the viability of the concept of vinyl fluoride metathesis is 
demonstrated in this chapter. In order to realize a proof of concept, we initially 
conducted several experiments involving simple vinyl chlorides that successfully 
cyclized using the Grubbs-II catalyst in toluene at 100 °C. More importantly, olefins 
containing fluoro and trifluoromethyl substituents were also successfully subjected 
to the same catalyst. These positive results clearly showed the viability of RCM as a 
suitable way to incorporate fluoride substituents in ring systems. It also strengthened 
our confidence that this strategy could be more widely applied to synthesize 
different kinds of heterocyclic building blocks with potential biological activity. 
Chapter 3 describes the investigation of RCM on several trifluoromethyl-
containing olefins 13 leading to a small library of the trifluoromethyl-containing 
heterocyclic building blocks 14. 
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The precursor molecules 13 were prepared via a one-pot three-component reaction, 
followed by standard introduction of the trifluoromethyl-containing side chain. The 
RCM precursor molecules were then readily cyclized using RCM at a somewhat 
lower temperature of 80 °C to prevent decomposition from taking place. Confident 
by these successful cyclizations, a different set of trifluoromethyl-containing olefins 
precursors was prepared starting from allylglycine and cyclized as well.  
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A similar strategy was applied to the functionalized vinyl fluorides 18 as 
discussed in Chapter 4. The sequence commenced with allylglycine (15), which was 
first transformed into the sulfonamides 16, followed by introduction of differently 
substituted benzylamines at the carboxylic acid position to give the amides 17. 
Finally, the 2-fluoro-2-propenyl substituent was introduced at the sulfonamide 
nitrogen obtaining the precursors olefins 18. Treatment with the Grubbs-II catalyst 
under the standard conditions then successfully provided the target heterocyclic 
molecules 19. Besides the development of this generally applicable route for the 
synthesis of vinyl fluoride-containing building blocks, different pathways were 
evaluated to probe combinatorial approaches resulting in series of highly 
functionalized, fluorinated and potentially bioactive cyclic amino acid derivatives. 
In Chapter 5 the general applicability of RCM is further demonstrated by 
synthesizing a series of fluoride- and trifluoromethyl-containing N-sulfonylated 
nitrogen heterocycles. 
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Starting from the readily available sulfonamides 20, the feasibility of a Mitsunobu 
approach to obtain RCM precursors 21 was probed. It appeared that straightforward 
alkylation (method A) was somewhat inferior to applying Mitsunobu conditions 
(method B) for the introduction of olefinic side chains. The precursors were then 
subjected to the RCM conditions leading to the corresponding fluoro- and 
trifluoromethyl-containing five-, six- and seven-membered heterocyclic building 
blocks 22. In addition, application of this methodology to N,O-acetal 25, readily 
available via aminopalladation of 23, resulted in a straightforward synthetic pathway 
to prepare the trifluoromethylated pyrrole 26. 
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Finally, inspired by the previous RCM results, we decided to extend this research to 
hydrazine derivatives in order to prepare orthogonally protected fluorinated cyclic 
six- and seven-membered hydrazines, which is described in Chapter 6. 
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The linear hydrazines 31 were prepared starting from tert-butyl carbazate (27), which 
was first condensed with benzaldehyde and then alkylated with vinylmagnesium 
bromide to give the Boc-protected hydrazine 29. In order to orthogonally protect the 
hydrazine moiety, at this stage a number of different protecting groups were 
introduced on the second nitrogen atom via conditions (a) which required extensive 
experimentation to reach reasonable selectivity and yields. The second alkylation (b) 
with the 2-(trifluoromethyl)allylating reagent 9 or 1-fluoro-2-chloro-2-propene 
provided the fluoro- and trifluoromethyl-containing hydrazine precursors 31. RCM 
provided the desired cyclic six-membered hydrazines 32. With a similar pathway, 
using allyl- instead of vinylmagnesium bromide, we obtained the first example of a 
fluorinated cyclic seven-membered hydrazine, whose structure was unambiguously 
confirmed via X-ray crystallographic determination of its crystal structure. 
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SAMENVATTING 
 
Gedurende de afgelopen tien jaar is overduidelijk geworden dat 
fluor(bevattende)-substituenten vaak een positief effect laten zien op de 
farmacokinetische en farmacodynamische eigenschappen van potentieel interessante 
geneesmiddelen. Als gevolg hiervan is de introductie van fluor(bevattende)-
substituenten een belangrijke methode geworden om de eigenschappen van 
biologisch actieve verbindingen te modificeren. De meeste van de huidige biologisch 
actieve gefluoreerde verbindingen bevatten ofwel een fluoride- danwel een 
trifluormethyl-gesubstitueerd aromatisch system, door de relatief eenvoudige 
toegankelijkheid tot deze functionele groepen. Dergelijke (hetero)aromatische 
systemen zijn vaak commercieel verkrijgbaar of kunnen op eenvoudige wijze 
worden bereid via beproefde synthetische methodologie. Echter, tot nu toe is de 
synthese van gefluoreerde niet-aromatische (hetero)cyclische verbindingen veel 
minder goed onderzocht. Wij hebben nu de mogelijkheden onderzocht om 
ringsluitingsmetathese (ring-closing metathesis, RCM) te gebruiken als algemene 
methode om fluoride- en trifluormethyl-gesubstitueerde olefinen om te zetten in de 
overeenkomstige gefluoreerde ringsystemen. 
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In dit proefschrift worden meer specifiek de mogelijkheden en de 
beperkingen beschreven van het toepassen van RCM voor de synthese van de 
gefluoreerde heterocyclische bouwstenen 1. Hiervoor zijn verschillende, tot nu toe 
onbekende, fluor- danwel trifluormethyl-gefunctionaliseerde olefinen 2 nodig. Deze 
zijn op hun beurt weer toegankelijk via de gefluoreerde allylische verbindingen 3. 
Hoofdstuk 1 geeft een kort historisch overzicht omtrent het toenemende 
belang van fluorchemie vanaf de jaren tachtig tot op heden en beschrijft diverse 
reagentia die momenteel beschikbaar zijn voor de introductie van fluor- en/of 
trifluormethyl-substituenten in organische verbindingen. Tot slot wordt een kort 
overzicht gegeven over de techniek ringsluitingsmetathese. 
Hoofdstuk 2 beschrijft een nieuwe en betrouwbare synthese van het 
trifluormethyl-bevattende allyleringsreagens 9 via een efficiënte route. 
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 Tevens wordt in dit hoofdstuk de haalbaarheid van metathese aan 
vinylfluoriden aangetoond. Om een proof of concept te realiseren zijn allereerst een 
aantal experimenten uitgevoerd met eenvoudige vinylchloriden, die succesvol 
cycliseerden onder invloed van de Grubbs-II katalysator in tolueen bij 100 ˚C. 
Vervolgens bleek ook dat olefinen met fluor- en trifluormethyl-substituenten 
succesvol konden worden blootgesteld aan dezelfde reactieomstandigheden, 
resulterend in de overeenkomstige cyclische systemen. Deze resultaten hebben 
duidelijk de haalbaarheid van RCM aangetoond als bruikbare methode om fluor-
substituenten aan te brengen in ringsystemen. Dit heeft bij ons ook het vertrouwen 
versterkt dat deze strategie breder inzetbaar is voor het synthetiseren van 
uiteenlopende soorten heterocyclische bouwstenen met potentiële biologische 
activiteit. 
 Hoofdstuk 3 betreft onderzoek naar de toepasbaarheid van RCM op de 
verschillende trifluormethyl-bevattende olefinen 13, die toegang geven tot een kleine 
bibliotheek van de trifluormethyl-bevattende heterocyclische bouwstenen 14. 
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 De uitgangsstoffen 13 werden gemaakt via een één-pots-drie-
componentenreactie, gevolgd door standaard introductie van trifluormethyl-
bevattende zijketens. Vervolgens werden deze eenvoudig gecycliseerd via RCM bij 
een enigszins lagere temperatuur van 80 ˚C om te voorkomen dat ontleding zou 
plaatsvinden. Aangemoedigd door deze succesvolle cyclisaties werden meer 
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trifluormethyl-bevattende olefinische bouwstenen bereid uitgaande van allylglycine 
en vervolgens ook gecycliseerd. 
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Een vergelijkbare strategie werd toegepast op de gefunctionaliseerde 
vinylfluoriden 18 zoals beschreven in Hoofdstuk 4. De toegepaste sequentie 
omvatte, uitgaande van allylglycine (15), omzetting naar de sulfonamiden 16, 
gevolgd door amidevorming met verschillende gesubstituerde benzylaminen tot de 
overeenkomstige amiden 17. Vervolgens leidde invoering van de 2-fluor-2-propenyl-
substituent op het sulfonamide, gevolgd door behandeling met de Grubbs-II 
katalysator onder de standaardcondities tot de beoogde heterocyclische moleculen 19 
in goede opbrengsten Naast de ontwikkeling van deze algemeen toepasbare route 
voor de synthese van vinylfluoride-bevattende bouwstenen werden ook andere 
routes onderzocht op de mogelijkheden om combinatoriële benaderingen toe te 
passen om potentieel biologisch actieve cyclische aminozuurderivaten te 
synthetiseren. 
 In Hoofdstuk 5 is de algemene toepasbaarheid van RCM verder aangetoond 
middels de synthese van een serie fluor- en trifluormethyl-bevattende sulfonamiden. 
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Uitgaande van het goed toegankelijke sulfonamide 20 werd de haalbaarheid 
van een Mitsunobu benadering bestudeerd om de RCM-uitgangsstoffen 21 te 
verkrijgen. Het bleek dat alkylering (methode A) minder algemeen toepasbaar was 
dan het gebruik van Mitsunobu condities (methode B) olefine-zijketens in te voeren. 
De uitgangsstoffen werden vervolgens onderworpen aan de gangbare RCM 
condities, waarna de overeenkomstige fluor- en trifluormethyl-bevattende vijf-, zes- 
en zeven-ring heterocyclische bouwstenen 22 werden verkregen. Toepassing van 
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deze methodologie op N,O-acetaal 25, eenvoudig toegankelijk via aminopalladering 
van 23, gaf tevens een eenvoudige route voor de synthese van het trifluormethyl-
bevattend pyrroolderivaat 26. 
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Aangemoedigd door deze RCM-resultaten werd tot slot onderzocht of deze 
methodologie uitgebreid kon worden tot de synthese van orthogonaal-beschermde 
fluor- en trifluormethyl-bevattende zes- en zeven-ring hydrazinen, zoals beschreven 
in Hoofdstuk 6. 
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De lineaire hydrazinen 31 werden bereid uitgaande van tert-butylcarbazaat (27), dat 
eerst was gecondenseerd met benzaldehyde en vervolgens gealkyleerd met 
vinylmagnesiumbromide onder vorming van het Boc-beschermde hydrazine 29. Om 
de hydrazine-groep orthogonaal te kunnen beschermen werd in dit stadium een 
aantal verschillende beschermgroepen (BG) ingevoerd op het tweede stikstofatoom 
via condities (a) die uitgebreid experimenteel onderzoek vereisten om tot een 
redelijke selectiviteit en opbrengst te komen. De tweede alkylering (b) met het 
eerdergenoemde allyleringsreagens 9 of 1-fluor-2-chloor-2-propeen gaf de 
trifluormethyl- en fluor-bevattende hydrazinebouwstenen 31. Tenslotte werd onder 
invloed van RCM het gewenste zes-ring hydrazine 32 verkregen Met een 
vergelijkbare route, uitgaande van allyl- in plaats van vinylmagnesiumbromide, 
werd het eerste voorbeeld verkregen van een gefluoreerd zeven-ring hydrazine, 
waarvan de structuur ondubbelzinnig werd bevestigd door middel van een röntgen-
kristallografische bepaling van de kristalstructuur.   
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